The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study) by Kuyken, Willem et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 19 ISSUE 73 SEPTEMBER 2015
ISSN 1366-5278
DOI 10.3310/hta19730
The effectiveness and cost-effectiveness of 
mindfulness-based cognitive therapy compared  
with maintenance antidepressant treatment in  
the prevention of depressive relapse/recurrence:  
results of a randomised controlled trial  
(the PREVENT study)
Willem Kuyken, Rachel Hayes, Barbara Barrett, Richard Byng,  
Tim Dalgleish, David Kessler, Glyn Lewis, Edward Watkins,  
Nicola Morant, Rod S Taylor and Sarah Byford

The effectiveness and cost-effectiveness of
mindfulness-based cognitive therapy
compared with maintenance
antidepressant treatment in the
prevention of depressive relapse/
recurrence: results of a randomised
controlled trial (the PREVENT study)
Willem Kuyken,1* Rachel Hayes,2 Barbara Barrett,3
Richard Byng,4 Tim Dalgleish,5 David Kessler,6
Glyn Lewis,7 Edward Watkins,8 Nicola Morant,9
Rod S Taylor2 and Sarah Byford3
1Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
2Exeter Medical School, University of Exeter, Exeter, UK
3Centre for the Economics of Mental and Physical Health, Institute of Psychiatry,
King’s College London, London, UK
4Primary Care Group, Plymouth University Peninsula Schools of Medicine and
Dentistry, Plymouth, UK
5Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
6School of Social and Community Medicine, University of Bristol, Bristol, UK
7Division of Psychiatry, University College London, London, UK
8Mood Disorders Centre, University of Exeter, Exeter, UK
9Department of Psychology, University of Cambridge, Cambridge, UK
*Corresponding author
Declared competing interests of authors: Willem Kuyken declares that he is a codirector of the
Mindfulness Network Community Interest Company.
Published September 2015
DOI: 10.3310/hta19730

This report should be referenced as follows:
Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, et al. The effectiveness and
cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant
treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial
(the PREVENT study). Health Technol Assess 2015;19(73).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.116
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 08/56/01. The contractual start date
was in January 2010. The draft report began editorial review in October 2014 and was accepted for publication in February 2015. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Kuyken et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR  
Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK
Professor John Norrie Health Services Research Unit, University of Aberdeen, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
The effectiveness and cost-effectiveness of mindfulness-based
cognitive therapy compared with maintenance antidepressant
treatment in the prevention of depressive relapse/recurrence:
results of a randomised controlled trial (the PREVENT study)
Willem Kuyken,1* Rachel Hayes,2 Barbara Barrett,3 Richard Byng,4
Tim Dalgleish,5 David Kessler,6 Glyn Lewis,7 Edward Watkins,8
Nicola Morant,9 Rod S Taylor2 and Sarah Byford3
1Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
2Exeter Medical School, University of Exeter, Exeter, UK
3Centre for the Economics of Mental and Physical Health, Institute of Psychiatry,
King’s College London, London, UK
4Primary Care Group, Plymouth University Peninsula Schools of Medicine and Dentistry,
Plymouth, UK
5Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
6School of Social and Community Medicine, University of Bristol, Bristol, UK
7Division of Psychiatry, University College London, London, UK
8Mood Disorders Centre, University of Exeter, Exeter, UK
9Department of Psychology, University of Cambridge, Cambridge, UK
*Corresponding author willem.kuyken@psych.ox.ac.uk
Background: Individuals with a history of recurrent depression have a high risk of repeated depressive
relapse/recurrence. Maintenance antidepressant medication (m-ADM) for at least 2 years is the current
recommended treatment, but many individuals are interested in alternatives to m-ADM. Mindfulness-based
cognitive therapy (MBCT) has been shown to reduce the risk of relapse/recurrence compared with usual
care but has not yet been compared with m-ADM in a definitive trial.
Objectives: To establish whether MBCT with support to taper and/or discontinue antidepressant
medication (MBCT-TS) is superior to and more cost-effective than an approach of m-ADM in a primary
care setting for patients with a history of recurrent depression followed up over a 2-year period in terms of
preventing depressive relapse/recurrence. Secondary aims examined MBCT’s acceptability and mechanism
of action.
Design: Single-blind, parallel, individual randomised controlled trial.
Setting: UK general practices.
Participants: Adult patients with a diagnosis of recurrent depression and who were taking m-ADM.
Interventions: Participants were randomised to MBCT-TS or m-ADM with stratification by centre and
symptomatic status. Outcome data were collected blind to treatment allocation and the primary analysis
was based on the principle of intention to treat. Process studies using quantitative and qualitative methods
examined MBCT’s acceptability and mechanism of action.
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Main outcomes measures: The primary outcome measure was time to relapse/recurrence of depression.
At each follow-up the following secondary outcomes were recorded: number of depression-free days,
residual depressive symptoms, quality of life, health-related quality of life and psychiatric and
medical comorbidities.
Results: In total, 212 patients were randomised to MBCT-TS and 212 to m-ADM. The primary analysis did
not find any evidence that MBCT-TS was superior to m-ADM in terms of the primary outcome of time to
depressive relapse/recurrence over 24 months [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.67 to
1.18] or for any of the secondary outcomes. Cost-effectiveness analysis did not support the hypothesis that
MBCT-TS is more cost-effective than m-ADM in terms of either relapse/recurrence or quality-adjusted
life-years. In planned subgroup analyses, a significant interaction was found between treatment group
and reported childhood abuse (HR 1.89, 95% CI 1.06 to 3.38), with delayed time to relapse/recurrence for
MBCT-TS participants with a more abusive childhood compared with those with a less abusive history.
Although changes in mindfulness were specific to MBCT (and not m-ADM), they did not predict outcome in
terms of relapse/recurrence at 24 months. In terms of acceptability, the qualitative analyses suggest that many
people have views about (dis)/continuing their ADM, which can serve as a facilitator or a barrier to taking part
in a trial that requires either continuation for 2 years or discontinuation.
Conclusions: There is no support for the hypothesis that MBCT-TS is superior to m-ADM in preventing
depressive relapse/recurrence among individuals at risk for depressive relapse/recurrence. Both treatments
appear to confer protection against relapse/recurrence. There is an indication that MBCT may be most
indicated for individuals at greatest risk of relapse/recurrence. It is important to characterise those most at
risk and carefully establish if and why MBCT may be most indicated for this group.
Trial registration: Current Controlled Trials ISRCTN26666654.
Funding: This project was funded by the NIHR Health Technology Assessment programme and the
National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care
South West Peninsula and will be published in full in Health Technology Assessment; Vol. 19, No. 73.
See the NIHR Journals Library website for further project information.
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Plain English summary
Research has shown that people who have had three or more episodes of depression have a high risk ofbecoming depressed again; however, this risk can be reduced if antidepressants are taken for 2 years
after recovery or if patients attend a course of mindfulness-based cognitive therapy (MBCT).
The PREVENT trial was designed to find out if over 24 months MBCT with support to taper/stop antidepressants
(MBCT-TS) reduced the number of relapses/recurrences compared with continuing antidepressants for patients
who had experienced three or more previous episodes of depression. In total, 424 people took part and half
were randomly allocated to attend an MBCT-TS course and stop taking antidepressants and half were allocated
to stay on their antidepressants.
Our results suggest that MBCT-TS is not better than antidepressants at preventing depression recurring;
at the end of the 24-month period the number of people who had become depressed again was very
similar in both groups (MBCT-TS 44%, antidepressants 47%). It would seem that both treatments were
relatively effective at keeping people well. We did not find a difference between the two treatments
in terms of cost. However, we did find that for people who are at a higher risk of relapse/recurrence
MBCT-TS may in fact be more effective than antidepressants and we recommend that further research is
carried out to explore this relationship in more depth.
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Scientific summary
Background
Depression typically runs a relapsing and recurrent course. Without ongoing treatment, individuals with
recurrent depression have a high risk of repeated depressive relapses/recurrences throughout their life, with
rates of relapse/recurrence typically in the range of 50–80%. Major inroads into the substantial health burden
attributable to depression could be made through interventions that prevent depressive relapse/recurrence
among people at highest risk. If the factors that make people vulnerable to depressive relapse/recurrence can
be attenuated, the recurrent course of depression could potentially be broken.
Currently, most depression is treated in primary care and maintenance antidepressant medication (m-ADM)
is the mainstay approach to preventing relapse/recurrence. The UK’s National Institute for Health and Care
Excellence (NICE) recommends that, to stay well, people with a history of recurrent depression should
continue on m-ADM for at least 2 years. However, adherence rates tend to be poor, m-ADM is protective
only for as long as it is taken and is contraindicated for some groups, patients at higher risk receive less
protection from m-ADM and many patients express a preference for psychosocial interventions that
provide long-term protection against relapse/recurrence.
Mindfulness-based cognitive therapy (MBCT) was developed as a psychosocial intervention to teach people
with recurrent depression the skills to stay well in the long term. A systematic review and meta-analysis of
six randomised controlled trials (n= 593) suggests that MBCT significantly reduces the rates of depressive
relapse/recurrence compared with usual care or placebo, corresponding to a relative risk reduction of 34%
[risk ratio 0.66, 95% confidence interval (CI) 0.53 to 0.82]. A key remaining uncertainty is whether MBCT
provides an alternative for people wishing to discontinue m-ADM. There is accumulating evidence that
MBCT may confer most benefit to patients at greatest risk.
Objectives
The overarching policy aim and research question of the PREVENT trial was to establish whether MBCT with
support to taper and/or discontinue antidepressant medication (MBCT-TS) is superior to and more cost-effective
than an approach of m-ADM in a primary care setting for patients with a history of recurrent depression
followed up over a 2-year period in terms of a primary outcome of preventing depressive relapse/recurrence.
Secondary outcomes were depression-free days, residual depressive symptoms, psychiatric and medical
comorbidity, quality of life and cost-effectiveness over 24 months. The trial also sought to address whether an
increase in mindfulness skills is the key mechanism of change of MBCT and explore barriers to participation in
MBCT-TS within the PREVENT study.
Methods
The PREVENT study was a two-arm, multicentre, single-blind superiority trial randomly allocating patients in
a 1 : 1 ratio to receive either MBCT-TS or m-ADM. The m-ADM was constant over the 2 years of the study
and the psychosocial intervention was a front-loaded, 8-week relapse/recurrence prevention programme.
Patients in the MBCT-TS arm received support to taper their antidepressant medication (ADM). The trial
included a parallel economic evaluation to examine the cost-effectiveness of MBCT-TS compared with
m-ADM. It included a mixed-methods process evaluation to examine the acceptability and mechanism of
action of MBCT.
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Participants were considered for inclusion if they:
l had had three or more previous major depressive episodes in which depression was the primary
disorder and which were not secondary to substance abuse, bereavement or a general
medical condition
l were aged ≥ 18 years
l were on a therapeutic dose of ADM in line with British National Formulary (BNF) and NICE guidance
l were open either to continue taking antidepressants for 2 years or to take part in a MBCT class and
stop their ADM.
Participants were considered unsuitable for inclusion if they:
l were currently depressed
l had a comorbid diagnosis of current substance abuse
l had organic brain damage
l had current/past psychosis, including bipolar disorder
l displayed persistent antisocial behaviour
l engaged in persistent self-injury that required clinical management/therapy
l were undergoing formal concurrent psychotherapy.
Searches were carried out of computerised general practice databases to identify patients who were
currently being prescribed a therapeutic dose of ADM in line with BNF and NICE guidance. Subsequent to
each participant giving written informed consent, participants were randomly allocated to receive either
m-ADM or an 8-week MBCT class that included support to taper/discontinue their m-ADM (MBCT-TS)
using computer-generated random permuted blocks and stratified by recruitment locality (four sites) and
participants’ symptomatic status (asymptomatic vs. partially symptomatic).
l MBCT-TS. MBCT is a manualised, group-based skills training programme designed to enable patients to
learn skills that prevent the recurrence of depression.
l m-ADM. Patients in the m-ADM arm received support from their general practitioner (GP) to maintain a
therapeutic level of ADM in line with BNF and NICE guidelines.
Data collection
Participants were assessed at six time points: baseline (prior to randomisation), 1 month after the end of
the 8-week MBCT-TS programme, which varied between 12 and 24 weeks post randomisation (or the
equivalent time in the m-ADM arm) and 9, 12, 18 and 24 months post randomisation.
The primary outcome measure was time to relapse/recurrence of depression. Relapse/recurrence was
defined as an episode meeting Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition
(DSM-IV) criteria for a major depressive episode. At each follow-up we recorded the secondary outcomes:
number of depression-free days, residual depressive symptoms, quality of life, health-related quality of life
and psychiatric and medical comorbidities.
The economic perspective included all hospital and community health and social services plus productivity
losses, known to be a substantial cost in depression.
Mechanisms were examined through an embedded process study in which the hypothesised mechanism
(change in mindfulness) was assessed before and after MBCT and outcome was assessed at 24 months’
follow-up. Acceptability was examined through an embedded qualitative study that enabled participants to
provide their views and experiences of the acceptability of MBCT through interviews and feedback booklets.
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Statistical analysis
Statistical analyses were conducted in accord with International Conference on Harmonisation (ICH-9)
statistical guidelines for clinical trials and updated Consolidated Standards of Reporting Trials (CONSORT)
guidelines for trials. All statistical analyses were undertaken in Stata version 13 (StataCorp LP, College
Station, TX, USA) following a predefined analysis plan agreed with the Trial Steering Committee (TSC).
The study was powered to detect a hazard ratio (HR) of 0.63 between the two treatments at 24 months
for the primary outcome, with 90% power and a two-sided 5% alpha level, assuming a small clustering
effect [intraclass correlation coefficient (ICC)= 0.01] and allowing for 20% loss to follow-up, producing a
target sample size of 420 (210 per arm).
The primary analysis was a between-group comparison of time to relapse/recurrence at 24 months using a
Cox regression proportional hazards model adjusted for stratification variables.
Secondary outcomes were compared across all time points using repeated-measures mixed-regression
models. Missing data were assumed missing at random and sensitivity analysis examined the effect of
missing data using multiple imputations. Between-group inference for secondary outcome analyses was
based on the complete case and imputed data sets are reported.
Interaction terms were used to undertake predefined exploratory subgroup analyses on the primary
outcome, across the stratification variables (recruitment centre and baseline depression severity) and
reported levels of childhood abuse. Participants with a more abusive childhood reported experiencing
childhood physical or sexual abuse and/or scored above the median score for the Measure of Parenting
Scale (MOPS) abuse subscale. Participants completed the MOPS at baseline as part of an embedded
process–outcome study. The abuse subscale asks participants to indicate how true they felt certain
statements about their parents’ behaviour were, for example ‘parent was physically violent or abusive to
me’, ‘parent made me feel unsafe’. Participants were categorised as either in the lower abusive childhood
group (i.e. scored below the median score for the MOPS abuse subscale and did not report childhood
physical or sexual abuse) or in the higher abusive childhood group (i.e. scored above the median score for
the MOPS abuse subscale or did report childhood physical or sexual abuse).
Differences in mean costs were analysed using standard parametric t-tests with the validity of results
confirmed using bias-corrected, non-parametric bootstrapping (repeat resampling). The primary economic
analysis compared MBCT-TS and m-ADM from the health and social care perspective preferred by NICE;
secondary analyses included productivity losses.
Results
Between 23 March 2010 and 21 October 2011 we recruited 424 patients, of whom 212 were allocated to
receive MBCT-TS and 212 were allocated to receive m-ADM. Primary outcome data were collected for
90% (383/424) of the participants. The remaining participants’ data were censored at their last follow-up.
We retained 86% (366/424) of participants over the 24-month follow-up period, with 5% (20/424) lost to
contact and 8% (34/424) withdrawing consent for further follow-up; in addition, 1% (4/424) died during
the trial. The pattern of primary outcome missing data was identical across trial arms (14% in each arm).
With respect to the primary outcome, primary intention-to-treat analysis showed no evidence of a reduction
in the hazard of relapse/recurrence with MBCT-TS compared with m-ADM (HR 0.89, 95% CI 0.67 to 1.18;
p= 0.43), with 44% (94/212) of the MBCT-TS patients relapsing compared with 47% (100/212) of the
m-ADM patients [log-rank χ2 (1)= 0.67; p= 0.41].
DOI: 10.3310/hta19730 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 73
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Kuyken et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxv
There was no difference in treatment effect on the primary outcome across either stratification variable
subgroup of severity of depression at baseline or recruitment centre. However, there was evidence
of a significant interaction between severity of reported childhood abuse and treatment group (HR 0.53,
95% CI 0.29 to 0.95; p= 0.03). Specifically, compared with m-ADM, MBCT-TS reduced the risk of
relapse/recurrence for participants with a higher severity of reported childhood abuse (47% vs. 59%)
whereas there was a slightly higher risk of relapse/recurrence with MBCT-TS compared with m-ADM in
the lower severity of childhood abuse subgroup (42% vs. 35%). Given their non-randomised nature,
these secondary analyses are prone to selection bias and confounding.
With respect to the secondary outcomes, there was no evidence of MBCT-TS’s superiority over m-ADM.
Over 24 months’ follow-up, group attendance in the MBCT-TS arm was estimated to cost £112 per
participant and the average cost of antidepressants was £40.10 in the MBCT-TS group and £69.79 in the
m-ADM group. Use of other health and social care services differed little between groups and hence there
was no significant difference in the total health and social care cost per participant between the MBCT-TS
group (£2484.52) and the m-ADM group (£2360.41; mean difference £124, 95% CI £–749.98 to £972.57;
p= 0.80). The results including patient costs (productivity losses and out-of-pocket expenditure) were also
non-significant (mean difference £449, 95% CI –£842.18 to £1286.26; p= 0.68). There were no significant
differences in quality-adjusted life-years (QALYs) over follow-up and the cost–utility and cost-effectiveness
analysis did not support the hypothesis that MBCT-TS is cost-effective compared with m-ADM.
To examine MBCT’s mechanism of action, meditational analyses were conducted, which showed that,
although changes in mindfulness were specific to MBCT (and not m-ADM), they did not predict outcome
in terms of relapse/recurrence at 24 months.
In terms of acceptability, the qualitative analyses suggest that many people have views about (dis)continuing
their ADM, which can serve as a facilitator or a barrier to taking part in a trial that requires either continuation
for 2 years or discontinuation. The most commonly cited reasons for non-participation in the PREVENT trial
were related to the treatment interventions provided. Together these accounted for 40% of all reasons given.
Within this, the largest category related to use of ADM (19% of all responses). Most commonly, people
reported that they did not want to stop taking ADM (49% of ADM reasons). Other reasons were that people
were no longer taking ADM (24%), were currently coming off ADM (9%) and were happy with their current
ADM use (11%).
Discussion
There was no evidence for the superiority of MBCT-TS over m-ADM for patients with recurrent depression
in terms of the primary outcome of time to depressive relapse/recurrence over 24 months or any of the
secondary outcomes. Cost-effectiveness analysis does not support the hypothesis that MBCT-TS is more
cost-effective than m-ADM in terms of either relapse/recurrence or QALYs.
Relapse/recurrence rates in people with three or more previous episodes can be as high as 80% over 2 years.
Moreover, meta-analyses consistently suggest that m-ADM reduces the odds of relapse/recurrence by
two-thirds compared with placebo, a halving of the absolute risk. Therefore, it is likely that MBCT would
provide benefits over and above either no treatment or pill placebo.
Across both treatment arms, outcomes were comparatively good over the 2 years of follow-up in terms of
relapse/recurrence (MBCT-TS 44%, m-ADM 47%), residual symptoms and quality of life.
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MBCT is hypothesised to work through teaching mindfulness, a skill that enables people to recognise and
respond resiliently in the face of early warning signs of depressive relapse/recurrence. Using a meditational
design and a self-report measure of mindfulness we found that, although changes in mindfulness are
specific to MBCT, they do not predict relapse/recurrence at 24 months. However, we used a self-report
measure and it is possible that alternative approaches to establishing mechanisms of action are needed.
The main barrier to participation in the PREVENT trial at the point of recruitment appears to be expectations
surrounding m-ADM use. This applied to both arms of the trial. For most people, their concerns centre on
being randomised to MBCT-TS, as they do not consider themselves to be in a position to taper their m-ADM.
For a smaller group of people, reluctance to participate relates to being randomised to the m-ADM arm, as
this carries an expectation of continuing on m-ADM for 2 years, a prospect that may not be acceptable.
Consistent with an emergent pattern of findings, MBCT may confer most benefit to patients at greatest risk
of relapse/recurrence. A reported history of abuse and adversity is associated with worse outcomes among
those who suffer from depression. Perhaps MBCT confers resilience in this group at highest risk because
patients learn skills that address some of the underlying mechanisms of relapse/recurrence, a question that
we will explore in a subsequent publication from this trial. Studies are needed that have the primary aim
of establishing the effectiveness and mechanism of action of MBCT for those at differing levels of risk of
relapse/recurrence, with robust measures of risk.
Implications for practice and directions for future research
1. MBCT-TS is not superior to m-ADM over 2 years of follow-up for patients with recurrent depression.
2. Benchmarked against epidemiological data, both treatments were associated with enduring positive
outcomes in terms of relapse/recurrence, residual depressive symptoms and quality of life.
3. This study provides important evidence that MBCT-TS may confer ongoing protection for patients who
would like an alternative to m-ADM.
4. For patients at low risk, m-ADM, which requires less patient commitment and is less costly, may be
indicated, whereas, for patients at highest risk, more intensive treatments such as MBCT may be
indicated. However, studies have tended to operationalise risk in somewhat different ways (e.g. early
adversity, unstable remission, a higher number of previous episodes, early age of onset) and, although
these risk factors overlap, future research should examine how and through what mechanism risk is
conferred and resilience learned.
Trial registration
This trial is registered as ISRCTN26666654.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research and the National Institute for Health Research Collaboration for Leadership in
Applied Health Research and Care South West Peninsula.
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Chapter 1 Introduction
Background
Depression is a major public health problem that, like other chronic conditions, tends to run a relapsing
and recurrent course,1 producing substantial decrements in health and well-being.2 The World Health
Organization (WHO) predicts that by 2020 depression will be the second leading cause of disability in the
world.3 The cost of mood disorders in the UK has been calculated at 7% of national income with a direct cost
to health services of £3B.4 More than 50% of patients experience at least two episodes of depression.5
Moreover, without ongoing treatment, people suffering recurrent depression suffer relapse/recurrence at
rates as high as 80%, even after successful acute treatment.5,6 Thus, most of the prevalence, burden and
cost of depression is a consequence of relapse/recurrence and the majority of the burden attributable to
depression could be offset through interventions aimed at preventing depressive relapse/recurrence.7
Current treatments for depression in primary care
Currently, the majority of depression is treated in primary care and treatment with maintenance antidepressant
medication (m-ADM) is the mainstay approach to preventing relapse/recurrence.8–11 To stay well the National
Institute for Health and Care Excellence (NICE) recommends that people with a history of recurrent depression
continue m-ADM for at least 2 years.8 However, many patients experience unpleasant side effects, rates of
m-ADM adherence tend to be low and patients often express a preference for psychosocial interventions.12–14
Service user organisations, such as Depression Alliance, therefore advocate greater availability of psychosocial
therapies. Government advisors Layard and Clark4 recommend that there should be parity of esteem for
mental and physical health. That is, today, evidence-based treatment should be as available for mental illness
as for physical illness. They provide a compelling narrative that this would be a cost-effective approach to
enhancing the mental health of the nation. In line with this, significant government initiatives, such as
Improving Access to Psychological Therapies, aim to offer accessible, acceptable and cost-effective psychosocial
models of care and the last 10 years has seen significant progress in the accessibility of evidence-based
mental health services in the UK.4,15,16
Psychosocial approaches to prevent depressive relapse/recurrence
There is a strong evidence base for psychosocial treatments for recurrent depression, most notably
cognitive–behavioural therapy (CBT) and interpersonal therapy, and promising evidence for several other
therapies.8,17 Policy initiatives, user groups and professional consensus recommend as priorities for future
research the development of psychosocial interventions to prevent depressive relapse/recurrence and
the use of non-traditional delivery systems, such as group interventions, to maximise accessibility and
cost-effectiveness.18,19 Mindfulness-based cognitive therapy (MBCT) is a psychosocial group-based relapse
prevention programme. It was developed from translational research into mechanisms of depressive
relapse/recurrence.20 It is recommended by NICE as a psychological approach to relapse prevention for
people who are currently well but who have experienced three or more previous episodes of depression.8
There is much clinical enthusiasm for MBCT, as evidenced by the high rates of patient engagement, the
development of MBCT therapist training programmes in the UK at the Universities of Bangor, Exeter and
Oxford and more recently the development of an All Party Parliamentary Group on Mindfulness.21
Implementation of MBCT throughout the NHS is patchy and variable but becoming more widespread.22,23
In summary, MBCT shows the potential to contribute significantly to reducing the prevalence of depression
in UK primary care settings.
DOI: 10.3310/hta19730 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 73
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Kuyken et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Review of the evidence for mindfulness-based cognitive
therapy up to the trial start date
Efficacy and effectiveness
The first two MBCT randomised controlled trials (RCTs) of patients with a history of recurrent depression,
currently in remission and not receiving any active treatment, reported in 200024 and 2004.25 Both found that
MBCT plus usual care halved the rate of relapse/recurrence compared with usual care alone over 60 weeks
of follow-up [hazard ratio (HR) 0.47, 95% confidence interval (CI) 0.27 to 0.84;25 HR 0.28, 95% CI 0.13 to
0.6024]. In both trials patients were able to seek help as they normally would over the course of the study
and rates of treatment update were comparable across both arms of the trial. However, to provide a robust
test of the potential effectiveness of MBCT over usual care, both trials included only people not currently
receiving antidepressant medication (ADM) at the time of study entry. Moreover, as a first test of MBCT, the
comparison was usual care rather than another active treatment.
A systematic review published in 2007 that included these first two trials and two further replications in
Europe showed a significant additive effect of MBCT over usual care for patients with recurrent depression,
but only for patients who have experienced three or more previous episodes.26 This is the same evidence
that led to NICE’s guidance that MBCT be offered as a relapse prevention approach to patients with three
or more episodes of depression.
Exploratory pilot trial
Through a Medical Research Council (MRC)-funded pilot trial27–29 we sought to address the gaps in the
evidence base outlined in the previous section by comparing MBCT with the current mainstay approach
to relapse prevention, m-ADM. In this pilot trial 123 patients who were currently taking m-ADM to
manage recurrent depression were randomised to either continue m-ADM or take part in a MBCT course
and then taper and discontinue their m-ADM. The findings suggested that MBCT may not only provide
an alternative to m-ADM (relapse/recurrences at 15 months: MBCT 47%, m-ADM 60%), but also,
in an adequately powered definitive trial, produce superior outcomes (Figure 1).28 Finally, the study
suggested that MBCT may also be superior to m-ADM in terms of improved quality of life, reduced
residual depressive symptoms and reduced psychiatric comorbidity. The study’s stated aims and
outcomes were:
i. Examine feasibility. The achievement of all study milestones within budget and on time
demonstrated feasibility.
ii. Establish recruitment methods. An acceptable and effective recruitment methodology was developed as
evidenced by our over-recruitment by 54%.
iii. Establish a training model for MBCT therapists. We developed a model of training with input from
John Teasdale, one of the developers of MBCT.
iv. Cost MBCT. The MBCT intervention was estimated to cost circa £200 per participant,28 which compares
favourably with an estimated cost of £750 for individual CBT.16
v. Elicit service user feedback. At the end of the pilot trial all participants were interviewed and asked
about their experience of MBCT as a relapse prevention programme.30 These studies informed
the PREVENT study to maximise MBCT’s acceptability and application to supporting patients taper
and discontinue their m-ADM.
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Costs and cost-effectiveness
To inform commissioning of care for people with recurrent depression we must establish MBCT’s
cost-effectiveness over an adequate follow-up period. In our pilot trial28 we found that the per-person cost
for the MBCT group was £274 more than that for the m-ADM group but this difference was not significant.
Cost-effectiveness analyses suggested that the additional cost of MBCT may be justified in terms of
improvement in the proportion of patients who undergo relapse/recurrence, but only if willingness to pay
for such improvements is ≥ £600. In terms of depression-free days, the incremental cost-effectiveness ratio
(ICER) of MBCT is comparable with that in similar studies, with a ratio of £30 per depression-free day for
total costs and £14 per depression-free day for health service costs. (Please note that these costs were reported
in reference 28 in international dollars using a conversion rate of 0.6.) Recent ICERs for collaborative care
programmes include £20 in terms of total outpatient costs31 and £12 in terms of total inpatient and outpatient
costs.32 Estimates of £8–14 have been reported for a depression relapse prevention programme.33 Exploration
of costs over time suggested that differences in cost converge and MBCT becomes cheaper than m-ADM over
the final 3-month period of the study. If this trend were to continue, the relative cost-effectiveness of MBCT
may increase over time. Future studies should consider longer follow-up periods to test this hypothesis.
Process studies to examine acceptability and mechanism
of change
As with the cost-effectiveness of MBCT, the evidence for the mechanism of change in outcomes with MBCT
therapy is limited. Coelho et al.26 found no evidence of the ‘specific effectiveness of MBCT, despite this being
the logical progression from the current research’ (p. 1004). In other words, no trials had shown whether
MBCT works through its specific hypothesised mechanisms and/or through non-specific cognitive–behavioural,
psychoeducation and group/therapist support components. They therefore recommended ‘the need for
randomised controlled trials to compare MBCT with other non-pharmacological approaches’ (p. 1005) and the
inclusion of tests of the specific and non-specific mechanisms of change.
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FIGURE 1 Kaplan–Meier survival curve in the exploratory trial. Survival estimates by intention to treat.
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Proposed mechanisms of action
Mindfulness-based cognitive therapy’s theoretical premise is that depressive relapse/recurrence is associated
with the reinstatement of negative modes of thinking and feeling that contribute to depressive relapse and
recurrence.34 This ‘reactivated’ network of negative thoughts and feelings can perpetuate into a depressive
episode. Laboratory studies support this model by showing that recovered depressed patients revert to a
depressive information processing style following a sad mood induction (for a review see Segal et al.35).
Following successful treatment for depression, those patients showing greater reactivation of dysfunctional
thinking styles in response to a sad mood provocation are at the highest risk of relapse/recurrence over an
18-month period.35 Moreover, patients who recovered with CBT showed significantly less cognitive
reactivation than those who recovered with ADM. Attenuating the reactivation of dysfunctional thinking
styles may therefore represent one mechanism by which CBT helps prevent depressive relapse/recurrence.
Mindfulness skills are taught as a means to note distressing thoughts and feelings, hold such experiences in
awareness and cultivate acceptance and self-compassion to break up associative networks and offset the risk
of relapse/recurrence.34 This dimension of mindfulness, which involves meeting distressing thoughts and
feelings with kindness, empathy, equanimity and patience, is woven into mindfulness-based applications and
is thought to be crucial to the change process.36 Intentional attention is learned in the first three MBCT
sessions using a range of core mindfulness practices (the body scan, mindful movement and mindfulness of
the breath). As well as developing attention, these early sessions highlight habitual patterns of reactivity that
arise during meditation (e.g. intrusive negative thoughts) and the associated aversion and judgements
(e.g. ‘I am no good at this, I am just more aware of how badly I feel’). As the person learns mindfulness skills,
he or she learns to give less authority to self-judgement and blame – the fuel for depressive thinking – and to
respond to these states with compassion, in short to step out of habitual unhelpful patterns of thinking.36
Elucidating these putative mechanisms of action of MBCT will improve theoretical understanding of how this
relatively new treatment works and provide the opportunity to enhance efficacy through emphasis of
these mechanisms.
Our previous mechanisms study, which was embedded in the pilot trial, demonstrated that, consistent with
MBCT’s theoretical premise, increases in mindfulness and self-compassion across treatment mediated
the effect of MBCT on depressive symptoms at 15 months’ follow-up.37 Furthermore, MBCT changed the
relationship between post-treatment cognitive reactivity and depressive outcome. In patients receiving
m-ADM, greater reactivity predicted poorer outcome, replicating previous findings.35 However, following
MBCT there was no support for this toxic relationship between reactivity and outcome, with an indication
that enhancement of self-compassion had nullified this relationship. These findings were consistent with an
evidence synthesis arguing that MBCT works through a ‘retraining of awareness and non-reactivity, allowing
the individual to more consciously choose those thoughts, emotions, and sensations, rather than habitually
reacting to them’ (p. 569).38 The results are also in line with data using a self-report measure of cognitive
reactivity showing that MBCT attenuates reactivity and its impact on depression.39 This is reflected in distinct
neural responses to sad mood in people who had undergone MBCT, suggesting a neural basis for these
findings.40 The findings suggest that, whereas negative mood may reactivate dysfunctional thinking patterns
in people who have participated in a MBCT class, it is their response to these dysfunctional thoughts that is
altering their impact at follow-up.
Rationale for the research
In summary, the evidence for MBCT indicates that it is more effective than usual care in preventing depressive
relapse/recurrence in people with a history of three or more episodes. Moreover, there is preliminary evidence
from our pilot trial to indicate that it may be cost-effective and that it works through its hypothesised
mechanism. An editorial published in 2012 in the British Medical Journal41 concluded that key remaining
uncertainties include (1) whether or not MBCT provides an alternative for people wishing to discontinue
m-ADM, (2) how acceptable MBCT is and (3) what mechanism MBCT works through.
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Aims and objectives
The overarching policy aim and research question of the PREVENT trial was to establish whether MBCT
with support to taper and/or discontinue antidepressant medication (MBCT-TS) is superior to and more
cost-effective than an approach of m-ADM in a primary care setting for patients with a history of recurrent
depression followed up over a 2-year period.
The specific objectives of the PREVENT trial were to compare MBCT-TS and m-ADM for patients with
recurrent depression in terms of:
l time to depressive relapse/recurrence over 2 years (primary outcome)
l depression-free days, residual depressive symptoms and health-related quality of life at 1 month post
treatment and 9, 12, 18 and 24 months post randomisation and psychiatric and medical comorbidity at
12 and 24 months post randomisation (secondary outcomes)
l costs and cost-effectiveness as assessed by incremental cost per relapse/recurrence prevented and
incremental cost per quality-adjusted life-year (QALY) at 1 month post treatment and 9, 12, 18 and
24 months post randomisation.
In addition, we asked whether or not an increase in mindfulness skills is the key mechanism of change
of MBCT.
To address these policy and explanatory questions patients were recruited through primary care and
treated in accessible primary care or community settings. This was a single-blind, parallel RCT examining
MBCT-TS compared with m-ADM. The m-ADM was constant over the 2 years of the study and the
psychosocial intervention was a front-loaded, 8-week relapse/recurrence prevention programme. Patients
in the MBCT-TS arm received support to taper their ADM. The process studies employed mixed methods.
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Chapter 2 Mindfulness-based cognitive therapy
with support to taper and/or discontinue
antidepressant medication
Mindfulness-based cognitive therapy
Mindfulness-based cognitive therapy is an 8-week, group-based programme (12–15 participants per group)
designed to teach skills that prevent the recurrence of depression.20 It is derived from both mindfulness-based
stress reduction (MBSR), a programme with demonstrated efficacy in ameliorating distress in people suffering
chronic disease,42 and CBT for acute depression,43 a programme with demonstrated efficacy in preventing
depressive relapse/recurrence.44 MBCT is based on theoretical and empirical work showing that depressive
relapse/recurrence is associated with the reinstatement of automatic modes of thinking, feeling and
behaving that are counterproductive in contributing to and maintaining depressive relapse and recurrence
(e.g. self-critical thinking and behavioural avoidance).45
Participants learn to recognise these ‘automatic pilot’ modes and respond to them in more functional
ways by employing complementary cognitive–behavioural and mindfulness practices. This involves
recognising early warning signs of depressive relapse/recurrence, being able to ‘turn towards’ them with
kindly interest and decentring in ways that ‘nip them in the bud’. The cognitive–behavioural component
involves responding to negative thinking and behavioural activation. In the latter stages of the course
participants develop a ‘response/action plan’ that sets out strategies for responding when they become
aware of early warning signs of relapse/recurrence. The mindfulness component involves extensive practice
of mindfulness skills (e.g. meditation practices) designed to improve participants’ attentional control,
ability to decentre from negative thinking and emotion regulation and increase self-compassion. There is
a movement towards meeting difficulty with curiosity, a quality of allowing and self-compassion before
deciding on skilful ways of responding. Participants are encouraged to bring these skills in to all aspects of
their lives.
Adaptations made to the mindfulness-based cognitive therapy
programme for the PREVENT trial
In the PREVENT trial delivery of MBCT followed the manual as described by Segal, Williams and Teasdale34
with a few adaptations based on (1) the need for therapists to support MBCT participants in tapering their
ADM and (2) experience from the pilot trial.28 Participants attended a one-to-one orientation session with the
therapist followed by group sessions lasting 2.25 hours over 8 consecutive weeks. Session content included
guided mindfulness practices (i.e. body scan, sitting meditation, movement); inquiry into participants’
experience of these practices; weekly review of home practice (i.e. 40 minutes of mindfulness practice per
day with the guidance of a CD, bringing mindfulness into everyday life); and teaching of/dialogue around
cognitive–behavioural skills. MBCT-TS patients also received an additional four group reunion sessions during
the first year of follow-up to provide ongoing support and rehearse the key components of the interventions.
The first of these booster sessions occurred within 3–5 weeks after the end of the 8-week MBCT-TS
programme as this was the time when patients would be tapering their ADM and may be in most need of
support. Such booster sessions significantly enhance relapse/recurrence prevention46 and were a match for
general practitioner (GP) attention, which was part of ongoing clinical management in the m-ADM group.
A list of the individual adaptations and when they were made is provided in Table 1.
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TABLE 1 Adaptations to the MBCT programme
Rationale for adaptation Adaptation When it came into effect
Preparation for tapering of
medication at session 6 by
increasing understanding of
relapse/recurrence and ways of
taking action/responding at an
earlier stage
l Inviting participants to complete
a short questionnaire prior to
the orientation session around
relapse/recurrence signatures and
ways of taking action
l Broadening relapse/recurrence
signature to include responding
(to link with what is learned on the
8-week course) as well as action
l Basing the learning about participants’
depression at orientation around their
relapse/recurrence signature
l In the 1-hour one-to-one orientation
session with the therapist prior to
the group starting
l Having the relapse/recurrence
signature and ways of
responding/acting as work
in progress throughout the
course – holding it in mind and
actively adding to it
l Referring to the relapse/recurrence
signature at appropriate moments
in inquiry throughout the course
l Actively inviting dialogue as part of
the home practice review from
session 3 onwards
Involving GPs in the participants’
response plan
l Inviting participants to provide a
copy of their plan for us to send to
their GP on completion of the group
with the discharge letter
l Relapse/recurrence signature/action
plan introduced at the orientation
session
l Plan collected at first follow-up
Supporting participants around
the early stages of tapering
l The first follow-up session was
planned shortly after the group
ended (3–5 weeks)
l The content was around maintaining
practice, turning towards the difficult
and adding to relapse/recurrence
signatures. This session was with the
original group but subsequent
follow-up sessions involved merged
groups from all trial groups
l 3–5 weeks after session 8 – this
date was included with the initial
dates and so in many ways felt like
session 9
Teaching about depression at an
experiential level, allowing
participants to track their process
with awareness, to illustrate the
potential for relapse/recurrence
around a drop in mood and how
mindfulness may offer the
possibility of somewhere else to
stand rather than being dragged
down the spiral
l A sequence of introducing the
automatic thoughts questionnaire as
a practice, brief inquiry, breathing
space, brief inquiry, watching slides
from The Black Dog illustrated book,
brief inquiry, walking practice, brief
inquiry, ‘Healing from Within’ DVD,
summary of session
l Session 4
Allowing more space for
working with difficulty
l Simplifying the sitting practice to
include breath, body and working
with difficulty. Following this up with
an optional CD ‘Exploring the
Difficult’ for home practice
l Session 5
MINDFULNESS-BASED COGNITIVE THERAPY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Chapter 3 Trial design and methods
Study design
The PREVENT trial was a two-arm, multicentre, single-blind superiority trial randomly allocating patients in
a 1 : 1 ratio to receive either MBCT-TS or m-ADM. The trial included a parallel economic evaluation to
examine the cost-effectiveness of MBCT-TS compared with m-ADM and a mixed-methods process
evaluation that used qualitative methods to assess the acceptability of MBCT-TS from the perspectives of
patients and included a quantitative analysis of potential mediators.
Setting, participants and recruitment
We recruited participants from 95 general practices in urban and rural settings in four UK centres:
Bristol, Exeter and East Devon, North and Mid Devon and South Devon. Inclusion and exclusion criteria for
patient participation were refined through the pilot trial28 to maximise real-world applicability to the
population of people in primary care with recurrent depression who are treated with ADM and who are
interested in considering a psychological approach to relapse/recurrence prevention. They are also based
on our experience of running a Devon NHS Primary Care Trust-commissioned depression service
(see www.centres.ex.ac.uk/mood/).
Inclusion criteria
Participants were considered for inclusion if they:
l had a diagnosis of recurrent major depressive disorder in full or partial remission according to the
Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)47
l had had three or more previous major depressive episodes in which depression was the primary
disorder and it was not secondary to substance abuse, bereavement or a general medical condition
l were aged ≥ 18 years
l were on a therapeutic dose of ADM in line with the British National Formulary (BNF)48 and
NICE guidance8
l were open either to continue taking antidepressants for 2 years or to take part in a MBCT class and
consider stopping their ADM.
Exclusion criteria
Participants were considered unsuitable for inclusion if they:
l were currently depressed, as assessed using the Structured Clinical Interview for DSM-IV (SCID)47
l had a comorbid diagnosis of current substance abuse (patients with previous substance abuse were
eligible for inclusion as long as they were in sustained full remission)
l had organic brain damage
l had current/past psychosis, including bipolar disorder
l displayed persistent antisocial behaviour
l engaged in persistent self-injury that required clinical management/therapy
l were undergoing formal concurrent psychotherapy.
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Recruitment procedure
The recruitment strategy for the PREVENT trial built on the protocol used in the pilot trial, which proved
acceptable and effective.29 This is summarised in the following pathway:
1. General practice searches identified patients who had been prescribed ADM at a therapeutic dose in
the last 3 months.
2. GPs were then asked to screen this list to exclude any patients who they knew met the
exclusion criteria.
3. Letters were sent to the remaining patients enclosing an information pamphlet and reply form.
4. Interested patients were telephoned to discuss the study and a short eligibility screening interview was
conducted over the telephone. Information about the study and MBCT was available to help people to
begin to make an informed decision about participation. This included the timings and locations of the
MBCT groups. The vast majority of exclusions were identified at this stage.
5. Patients who met the telephone screening criteria were invited to attend a face-to-face
baseline interview.
6. Consenting patients who met the PREVENT inclusion criteria joined the trial during the
baseline assessment.
7. Within a month of the start of the next MBCT-TS group a current GRID-Hamilton Depression Rating
Scale (GRID-HAMD)49 score was obtained for each participant so that randomisation could occur.
Although the majority of referrals were through GP surgeries, interested patients were also able to
self-refer into the study. We employed a number of different strategies to advertise the trial including
placing posters in carefully targeted sites, developing a website, regional media coverage and leaflet
dropping in local chemists.
Patients were recruited in cohorts during recruitment ‘time slices’ that corresponded to the 6–8 weeks
before the next MBCT-TS group was due to start. Baseline assessments were conducted as close as
possible to the start of the MBCT-TS group as residual depressive symptoms are a powerful predictor of
relapse/recurrence.50 On average, each researcher recruited six patients per month (Figure 2).
Randomisation and concealment
Patients were randomised in a 1 : 1 ratio to either MBCT-TS or m-ADM using computer-generated random
permuted blocks and stratified by recruitment locality (four sites) and symptomatic status (asymptomatic:
GRID-HAMD score < 8 vs. partially symptomatic: GRID-HAMD score ≥ 8). Stratification by locality enabled a
proportionate workload for research staff and therapists. Residual depressive symptoms are a powerful
predictor of relapse/recurrence.50 Moreover, the pilot trial suggested the importance of this stratification
variable in predicting outcome.27 To ensure concealment randomisation was conducted using a
password-protected trial website that was maintained by the Peninsula Clinical Trials Unit (CTU), a UK
Clinical Research Collaboration (UKCRC)-accredited CTU. Participants were informed of the outcome of
randomisation in a letter sent from the trial administrator. Research assessors were blind to treatment
allocation; in cases in which blindness was broken participants were assigned to another research assessor.
The fidelity of this masking was moderate, with assessors correctly guessing allocation for 56% of assessments.
Given the nature of the interventions, patients and clinicians were aware of treatment allocation.
Patients were randomised in the month before the next MBCT-TS group began. If a participant’s baseline
assessment occurred more than a month before the next MBCT-TS group began he or she received a brief
‘randomisation assessment’ before being randomised. During this assessment the patient was asked to
give a verbal reaffirmation of his or her wish to take part in the trial and researchers ensured that the
patient’s situation had not changed significantly and also obtained a current GRID-HAMD score.
TRIAL DESIGN AND METHODS
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Case note screening identifies eligible patients
GP reviews list against inclusion/exclusion criteria
Patient sent information and reply form
Patient expresses an
interest in PREVENT 
Patient self-refers
to PREVENT 
Telephone assessment
Telephone randomisation assessment – within
1 month from start of next MBCT-TS group
GRID-HAMD, verbal reaffirmation of consent 
Patient randomised to MBCT-TS
Patient randomised to m-ADM
Face-to-face MBCT + 1 assessment
SCID (mood disorders section),
GRID-HAMD, BDI-II, EQ-5D, WHOQOL
Attend MBCT-TS
Face-to-face baseline assessment: within
1 month from start of next MBCT-TS group
SCID with psychiatric comorbidity, GRID-HAMD,
BDI-II, MSCL, EQ-5D, WHOQOL  
Face-to-face baseline assessment: 1–3 months
from start of next MBCT-TS group
SCID with psychiatric comorbidity, BDI-II, MSCL,
EQ-5D, WHOQOL 
Face-to-face 9-month assessment
SCID (mood disorders section),
GRID-HAMD, BDI-II, EQ-5D, WHOQOL 
Randomisation
GP excluded
patients 
Face-to-face 12-month assessment
SCID with psychiatric comorbidity,
GRID-HAMD, BDI-II, MSCL, EQ-5D, WHOQOL
Face-to-face 18-month assessment
SCID (mood disorders section),
GRID-HAMD, BDI-II, EQ-5D, WHOQOL 
Face-to-face 24-month assessment
SCID with psychiatric comorbidity,
GRID-HAMD, BDI-II, MSCL, EQ-5D, WHOQOL 
FIGURE 2 Summary of the PREVENT recruitment process and follow-up assessments. BDI-ll, Beck Depression Inventory,
second edition; EQ-5D, European Quality of Life-5 Dimensions; MSCL, Medical Symptom Checklist; WHOQOL, WHO
Quality of Life.
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Health technologies assessed
Maintenance antidepressants
The m-ADM relapse/recurrence prevention intervention consisted of maintenance of the ADM treatment
that was an inclusion criterion for the trial. Participants were monitored and treated by their physician in a
primary care setting. During the maintenance phase, physicians were asked to manage m-ADM in line with
standard clinical practice and the BNF. Primary care physicians were asked to meet with patients regularly
to review their medication. Changes in medication sometimes occurred during the maintenance treatment
stage but physicians and participants were asked to ensure that the dose remained within therapeutic
limits. The trial GPs (Dr Richard Byng and Dr David Kessler) and trial psychiatrist (Professor Glyn Lewis)
provided materials for all participants and participating GPs on m-ADM and ongoing support as required.
We encouraged participants to adhere to medication for the full length of the trial by sending them letters
signed by the chief investigator and their GP after each follow-up, reminding them that the trial was seeking
to compare staying on antidepressants for 2 years with taking part in mindfulness classes and stopping ADM.
If difficulties with continuation of medication were identified, the trial manager first contacted the participant
to understand the difficulty and then whenever appropriate encouraged the participant together with his or
her GP to consider maintaining m-ADM in line with standard clinical practice and the BNF. Patients in the
m-ADM arm who did not maintain m-ADM in line with BNF and NICE guidelines still remained in the trial and
follow-up data were collected as per those who did maintain m-ADM in line with guidelines.
Mindfulness-based cognitive therapy with support to taper and/or
discontinue antidepressant medication
A total of 21 MBCT-TS groups were delivered by four therapists in a variety of settings including university
campuses, hospital sites and other community-based rooms. Two of the therapists ran seven groups, one ran
five and one ran two groups. Two of the groups ran in the evening and the rest were held during the day
from Monday to Friday. There were between 4 and 14 participants in each group with an average of
10 per group [standard deviation (SD) 2.6 per group]. The treatment programme involved eight 2.25-hour
group sessions, normally over consecutive weeks, with up to four refresher sessions offered in the year
following the end of the 8-week programme. In line with previous MBCT trials,24,28,51 an adequate dose of
MBCT-TS was defined as participation in at least four of the eight MBCT-TS group sessions. If participants did
not receive an adequate dose of MBCT-TS they were not asked to taper/discontinue their m-ADM; however,
outcome data were still collected as per those who did receive an adequate dose.
The four MBCT therapists were all mental health professionals (two clinical psychologists and two occupational
therapists). They had post-qualification experience ranging from 9 to 30 years, with an average of 19 years
(SD 8.9 years). All had extensive training and experience in leading MBCT groups (minimum 4 years) and a
long-standing ongoing personal mindfulness practice (minimum 7 years). An independent check on therapist
competency was established before therapists progressed to running trial groups. An experienced MBCT
therapist independent of the trial rated at least two videotapes of MBCT-TS therapy sessions and, using the
Mindfulness-Based Interventions – Teacher Assessment Criteria (MBI-TAC),52 made an overall judgement about
whether the therapists were competent. During the trial, all four therapists received supervision every 2 weeks
for 3 hours; this was attended once per month by the chief investigator.
All trial groups were videotaped with a digital camera for therapist supervision and checks on therapist
competence and adherence. Randomly selected samples of two sessions for each 8-week course
(42 sessions in total) were assessed by a MBCT expert independent of the trial team. As for the initial
competency checks the MBI-TAC was used and these checks indicated that the MBCT teaching was at and
above required levels (Table 2). The mean total adherence score in the trial (23.6, SD 4.30) was at least
comparable with those reported in the psychometric evaluation of this scale53 and indicate acceptable
adherence to protocol. There were no significant differences between therapists’ total adherence scores as
determined by one-way analysis of variance (ANOVA) (F3,37= 0.64; p= 0.59).
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Participants in the MBCT-TS arm were encouraged to taper and discontinue their m-ADM and the study
team provided guideline information to physicians and participants about typical tapering/discontinuation
regimes and possible withdrawal effects; however, the actual timeline and regime used were determined
by physicians and participants. The original MBCT manual34 was adapted to include more work on
developing a relapse/recurrence signature and response plan that explicitly included participants considering
reduction/discontinuation of m-ADM. Participants in the MBCT-TS arm who experienced a significant
deterioration following tapering were encouraged to use the skills developed as part of the treatment. Letters
signed by the chief investigator and trial GP were sent to each participant’s GP, copied to the participant,
prompting the GP to have a discussion with the participant about a suitable tapering/discontinuation regime
after 4–5 weeks of the MBCT-TS group. At the end of the MBCT-TS group another letter was sent reminding
the GP to ensure that a tapering/discontinuation regime was in place. We also encouraged participants to
taper/discontinue their medication by writing to them and their GP after each follow-up reminding them that
the trial was seeking to compare staying on antidepressants with taking part in mindfulness classes and
stopping ADM.
If at any time the study team became aware of difficulties with medication tapering/discontinuation, the
trial manager first contacted the participant to understand the difficulty and then whenever appropriate
encouraged the participant together with his or her GP to once more consider tapering/discontinuing
m-ADM. Participants in the MBCT-TS arm who did not taper or discontinue their m-ADM still remained in
the trial and follow-up data were collected as per those who did discontinue.
If participants experienced a relapse/recurrence during the course of the trial we encouraged them to
discuss the most appropriate treatment with their GP and made no further requests that they consider
tapering/discontinuing their medication. However, participants who had relapsed still remained in the trial
and further secondary outcome data were collected on the same schedule as per participants who had
not relapsed.
TABLE 2 Profile of MBCT session teacher competency scores across the 42 sampled sessions
MBI-TAC domains
Count (and percentage) for each rating across 42 tapes
Incompetent Beginner
Advanced
beginner Competent Proficient Advanced
Coverage, pacing and organisation
of the session curriculum
0 (0) 0 (0) 1 (2.4) 5 (11.9) 14 (33.3) 22 (52.4)
Relational skills 0 (0) 0 (0) 1 (2.4) 8 (19.0) 10 (23.8) 23 (54.8)
Embodimenta 0 (0) 0 (0) 1 (2.4) 8 (19.5) 13 (31.7) 19 (46.3)
Guiding mindfulness practices 0 (0) 0 (0) 3 (7.1) 1 (2.4) 15 (35.7) 23 (54.8)
Conveying course themes through
interactive inquiry and didactic
teaching
0 (0) 0 (0) 2 (4.8) 7 (16.7) 15 (35.7) 18 (42.9)
Facilitation of the group learning
environment
0 (0) 0 (0) 2 (4.8) 12 (28.6) 11 (26.2) 17 (40.5)
a Under the domain of embodiment there was one occasion when the external assessor felt unable to rate.
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Data collection
Baseline assessments did not occur more than 3 months from the start of the next MBCT-TS group, with
the start defined as the first orientation session. Following randomisation, participants were assessed at
five time points: 1 month after the end of the 8-week MBCT-TS programme (or the equivalent time in the
m-ADM arm), which varied between 12 and 24 weeks post randomisation, and 9, 12, 18 and 24 months
post randomisation.
Outcomes
Primary outcome
The occurrence of any depressive relapse/recurrence, and time from randomisation to relapse/recurrence,
were assessed using the Longitudinal Interval Follow-up Evaluation (LIFE),54 a form of the SCID47 designed
for longitudinal studies of depression. A participant was judged to have had a relapse/recurrence if he or
she was diagnosed as having a major depressive episode (a score of 5 for 2 consecutive weeks) at any
time during the 24-month follow-up period. In conducting the SCID-LIFE interviews, researchers took care
to establish the onset of the relapse/recurrence as closely as possible. If the day could not be established
they tried to establish the closest week and take the mid-point of that week; if the week could not be
established then the closest month or season was established and the mid-point taken.
An experienced clinical psychologist with formal training in the use of the SCID supervised the training
of the research staff. To examine inter-rater reliability, we followed the method described in the
first MBCT RCT,24 which had the added benefit of guaranteeing that all assessments were carried out
blind to treatment condition. For every first actual, borderline or probable relapse/recurrence, a blinded and
experienced rater second rated an audio recording of the SCID interview. In total, 198 recordings were
second rated, with agreement being recorded on 89.9% of the recordings. The kappa coefficient for
agreement between the study interviewer and the blinded rater was 0.62, suggesting good agreement.
When there were disagreements between the first and second rater, consensus was reached through
discussion. If a relapse/recurrence was considered marginal, a conservative position of no relapse was
recorded. Once a judgement about relapse/recurrence was made, the onset of relapse/recurrence was dated
from randomisation to the point at which criteria were met.
A subset of 112 SCID diagnoses were also second rated by an experienced rater who was independent of
the trial and agreement was recorded on 95.5% of these diagnosis. The kappa coefficient for these ratings
was 0.89, suggesting excellent agreement.
Secondary outcomes
Depression-free days were calculated using the SCID interview and residual depressive symptoms were
assessed with the observer-rated interviewer-administered 17-item GRID-HAMD49 and a well-established
self-report measure, the Beck Depression Inventory, second edition (BDI-II).55 Psychiatric comorbidity was
assessed with the full SCID,47 medical comorbidities were assessed at baseline, 12 and 24 months using the
MSCL56 and health-related quality of life status was assessed using the European Quality of Life-5 Dimensions
three-level version (EQ-5D-3L)57,58 and the WHO Quality of Life-BREF (WHOQOL-BREF).59,60
Depression-free days
Depression-free days were calculated from the SCID by first establishing the duration in days of any episodes
of depression throughout the follow-up period using the method described earlier. Care was taken to establish
the last day of a relapse/recurrence or recurrence of clinically significant symptoms. As before, if the day could
not be established then the mid-point of the shortest time period that could be established was used. Each
new reported recurrence of depression required that there was a period of 2 months in which remission from
the previous episode had been achieved. If there was no remission between two recorded episodes the second
episode was regarded as a continuation of the first.
TRIAL DESIGN AND METHODS
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Residual depressive symptoms
The GRID-HAMD is a 17-item modified version of the popular depression rating scale developed by
Hamilton in 1960.61 This scale is an interviewer-administered measure of depressive symptoms with an
emphasis on somatic symptoms. Scores range from 0 to 88, with higher scores representing higher levels
of depression. The GRID-HAMD was designed to permit the rater to consider the dimensions of intensity
and frequency independently for each relevant item in the scale. Symptom intensity is considered on the
‘vertical axis’ and symptom frequency on the ‘horizontal axis’. Symptom intensity, which includes degree of
symptom magnitude as well as subjective distress and functional impairment, is rated as absent, mild,
moderate, severe or very severe. Symptom frequency is rated as absent, occasional, much of the time or
almost all of the time. The GRID-HAMD was administered at every assessment during the 24-month
follow-up period.
The vast majority of depression trials fail to measure or report the reliability of their employed instruments,
especially secondary outcome measures such as the GRID-HAMD. In the rare circumstances in which reliability
is measured, it is carried out in an arbitrary and atheoretical manner. As such, and for the purposes of this trial,
we compared the inter-rater reliability of the GRID-HAMD using a subsample of 20 assessments. This sample
size was selected in accordance with the method of Walter et al.62 for calculating the sample size for inter-rater
reliability analyses. Walter et al.62 estimated that a sample size of about 18–20 observations made between
two raters is sufficient to obtain an expected intraclass correlation coefficient (ICC) of 0.9, with a minimum
acceptable ICC of 0.7. Further, there is evidence which suggests that the reliability of the GRID-HAMD ratings
is dependent on the assessor’s experience.63 Thus, 10 of the 20 observations were randomly selected from
assessments completed by an experienced assessor and 10 were selected from assessments completed by a
more novice assessor. All 20 assessments from both researchers were obtained from the 18-month follow-up
period. The overall ICC for the 20 observations was 0.98, suggesting excellent agreement. The ICC for
the 10 assessments completed by the experienced assessor was 0.99, while the ICC for the remaining
10 assessments completed by the novice assessor was 0.86, both suggesting excellent agreement.
The BDI-II55 is a 21-item self-report instrument developed to measure the severity of depression with an
emphasis on affective and cognitive symptoms. Higher scores represent greater depression severity
(range 0–63) and minimal (0–13), mild (14–19), moderate (20–28) and severe (29–63) symptom severity
ranges have been specified. The BDI-II was administered at every assessment during the 24-month
follow-up period.
Medical and psychiatric comorbidities
We used the MSCL and the SCID relevant modules at baseline and 12 and 24 months’ follow-up. The
MSCL is a list of 115 common medical symptoms and respondents are asked to indicate those that they
have experienced as bothersome in the past month.56 The score is the total number of symptoms checked.
Although the reliability and validity of the MSCL have not been evaluated, several studies of MBSR have
shown significant reductions in the MSCL score associated with participation in the programme.64–67
Health-related quality of life
Health-related quality of life status was assessed using the EQ-5D-3L,57,58 a non-disease-specific measure for
describing and valuing health-related quality of life. It has particular value as a measure because it is capable
of generating a generic preference-based measure of outcome (the QALY) that allows for outcomes and
cost-effectiveness to be compared across disease areas.68,69 The measure includes a rating of own health in
several domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a rating of
own health by means of a ‘thermometer’ (score 0–100). It has been used extensively and thus has large
comparative data sets and its psychometric properties are adequate.57 The EQ-5D-3L was administered at
every assessment during the 24-month follow-up period.
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Quality of life was assessed using the WHOQOL-BREF,59,60 a generic 26-item measure covering the domains of
physical health, psychological health, social relationships and environment. It differs from the EQ-5D-3L in
providing a more subjective and holistic assessment of quality of life, rather than a self-report measure of health
status. The WHOQOL-BREF is based on a longer version of the original instrument, the WHOQOL-100.70,71
The WHOQOL-BREF was administered at every assessment during the 24-month follow-up period.
Adverse events
We followed the guidelines laid down by the Medicines and Healthcare products Regulatory Agency (MHRA)
for identifying, acting on and reporting adverse events, which were defined as any event that resulted
in death, was life-threatening, required hospitalisation or prolongation of existing hospitalisation, resulted in
persistent or significant disability or incapacity or consisted of a congenital anomaly or birth defect.
As soon as a researcher became aware of an adverse event they reported this to the trial manager, who
then completed a serious adverse event form (see Appendix 1). Copies of these forms were sent to the
Data Monitoring Committee (DMC), the main NHS Research Ethics Committee and the trial sponsor.
No adverse reactions were judged by these committees to be suspected unexpected serious adverse
reactions or SUSARs.
Sample size
Different relapse prevention interventions with different populations produce different absolute rates of
depressive relapse/recurrence. Therefore, we based our sample size on estimated HRs for MBCT-TS compared
with m-ADM rather than estimated absolute relapse/recurrence rates. We canvassed service users and
clinicians who concurred that a relative reduction in relapse/recurrence of 10% would be clinically important.
We used the systematic review of MBCT compared with usual care for patients with recurrent depression
that reported HRs of 0.28–0.47 for relapse/recurrence.26 We applied several conservative assumptions
(first row of Table 3). First, even though the pilot trial data suggest that the HR was improving in favour of
MBCT as the length of follow-up increased,28 we assumed a HR of 0.63 at 15 months to power the trial at
24-months’ follow-up. Second, even though attrition from MBCT trials to date is consistently < 15%,
we assumed an attrition rate of 20% over the 24 months of follow-up. Finally, in spite of evidence to the
contrary, we assumed that there may be a small clustering effect (ICC= 0.01). The resultant sample size
calculation assumptions and outputs are shown in Table 3, based on 90% power and significance set at
0.05. This led to a total sample size of 420 across the two groups.
For the secondary outcomes, meta-analyses of generic mindfulness approaches suggest medium effect
sizes in terms of changes in depressive symptoms72,73 and our pilot trial suggested medium effect sizes for
the secondary outcomes of residual depressive symptoms, psychiatric comorbidity and quality of life.28 The
sample size estimate for our policy question enabled us to detect a medium between-groups effect size
(standardised mean difference or Cohen’s d= 0.40) for the main secondary outcomes.
TABLE 3 Sample calculation scenarios
Study Comparison Mean HR ICC Design factor Attrition rate
Sample size
per groupa
Conservative scenario MBCT vs. m-ADM 0.63 0.01 1.11 20% 210
Kuyken et al.28 MBCT vs. m-ADM 0.63 –0.02 1.0 7%b 160
Ma and Teasdale25 MBCT vs. usual care 0.28 –0.008 1.0 3%c 14d
Teasdale et al.24 MBCT vs. usual care 0.47 –0.04 1.0 5%c 41d
a Sample size necessary for 90% power at 5% significance at 24 months.
b At 15 months.
c At 60 weeks.
d Assuming exponential survival function.
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Statistical analysis
Statistical analyses were conducted in accordance with International Conference on Harmonisation (ICH-9)
statistical guidelines for clinical trials74 and updated Consolidated Standards of Reporting Trials (CONSORT)
guidelines for trials.75,76 All statistical analyses were undertaken in Stata version 13 (StataCorp LP, College
Station, TX, USA) following a predefined analysis plan agreed with the Trial Steering Committee (TSC).
Baseline equivalence was assessed descriptively by comparing the summary baseline characteristics and
outcome values in both groups (MBCT-TS and m-ADM). Although there was a difference in gender
between groups (see Table 8), as we know of no strong evidence that gender moderates MBCT treatment
outcomes28 it was decided not to include and adjust for this variable in statistical models.
The primary analysis model for all primary and secondary outcomes was conducted on an intention-to-treat
(ITT) basis, that is, between-group comparison based on the random allocation of patients and using
complete data sets. All models adjusted for the stratification variables (centre and severity of depression).
For the primary outcome the primary analysis included all patients and censored for missing data at
24 months’ follow-up. To examine the sensitivity of the results to missing data, secondary outcomes models
were also run following multiple imputation (using the ‘ICE’ and ‘MIM’ Stata commands and 10 imputation
cycles) and based on the assumption that data were missing at random.
The primary outcome (time to relapse/recurrence) was analysed using a Cox regression proportional
hazards model including treatment condition (MBCT-TS/m-ADM). We assessed the proportionality
of hazards over time by plotting −ln[−ln(survival)] against ln(analysis time) and tested this using Schoenfeld
residuals.23,24 We found no major violations of the proportional hazards assumption. Secondary outcomes
were compared using hierarchical repeated measures regression models adjusting for outcome at baseline.
To explore potential treatment moderator effects, interaction terms were included in the Cox regression model
for the primary outcome at 24 months for three predefined subgroups: the two stratification variables (centre
and severity of depression) and participants in two groups characterised by how abusive their childhood had
been. Participants with a more abusive childhood reported experiencing childhood physical or sexual abuse
and/or scored above the median score for the Measure of Parenting Scale (MOPS)77 abuse subscale.
Participants completed the MOPS at baseline as part of an embedded process–outcome study.78 The abuse
subscale asks participants to indicate how true they felt certain statements about their parents’ behaviour was,
for example ‘parent was physically violent or abusive to me’, ‘parent made me feel unsafe’. Participants were
categorised either in the lower abusive childhood group (i.e. scored below the median score for the MOPS
abuse subscale and did not report childhood physical or sexual abuse) or in the higher abusive childhood group
(i.e. scored above the median score for the MOPS abuse subscale or did report childhood physical or
sexual abuse).
Given the variable levels of patient adherence to the stated treatment protocol in both the ADM-m and
the MBCT-TC groups, we sought to undertake predefined secondary (per-protocol) analyses to examine
the potential impact on the primary outcome at 24 months. We first described adherence in the PREVENT
trial according to the principles set out by Dodd et al.79 in their systematic review exploring adherence
reporting in RCTs by reporting the rates of adherence in the format displayed in Box 1.
We then undertook two secondary analyses of the primary outcome comparing groups according to
whether participants had (1) received an adequate dose of treatment and (2) adhered to treatment as
invited. Definitions of these groups are displayed in Table 4.
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Data management
Missingness within an outcome measure
Data entry and cleaning were overseen by the trial manager and research staff checked each outcome
measure for missing data during every assessment and when possible collected missing items at this point.
In cases in which ambiguous data were not clarified with the participant we operated a ‘score down
policy’, meaning that if two items were checked the item with the lower rating was entered. When < 10%
of the total or subtotal items for one outcome were missing, the mean as an integer of the missing items
subscale was imputed in place of the missing value. If > 10% of the total was missing then the whole
questionnaire was recorded as missing and, if > 10% of any one subtotal was missing, the whole of that
subtotal was marked as missing.
Missing assessments
When substantive missing values arose, analyses was undertaken to assess their impact on the findings of
the trial. Missing data were assumed to be ‘missing at random’,80 regression-based models were used to
assess the relationship between covariates and outcome measure in completers and missing cases were
substituted with a predicted outcome value.81 A sensitivity analysis (with and without imputed data) was
undertaken to assess the potential impact of imputation on the trial findings.
BOX 1 Categories of adherence to treatment in each trial arm
For the m-ADM arm
l The number of participants who remained on a BNF therapeutically stable dose for the duration of the trial.
l The number of participants who did not remain on a BNF therapeutically stable dose for the duration of
the trial.
For the MBCT-TS arm
l The number of participants who did not initiate MBCT-TS treatment.
l The number of participants who initiated MBCT-TS treatment.
l The mean, mode and SD of number of MBCT-TS sessions (0–8) and follow-up sessions attended (0–4).
l The number of participants who completed MBCT-TS treatment.
For those who attended four or more MBCT-TS sessions
l The number of participants who made no reduction to their ADM dose.
l The number of participants who reduced their ADM dose.
l The number of participants who discontinued their ADM.
TABLE 4 Definitions of adherence for each reported secondary sensitivity analysis
Group Adequate dose of treatment Adhering to treatment as invited
m-ADM BNF therapeutic dose of ADM throughout
follow-up period
BNF therapeutic dose of ADM throughout
follow-up period
MBCT-TS Attended four or more classes Discontinued or reduced ADM and
attended four or more classes
TRIAL DESIGN AND METHODS
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Ethical approval and research governance
Multicentre ethical approval for the study was given by the South West Research Ethics Committee (reference
number 09/H0206/43) and local research governance approval was obtained for all sites (NHS Devon
covering Exeter and Mid and North Devon – PCT0739; NHS Bristol, covering the Bristol site – 2010–004; NHS
Plymouth and NHS Torbay, covering the South Devon site – PLY-TOR001). The trial was registered with the
International Standard Randomised Controlled Trial Register with the reference number ISRCTN26666654.
This trial was classed as a Clinical Trial of an Investigational Medicinal Product (CTIMP) as the MBCT-TS arm
randomised patients to alter their standard ADM and as such approval to commence the trial was received
from the MHRA (EudraCT number 2009–012428–10). A summary of the changes made to the original
protocol is given in Table 5.
The University of Exeter sponsored the trial, which was hosted in the Mood Disorders Centre
[see www.centres.ex.ac.uk/mood/ (accessed 16 March 2015)], a clinical research setting specialising in
translational research hosting current MRC-, Wellcome Trust-, National Institute of Mental Health- and
National Institute for Health Research Health Technology Assessment (HTA) programme-funded trials.
The trial was overseen by the independent TSC (Chris Leach – Chairperson, Richard Moore and
Glenys Parry) and the DMC (Paul Ewings – Chairperson, Andy Field and Joanne MacKenzie).
TABLE 5 Summary of changes to the original PREVENT protocol approved by the South West Research
Ethics Committee
Change to protocol Date
Case note screening not undertaken by research staff and subsequent changes to the patient
information sheet
December 2009
Replacement of the follow-up measure SHAP with the DPES December 2009
Pilot of 3-month follow-up measures on formally depressed individuals who will not be taking part in
the main trial
December 2009
Ask pharmacists to insert a short flyer about the trial when dispensing ADM December 2009
Reimburse reasonable costs incurred when attending MBCT-TS groups for participants who would
otherwise be unable to join the trial
July 2010
Pilot qualitative feedback booklets with former NHS patients who have taken part in a previous
MBCT group
July 2010
Addition of the FFMQ, SCS, DPES, CERQ and DSC at the 24 months’ follow-up April 2012
Addition of two follow-ups at 36 and 48 months following an invitation from the National Institute
for Health Research HTA programme to submit a bid; however, we were unsuccessful in obtaining
the funding and therefore these additional follow-ups did not take place
April 2012
Collaboration with the Mental Health Research Network (MHRN) to give all participants an exit
questionnaire at their final follow-up exploring the reasons why they chose to take part in
the research
June 2012
Change of principal investigator at the Bristol site because of a move to University College London
(Dr David Kessler replaced Professor Glyn Lewis)
June 2012
Permission to ask for consent to conduct further analysis on participants’ previously provided
DNA sample
August 2013
CERQ, Cognitive Emotion Regulation Questionnaire; DPES, Dispositional Positive Emotions Scale; DSC, Depressed States
Checklist; FFMQ, Five Factor Mindfulness Questionnaire; SCS, Self-Compassion Scale; SHAP, Snaith–Hamilton
Pleasure Scale.
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Informed consent
Our recruitment process gave patients several points at which they could learn about the project, either from
reading the patient summary pamphlet and information sheet or through discussion with their GP, research
staff or others. Consent was finally given through an interview with a researcher following an opportunity
for questions. Research staff were trained and all interviews were recorded and supervised.
Participant welfare
Patients’ GPs approved their participation in the trial and were informed about the outcome of
randomisation. The trial psychiatrist (Glyn Lewis) and GPs (Richard Byng and David Kessler) were on
hand to offer participants’ GPs further information about the trial and to support GPs in their
management of participants’ ADM. At the end of the MBCT-TS group, trial staff wrote to GPs to remind
them that ADM tapering should normally have started and to ask them to be mindful of the possibility of
relapse/recurrence. Over the follow-up period the MBCT-TS patients were invited to attend reunion
sessions every 3 months and the therapists remained available by telephone throughout this period. If
symptom exacerbation occurred without a full relapse/recurrence, initial management was encouraged to
be within the appropriate treatment arm; however, if either patient preference and/or clinical judgement
indicated other interventions, these were pursued.
Confidentiality
All of the information collected was kept strictly confidential and held in accordance with the principles of
the Data Protection Act 1998.82 Each participant was assigned a research number and all data were stored
without subject identification. Data were held on a secure database on a password-protected computer
at the University of Exeter. Access to data was and continues to be restricted to the research team.
To enable follow-up contacts it was necessary to identify patients, but access to contact details (e.g. name
and address) was restricted to the key members of the research team who arranged appointments. Any
information about patients obtained (with their consent) from their medical records was recorded against
their research number. Interviews audiotaped as part of the qualitative study (using a digital voice recorder)
were transcribed verbatim and stored securely. Recordings of MBCT-TS sessions were stored securely
(indexed by research number only) on a password-protected computer at the University of Exeter.
Disclosure of suicidal thoughts protocol
As the participants in this study have depression, it was appropriate to have a policy in place should any
participant disclose suicidal thoughts to a research officer. Research officers assessed participants’
depression status at the study’s intake assessment and at each follow-up, which included questions about
suicidal thoughts and plans. If a participant disclosed any suicidal thoughts the research officer followed
the TSC-approved suicidal thoughts protocol and completed a suicidal thoughts report (see Appendix 1),
which was countersigned by the site clinical lead. The information in this report was forwarded to the
participant’s GP to better inform his or her clinical management. The patient information sheet informed
the participant that if we were very concerned about his or her safety, or someone else’s safety, we would
need to break confidentiality.
Unexpected serious adverse events
We followed the guidelines laid down by the MHRA for identifying, acting on and reporting adverse
events [see www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Clinicaltrials/
Safetyreporting-SUSARSandASRs/index.htm (accessed 16 March 2015)]. We adopted its definitions of
adverse events and serious adverse reactions, reporting a total of 10 serious adverse events, none of which
were classified as SUSARs by the TSC or the DMC.
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Patient and public involvement
The PREVENT trial has benefited from the expertise of many people with lived experience of mental health
difficulties including members of a locally organised voluntary group called the Lived Experience Group
(LEG). The LEG has assisted the PREVENT trial at every stage of its development and the following sections
detail a few examples of the ways in which the PREVENT trial has been shaped by patient and
public involvement.
Protocol development
Patient and public involvement was sought in the development of the initial study protocol when developing
the proposal and in the finalisation of the protocol prior to starting the trial through co-authorship
(Rev. Paul Lanham).
Risk training
We sought the advice of the LEG both on the processes contained in the disclosure of suicidal thoughts
protocol and in training and supporting our research team to activate this protocol. This training was
particularly valuable as many of our team were anxious about discussing suicidal thoughts and did not feel
confident in their ability to explore such thoughts with participants and GPs. The training gave researchers
the chance to role-play these discussions, with advice and reassurance from the LEG.
Seeking consent
A member of the LEG provided specific training to our research staff to ensure that the consenting process
was coherent and transparent.
Patient information
Given the variability of people’s experiences and the importance of the patient information sheet, we
asked a number of different members of the LEG to review the early drafts and combined the suggestions
into our final version.
Management and governance of the trial
Sitting on both our Trial Management Group and our TSC is the previous Chairperson of the Board of
Trustees for the charity Depression Alliance, the Rev. Paul Lanham. Rev. Lanham has a lifetime history of
living with mental health difficulties and his involvement has been key in helping to ensure that the trial is
asking questions that are relevant and valid.
Qualitative interviews and feedback
A large component of our trial was asking the research participants about their experiences of the therapies
offered (see Chapter 7). We did this predominantly by asking all participants to complete an eight-page
feedback booklet and also by conducting in-depth interviews with a subset of participants. Both the feedback
booklet and the interview questions were reviewed and then trialled by several members of the LEG, who
suggested a number of fundamental changes. The benefit of these changes became apparent as we began
the process of analysis and could see the richness of the data that were emerging.
Dissemination of results
It was very important to us that we disseminate the results of our trial to the participants who took part
and that this was carried out in the most sensitive and accessible way possible. We organised three
separate events across the recruitment sites to disseminate the results of our trial to participants and
consulted with a PREVENT trial participant who had since joined the LEG about the format and content
of these events. This participant co-organised and chaired the largest of the events.
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Chapter 4 Trial results
Participant flow
During the 19 months of recruitment, between 23 March 2010 and 21 October 2011, we identified 28,597
patients from GP practice searches. GPs excluded 8989 patients as unsuitable and invitation letters were sent
to the remaining 19,608 patients. Although we asked all GPs to provide reasons for excluding patients, in
56% of cases this information was missing. For the remaining exclusions the most common reasons given
were dementia (2%), psychosis (2%) and substance abuse (1%). In total, 3060 patients responded positively
to our invitation and a further 89 patients self-referred. Full telephone screens were completed for 2188
patients, which resulted in 498 patients attending for a baseline assessment, of whom 424 patients were
randomised. The most common reasons why patients were not eligible for the PREVENT trial were that they
had recently stopped taking ADMs or wanted to reduce them (30%), they had not had three previous
episodes of depression (19%) or they were currently depressed (17%). The reasons given for not wishing to
take part in the PREVENT trial are explored in Chapter 7. Primary outcome data were collected for 90.3%
(383/424) of participants and the remaining participants’ data were censored at their last assessment. We
retained 86.3% (366/424) of participants over the 24-month follow-up period, with 4.7% (20/424) lost to
contact, 8.0% (34/424) withdrawing consent for further follow-up and 0.9% (4/424) dying during the trial;
the pattern of missing data was similar across interventions. The flow of participants through the trial is
depicted in Figure 3.
Missing data
The missing data rates for each time point are shown in Table 6.
Baseline characteristics
Of the 424 randomised participants, 212 were allocated to receive MBCT-TS and 212 were allocated to
receive m-ADM. As indicated in Table 7, baseline characteristics were balanced between the two groups
with the possible exception of gender. As we know of no strong evidence that gender moderates MBCT
treatment outcomes28 we did not add gender to the primary analysis model. It is interesting to note
that the psychiatric history of these participants differs in a number of ways from the history of those
randomised in the pilot trial (Table 8),28 with PREVENT participants reporting lower BDI scores and fewer
comorbidities and a smaller proportion previously attempting suicide. A much larger percentage of the
PREVENT participants also previously accessed psychiatric treatment, which is likely to be the result of the
recent significant progress made in improving the accessibility of evidence-based mental health services in
the UK.4,15,16
Treatment adherence in each trial arm and the extent to which patients followed invitations to (dis)continue
m-ADM are reported in Table 9; > 75% of patients adhered to treatment as intended. Details of the ADM
that was taken are provided in Appendix 2.
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Follow-up
Analysis
Enrolment
Allocation
Excluded (n = 1764)
   1120 not eligible
   644 declined (187
   after telephone screen)
872 could not contact
Randomisation (n = 424)
Invites sent (n = 19,608) 
   1881 declined further contact
   3060 requested more information
   (including 89 self-referrers)
   14,667 no response
Assessed for eligibility (n = 2188)
   2188 telephone screens resulting
   in 498 baselines 
Identified on search (n = 28,597)
8989 GP excluded 
MBCT + 1 follow-up
   186 (87.7%) completed, 17 (8.0%) lost 
   to contact, 9 (4.2%) withdrew
9-month follow-up
   178 (84.0%) completed, 23 (10.8%) lost 
   to contact, 11 (5.2%) withdrew
12-month follow-up
   184 (86.8%) completed, 15 (7.1%) lost
   to contact, 13 (6.1%) withdrew
18-month follow-up
   175 (82.5%) completed, 20 (9.4%) lost to
   contact, 15 (7.1%) withdrew, 2 (0.9%) died
24-month follow-up
   183 (86.3%) completed, 10 (4.7%) lost to 
   contact, 17 (8.0%) withdrew, 2 (0.9%) died
MBCT-TS (n = 212)
   176 (83.0%) completed four or more sessions
   30 (14.2%) initiated treatment but
   attended less than four sessions
   6 (2.8%) did not initiate treatment
MBCT + 1 follow-up
   184 (86.8%) completed, 20 (9.4%) lost
   to contact, 8 (3.8%) withdrew
9-month follow-up
   176 (83.0%) completed, 26 (12.3%) lost
   to contact, 10 (4.7%) withdrew
12-month follow-up
   183 (86.3%) completed, 18 (8.5%) lost 
   to contact, 11 (5.2%) withdrew
18-month follow-up
   175 (82.5%) completed, 20 (9.4%) lost to
   contact, 16 (7.5%) withdrew, 1 (0.5%) died
24-month follow-up
   183 (86.3%) completed, 10 (4.7%) lost to
   contact, 17 (8.0%) withdrew, 2 (0.9%) died
m-ADM (n = 212)
   162 (76.4%) remained on a BNF 
   therapeutic dose of ADM
   50 (23.6%) did not remain on a BNF
   therapeutic dose of ADM
ITT: analysed n = 212 (100.0%)
   0 excluded from analysis
ITT: analysed n = 212 (100.0%)
   0 excluded from analysis 
Received adequate treatment: analysed
n = 176 (83.0%)
   Excluded from analysis due to not attending
      4 sessions: 36 (17.0%) 
Received adequate treatment: analysed
n = 162 (76.4%)
   Excluded from analysis due to not taking
   BNF therapeutic dose: 50 (23.6%) 
Followed invited treatment with respect to
ADM use: analysed n = 153 (72.2%)
   Excluded from analysis due to not reducing
   ADM: 23 (10.8%) and not attending
      4 sessions: 36 (17.0%)
Followed invited treatment with respect to
ADM use: analysed n = 162 (76.4%)
   Excluded from analysis due to not taking
   BNF therapeutic dose: 50 (23.6%)  
Severity of abuse: analysed n = 210 (99.1%)
   Excluded from analysis due to missing
   data: 2 (0.9%) 
Severity of abuse: analysed n = 212 (100.0%)
   Excluded from analysis due to missing
   data: 0 (0.0%) 
>
>
FIGURE 3 The CONSORT flow chart illustrating the flow of participants into the PREVENT trial.
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TABLE 6 Rates of missing data at each time point
Outcome
Number of participants
Baseline MBCT+1 9 months 12 months 18 months 24 months
Primary outcome: days till relapse/recurrence, n (%)
Valid cases – 402 (95) 398 (94) 395 (93) 387 (91) 383 (90)
Censored prior to 24 months – 22 (5) 26 (6) 29 (7) 37 (9) 41 (10)
Secondary outcomes
Depression-free days, n (%)
Valid cases – 402 (95) 396 (93) 392 (92) 377 (89) 366 (86)
Data missing – 22 (5) 28 (7) 32 (8) 47 (11) 58 (14)
Residual depressive symptoms, n (%)
BDI-II
Valid cases 416 (98) 348 (82) 293 (69) 324 (76) 291 (69) 336 (79)
Individual missing items within valid
cases
16 (0.2) 2 (0.03) 3 (0.05) 0 2 (0.03) 0
Participants who contributed no data 8 (2) 76 (18) 131 (31) 100 (24) 133 (31) 88 (21)
GRID-HAMD
Valid cases 424 (100) 369 (87) 352 (83) 365 (86) 348 (82) 366 (86)
Individual missing items within valid
cases
0 0 0 0 0 0
Participants who contributed no data 0 55 (13) 72 (17) 59 (14) 76 (18) 58 (14)
Psychiatric comorbidity: SCID, n (%)
Valid cases 424 (100) – – 392 (92) – 366 (86)
Data missing 0 – – 32 (8) – 58 (14)
Medical comorbidity: MSCL, n (%)
Valid cases 416 (98) – – 323 (76) – 336 (79)
Individual missing items within valid cases 0 – – 0 – 7 (0.02)
Participants who contributed no data 8 (2) – – 101 (24) – 88 (21)
Quality of life: WHOQOL-BREF, n (%)
Valid cases 414 (98) 348 (82) 292 (69) 323 (76) 290 (68) 336 (79)
Individual missing items within valid cases 36 (0.3) 15 (0.2) 8 (0.1) 5 (0.1) 4 (0.1) 3 (0.03)
Participants who contributed no data 10 (2) 76 (18) 132 (31) 101 (24) 134 (32) 88 (21)
EQ-5D-3L
Valid cases 413 (97) 347 (82) 293 (69) 324 (76) 291 (69) 336 (79)
Individual missing items within valid cases 2 (0.1) 0 0 1 (0.1) 0 0
Participants who contributed no data 11 (3) 77 (18) 131 (31) 100 (24) 133 (31) 88 (21)
MBCT+1, assessment point 1 month after the end of MBCT treatment in the MBCT arm and at the equivalent time point in
the m-ADM arm.
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TABLE 7 Baseline characteristics of the trial participants
Characteristic/variable MBCT-TS (n= 212) ADM (n= 212)
Demographic characteristics
Female, n (%) 151 (71) 174 (82)
White, n (%) 210 (99) 210 (99)
Age (years)
Mean (SD) 50 (12) 49 (13)
Range 22–78 20–79
Marital status, n (%)
Single 42 (20) 38 (18)
Married, cohabiting or civil partnership 125 (59) 140 (66)
Separated, divorced or widowed 44 (21) 33 (16)
Missing 1 (0) 1 (0)
Level of education, n (%)
No educational qualifications 10 (5) 10 (5)
Some school qualifications 36 (17) 45 (21)
High school and/or vocational qualification 84 (40) 92 (43)
University degree/professional qualification 77 (36) 61(29)
Missing 5 (2) 4 (2)
Religion, n (%)
Christian 133 (63) 139 (66)
Other 10 (5) 4 (2)
None 68 (32) 68 (32)
Missing 1 (0) 1 (0)
Salary (£ sterling)
Mean (SD) 19,930 (13,387) 18,024 (13,582)
Range 1200–72,000 792–80,000
Social class, n (%)a
Class 0 96 (45) 76 (36)
Class 1 53 (25) 52 (25)
Class 2 22 (10) 38 (18)
Class 3 5 (2) 6 (3)
Class 4 0 (0) 2 (1)
Class 5 35 (17) 37 (17)
Not classified 1 (0) 1 (0)
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TABLE 7 Baseline characteristics of the trial participants (continued )
Characteristic/variable MBCT-TS (n= 212) ADM (n= 212)
Stratification variables
Depressive symptomology at randomisation, n (%)
Asymptomatic 163 (77) 162 (76)
Symptomatic 49 (23) 50 (24)
Recruitment site, n (%)
Bristol 33 (16) 31 (15)
Exeter and East Devon 72 (34) 76 (36)
North and Mid Devon 55 (26) 54 (25)
South Devon 52 (25) 51 (24)
Psychiatric characteristics
Current depressive symptomology, mean (SD)
GRID-HAMD score 4.8 (4.3) 4.6 (4.3)
BDI-II score 13.8 (10.2) 14.5 (10.1)
Previous major depressive episodes, n (%)
Fewer than six episodes 120 (57) 106 (50)
Six or more episodes 92 (43) 106 (50)
Age (years) at first depression onset, mean (SD) 24.4 (11.5) 25.4 (13.3)
Time (months) since last depressive episode, mean (SD) 21.2 (27.0) 17.1 (23.0)
No. of comorbid DSM-IV Axis I psychiatric diagnoses, mean (SD) 0.5 (0.9) 0.7 (0.9)
Received outpatient psychiatric or psychological treatment, n (%) 103 (49) 108 (51)
Attempted suicide, n (%) 48 (23) 53 (25)
No. of previous suicide attempts, mean (SD) 1.7 (1.1) 1.9 (1.5)
Severity of reported childhood abuse, n (%)
High 105 (50) 111 (52)
Low 105 (50) 101 (48)
Missing 2 (1) 0 (0)
Quality of life, mean (SD)b
How would you rate your quality of life? 3.7 (0.8) 3.7 (0.8)
How satisfied are you with your health? 2.9 (1.0) 3.1 (1.0)
Physical 14.5 (6.5) 14.4 (5.1)
Psychological 12.6 (2.6) 12.3 (2.6)
Social 13.4 (3.4) 13.1 (3.4)
Environment 15.0 (2.4) 15.1 (2.6)
Health-related quality of life (EQ-5D-3L tariffs), mean (SD) 0.760 (0.268) 0.778 (0.211)
a Social class was determined according to the UK Office for National Statistics and the range was from professional and
managerial occupations (class 1) to semiroutine and routine occupations (class 5); class 0 represents those who have
never worked, the long-term unemployed, students or retired people [see www.ons.gov.uk/ons/guide-method/
classifications/current-standard-classifications/soc2010/index.html (accessed 20 July 2015)].
b Data determined on the basis of the WHOQOL-BREF assessment.
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TABLE 8 Baseline characteristics of the pilot trial participants28
Characteristic/variable MBCT (n= 61) m-ADM (n= 62)
Demographic characteristics
Female, n (%) 47 (77) 47 (76)
White, n (%)a 60 (98) 62 (100)
Age (years)
Mean (SD) 48.95 (10.55) 49.37 (11.84)
Range 26–66 21–72
Marital status, n (%)
Single 4 (7) 9 (15)
Married or cohabiting 42 (69) 40 (65)
Separated, divorced or widowed 15 (25) 13 (21)
Level of education, n (%)
No educational qualifications 9 (15) 17 (27)
Some school qualifications 16 (26) 16 (26)
High school and/or vocational qualification 24 (39) 15 (24)
University degree/professional qualification 12 (20) 14 (23)
Religion, n (%)
None 12 (20) 16 (26)
Christian 46 (75) 45 (73)
Otherb 3 (5) 1 (2)
Social class, n (%)c
Class 1 22 (36) 23 (37)
Class 2 15 (25) 12 (19)
Class 3 7 (11) 7 (11)
Class 4 6 (10) 2 (3)
Class 5 11 (18) 17 (27)
Psychiatric characteristics
Depression, mean (SD)
HRSD score, mean (SD) 5.62 (4.3) 5.76 (4.69)
BDI-II score, mean (SD) 18.51 (10.91) 20.15 (12.86)
Depression diagnosis at intake, n (%)
In full remission 42 (69) 41 (66)
In partial remission 19 (31) 21 (34)
Previous episodes of depression
Mean (SD) 6.43 (3.04) 6.35 (2.91)
Median 6 6
≥ 10 episodes, n (%) 23 (38) 19 (31)
Number of comorbid DSM-IV Axis I psychiatric diagnoses, mean (SD) 0.83 (0.96) 1.04 (1.11)
Age (years) at first depression onset, mean (SD) 26.34 (11.7) 26.11 (12.65)
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TABLE 8 Baseline characteristics of the pilot trial participants28 (continued )
Characteristic/variable MBCT (n= 61) m-ADM (n= 62)
Time (months) since last depressive episode, mean (SD) 24.20 (27.74) 18.68 (23.89)
Severity of last depressive episode (no. of DSM-IV symptoms recorded), mean (SD) 7.27 (1.3) 7.04 (1.35)
Attempted suicide, n (%) 20 (33) 22 (35)
Number of previous attempts
Mean (SD) 0.69 (1.37) 0.66 (1.05)
Range 0–7 0–4
Previous psychiatric treatment, mean (SD) 17 (28) 13 (21)
Quality of life, mean (SD)d
Physical 22.64 (5.59) 23.0 (5.18)
Psychological 17.8 (3.82) 18.03 (3.63)
Social 9.52 (2.32) 9.27 (2.65)
HRSD, Hamilton Rating Scale for Depression.
a The non-white participant was British Asian.
b There was one Muslim in the m-ADM group and one Bahai, one Buddhist and one spiritualist in the MBCT group.
c Social class was determined according to the UK Office for National Statistics and the range was from professional
and managerial occupations (class 1) to semiroutine and routine occupations (class 5) [see www.ons.gov.uk/ons/
guide-method/classifications/current-standard-classifications/soc2010/index.html (accessed 20 July 2015)]. Data were
missing for one case in the m-ADM arm of the trial.
d Data determined on the basis of the WHOQOL-BREF assessment.
TABLE 9 Adherence to treatment in each trial arm
Treatment adherence n (%)
m-ADM
Remained on therapeutic dose 162 (76)
Did not remain on therapeutic dose 50 (24)
MBCT-TS
Participants who did not initiate MBCT treatment 6 (3)
Participants who initiated MBCT treatment 206 (97)
Number of sessions attended
Mean 6
Mode 8
SD 2.4
Completed four or more MBCT sessions 176 (83)
ADM use among patients who attended four or more MBCT sessions
No reduction in ADM dose 23 (13)
Reduction in ADM dose 29 (17)
Discontinued ADM 124 (71)
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Primary outcome
Intention-to-treat analysis
We observed little or no clustering in primary or secondary outcomes by therapist. As model results
accounting for clustering by therapist were identical to those obtained for the primary ITT analysis,
outcome findings without consideration of therapist clustering are reported.
With respect to the primary outcome, the primary ITT analysis showed no evidence of a reduction in the
hazard of relapse/recurrence with MBCT-TS compared with m-ADM (HR 0.89, 95% CI 0.67 to 1.18;
p= 0.43), with 44% (94/212) of the MBCT-TS patients relapsing compared with 47% (100/212) of
the m-ADM patients (Figure 4).
Secondary analyses
Two secondary analyses of the primary outcome were undertaken to explore the impact of variations in
intervention adherence in the MBCT-TS and m-ADM groups.
There was a non-significant reduction in the hazard of relapse/recurrence with MBCT-TS compared with
m-ADM at 24 months in those participants who received an adequate dose of treatment (HR 0.79,
95% CI 0.58 to 1.08; p= 0.14), with 46% (81/176) of the MBCT-TS patients relapsing compared with
49% (80/162) of the m-ADM patients (Figure 5). In this subgroup, the m-ADM group included more
women and participants with a greater number of comorbidities than the MBCT-TS group (see Appendix 3).
There was a non-significant reduction in the hazard of relapse/recurrence with MBCT-TS compared
with m-ADM at 24 months in participants who followed the invited treatment with respect to ADM use
(HR 0.77, 95% CI 0.56 to 1.06; p= 0.10), with 46% (70/153) of the MBCT-TS patients relapsing
compared with 49% (80/162) of the m-ADM patients (Figure 6). In this subgroup, the m-ADM group
included younger participants, lower earners, more women and participants with a greater number of
comorbidities than the MBCT-TS group (see Appendix 4). Given their non-randomised nature, these
secondary analyses are prone to selection bias and confounding.
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There was no difference in treatment effect on the primary outcome across either stratification variable
subgroup (severity of depression at baseline or centre) (Table 10). However, there was evidence of a significant
interaction between the severity of reported childhood abuse and treatment group (HR 0.53, 95% CI 0.29 to
0.95; p= 0.03). Specifically, compared with ADM-m, MBCT-TS reduced the risk of relapse/recurrence for
participants with a higher severity of reported childhood abuse (MBCT-TS 47% vs. ADM-m 59%) whereas
there was a slightly higher risk of relapse/recurrence with MBCT-TS in the lower severity of reported childhood
abuse subgroup (MBCT-TS 42% vs. ADM-m 35%) (see Table 10). Comparing the baseline characteristics of
those with high and low severities of reported childhood abuse we find a number of differences. Participants
who reported a more abusive childhood had had more previous psychiatric treatments, including more
hospitalisations, had experienced more previous episodes of depression and made more suicide attempts,
had a greater chance of a familial history of both suicide and mental illness and were more likely to smoke
(see Appendix 5). Given their non-randomised nature, these secondary analyses are prone to selection bias
and confounding
Secondary outcomes
With respect to the secondary outcomes, there was again no evidence of MBCT-TS’s superiority over
m-ADM (Table 11). Furthermore, none of the secondary outcome treatment effects at any follow-up point
exceeded a standardised mean difference of 0.4. The health economics outcomes are reported in full
in Chapter 5.
TABLE 10 Treatment effect subgroup analyses
Subgroup Stratified HR (95% CI) Interaction HR (95% CI), p-value
Depression severity
Asymptomatic (HRSD score < 8)a 0.83 (0.60 to 1.15) 1.27 (0.68 to 2.39), 0.46
Symptomatic (HRSD ≥ 8) 1.06 (0.62 to 1.18)
Centre
South Devona 0.61 (0.33 to 1.13) 1.75 (0.70 to 4.39)
Bristol 1.60 (0.54 to 2.12) 1.81 (0.83 to 3.96)
Exeter and East Devon 1.10 (0.68 to 1.81) 1.37 (0.61 to 3.08), 0.47b
North and Mid Devon 0.84 (0.49 to 1.43)
Childhood abuse
Lower riska 1.31 (0.83 to 2.04) 0.53 (0.29 to 0.95), 0.03
Higher risk 0.69 (0.47 to 1.00)
HRSD, Hamilton Rating Scale for Depression.
a Reference subgroup.
b p-value for treatment–centre interaction across centres.
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Adverse events
A total of 10 serious adverse events were reported and are summarised in Table 12. Following discussion
with the centre principal investigators and confirmation from the DMC we concluded that there was no
reason to believe that any of the serious adverse events were intervention or trial related.
Over the 24 months there was no difference in the total number of suicidal ideations reported between
the MBCT-TS group (n= 44 events) and the m-ADM group (n= 46 events) (rate ratio 0.94, 95% CI 0.64 to
1.38; p= 0.75).
TABLE 12 Serious adverse events reported over the 24-month follow-up of the trial
Event Date reported
MBCT-TS arm
Attempted suicide 5 November 2010
Death from lung cancer 11 September 2012
Death from pancreatic cancer 14 November 2012
Non-fatal stroke 27 February 2013
Attempted suicide 2 July 2013
Non-fatal hemotympanum resulting in a blood clot 19 July 2013
m-ADM arm
Completed suicide 15 June 2012
Death from hyperischaemic heart disease 19 July 2012
Attempted suicide 8 March 2013
Non-fatal hysterectomy because of cancer and admitted to hospital for 2 nights 14 May 2013
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Chapter 5 Economic evaluation
Introduction
Aim
The aim of the economic evaluation was to assess the cost-effectiveness of MBCT-TS compared with
m-ADM in patients with recurrent major depressive disorder, in full or partial remission, in primary care
over 24 months. The economic evaluation followed the methods developed in the pilot trial28 and was
carried out alongside the main RCT.78,83
Methods
Perspective
In the first instance the economic evaluation took a NHS/Personal Social Services (PSS) perspective, which
is recommended by NICE84 and covers the use of all hospital, community health and social services. In
addition, as depression is known to impact on an individual’s ability to work, resulting in substantial losses
in the workplace,85 we also widened our perspective to include productivity losses resulting from time off
work and reduced productivity at work because of illness.
Method of economic evaluation
The primary economic analysis is focused on the policy question and is therefore a cost-effectiveness
analysis with outcomes expressed as relapse/recurrence prevented. A secondary cost–utility analysis was
also undertaken in which outcomes were expressed as QALYs, as recommended by NICE.84
Outcomes
The primary outcome for the study was time to recurrence of depression and is detailed in Chapter 3.
For the purpose of the economic evaluation we created a binary outcome based on whether or not a
relapse/recurrence had occurred.
Quality-adjusted life-years were calculated from EQ-5D scores at baseline, 1 month after treatment
and 9, 12, 18 and 24 months’ follow-up. The EQ-5D is a non-disease-specific measure for describing and
valuing health-related quality of life.86 The measure includes a rating of own health in five domains
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a rating of own health
by means of a visual analogue scale (a ‘thermometer’) (score 0–100). It has been established that the
EQ-5D can be used with confidence in economic evaluations for common mental health disorders.87
The health states from the EQ-5D were given a utility score using responses from a representative sample
of adults in the UK.88 From these, QALYs were calculated using the area under the curve approach as
defined by the utility values at baseline and each follow-up. It was assumed that changes in utility score
over time followed a linear path.89 QALYs in the second year were discounted at a rate of 3.5% as
recommended by NICE.84
Calculation of costs
The calculation of costs was separated into the identification, measurement and valuation of relevant
resources. All unit costs are for the financial year 2011/12, uprated when necessary using the Hospital and
Community Health Services Index.90 Costs in the second year were discounted at a rate of 3.5% as
recommended by NICE.84
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Identification of resources
We identified relevant resources based on the results of the pilot trial28 and in discussion with study
clinicians and patient representatives. We collected resource use in the following domains:
l delivery of the MBCT-TS intervention
l use of NHS secondary care services:
¢ inpatient stays (mental health and all medical specialties)
¢ outpatient appointments (mental health and all medical specialties)
¢ accident and emergency attendances
l use of NHS primary care services:
¢ GP (in surgery, at home and by telephone)
¢ practice nurse
¢ other community nurse (for example district nurse, health visitor, midwife)
¢ support and recovery (STAR) or health-care support worker
¢ community psychiatric nurse
¢ community psychiatrist
¢ community occupational therapist
¢ community art/music/drama therapist
l use of medication in the following areas:
¢ antidepressants
¢ sleeping tablets
¢ mood stabilisers/antipsychotic
¢ painkiller
l use of social care and voluntary sector services:
¢ social worker
¢ marriage counselling service
¢ advice service, for example Citizen’s Advice Bureau
¢ helpline, for example Samaritans/Mind
¢ day centre/drop-in centre
l costs to patients and their carers
¢ travel to trial MBCT-TS sessions
l productivity costs
¢ time off work (absenteeism) and reduced productivity at work (presenteeism).
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Measurement of resources
Delivery of the MBCT-TS intervention
Throughout the trial, the MBCT-TS therapists recorded details of attendance and non-attendance at group
sessions for each study participant and these were used as the basis for the calculation of the total cost
of the intervention.
Contact with general practitioners and antidepressant medication
Information on the numbers and types of contact with GPs and on prescriptions for ADM for the
24-month follow-up period was collected through a search of GP records by research assistants blind to
randomisation status.
Use of all other health, social and voluntary sector services and out-of-pocket costs
Data on use of all other services included in the study were collected using the Adult Service Use Schedule
(AD-SUS; see Appendix 6). The AD-SUS has been developed in several mental health trials and was further
modified and successfully employed in the pilot trial.28 Information about the study participants’ use of
services was collected in interviews with a researcher at baseline and at 1 month post treatment and 9, 12,
18 and 24 months’ follow-up. At baseline, information covered the previous 3 months. At each of the
follow-up interviews, service use since the previous interview was recorded; in this way the entire period
from baseline to the final follow-up was covered. The AD-SUS asks participants for the number and
duration of contacts with various services and professionals. In addition to the researcher-completed
component of the AD-SUS, we also created a self-complete section that asked participants about their use
of non-trial psychological therapies, sleeping tablets, mood stabilisers and painkillers and any out-of-pocket
costs associated with their attendance at a MBCT-TS group. The self-complete questionnaire was included
to ensure that the researchers maintained blindness to randomisation allocation at each follow-up.
Productivity losses
Information about time off work (absenteeism) and reduced productivity whilst at work (presenteeism) was
collected by researchers alongside the AD-SUS using the productivity questions of the WHO Work
Performance Questionnaire.91
Valuation of resources
A unit cost was applied to each resource use to calculate the total cost of resources used by each
study participant.
Trial MBCT-TS sessions
We used the approach developed by the Personal Social Services Research Unit (PSSRU) at the University of
Kent92 for the calculation of the unit cost of the MBCT-TS group intervention. Trial therapists were on band 7
of the Agenda for Change salary scale and employer’s national insurance, superannuation contributions and
overheads were added to the average salary. We collected information from trial therapists on the time that
they spent running the MBCT-TS sessions and the time that they spent on other activities and calculated a
direct–indirect ratio of 1 : 0.67. MBCT-TS sessions lasted for 2 hours and there were 12 participants allocated
to each group. We thus calculated the cost per participant per session at £14 (Table 13). Although there is no
clear agreement on how the costs of group interventions should be allocated,93 we decided to calculate
the cost of the intervention on the basis of allocation to a MBCT-TS group, regardless of whether or not the
individual attended, because if participants did not attend they were not replaced.
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Antidepressants and other medication
Medication costs were calculated using daily dose information and the cost of the generic drugs as listed in
the BNF.94
Secondary care services
The unit costs for all hospital services were taken from the National Schedule of NHS Reference costs for
2012.95 The costs used in the analysis are summarised in Table 14.
Primary care services and social care and voluntary services
For NHS primary care services and social care and voluntary services we used costs contained in Curtis.90
Costs to patients
The cost of travel to MBCT-TS treatment groups was calculated by multiplying mileage information by
estimates of running costs from the UK Automobile Association [see www.theaa.com/motoring_advice/
running_costs (accessed 17 March 2015)].
Productivity costs
For productivity losses, absenteeism costs were calculated using the friction cost approach96 and
presenteeism costs were calculated using the method set out by Kessler et al.91
TABLE 13 Unit cost schema for MBCT-TS
Unit Unit cost 2011/12 (£ per year)
Salary 37,800
Salary oncosts including employers’ national insurance and
superannuation contribution
9532
Overheads
Management, administration and estates 9140
Non-staff 19,865
Capital overheads 2682
Working time 42.7 weeks per annum, 37.5 hours per week
Ratio of direct face-to-face to indirect time 1 : 0.67
Length of sessions 2 hours
Total £49 per hour, £82 per direct contact hour, £165 per session,
£14 per participant per session
Source: Curtis.90
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Data analysis
Complete case analysis was used in the economic evaluation.
Resource use
Resource use by study participants is reported as the mean by group and as a percentage of the group
who had at least one contact. Differences in the use of services between randomised groups at
24 months’ follow-up are reported descriptively and are not compared statistically to avoid problems
associated with multiple testing and because the focus of the economic evaluation was on a quantitative
analysis of cost and cost-effectiveness.
Difference in costs
Differences in mean costs between randomised groups at 24 months’ follow-up were analysed using
standard parametric t-tests with the validity of the results confirmed using bias-corrected, non-parametric
bootstrapping (repeat resampling).97 Despite the skewed nature of cost data, this approach is recommended
to enable inferences to be made about the arithmetic mean.98
TABLE 14 Unit costs applied to economic data
Service Unit Cost (£)
MBCT-TS Per session 14.00
Medication Per daily dose Various
Inpatient Per night 496.48–585.58
Outpatient Per appointment 60–234
Accident and emergency Per attendance 108–157
Ambulance Per attendance 214
GP surgery Per minute of patient contact 2.78
GP home Per home visit minute 3.55
GP telephone Per minute of patient contact 2.78
Practice nurse Per minute of face-to-face contact 0.75
District nurse, health visitor, midwife Per home visit minute 1.05
Community psychiatric nurse Per minute of face-to-face contact 1.12
Community psychiatrist Per minute of patient contact 1.93
Clinical psychologist Per minute of patient contact 2.27
Occupational therapist Per minute of patient contact 0.67
Physiotherapist Per minute of patient contact 0.50
Counselling Per minute of patient contact 1.08
Art/drama/music therapist Per minute of patient contact 0.67
Chiropodist Per minute of patient contact 0.50
Dietician Per minute of patient contact 0.67
Social worker Per minute of patient contact 2.60
Support worker Per minute of patient contact 0.47
Advice service Per minute of patient contact 0.47
Day centre Per user per session 37.00
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Cost-effectiveness and cost–utility analyses
The primary economic analysis focused on the policy question: MBCT-TS compared with m-ADM at
24 months and assessed cost-effectiveness in terms of cost per relapse/recurrence prevented. A secondary
cost–utility analysis was undertaken using QALYs calculated from the EQ-5D measure of quality of life.
Initially, ICERs – the difference in mean cost divided by the difference in mean effect – were calculated.99
Because ICERs are calculated from four sample means and are therefore subject to statistical uncertainty,
repeat resampling (bootstrapping) from the cost and outcomes data was used to generate a distribution of
mean costs and effects for each of the relapse/recurrence and QALY outcomes.100 These distributions were
used to calculate the probability that each of the treatments is the optimal choice, subject to a range of
possible maximum values (the ceiling ratio, λ) that a decision-maker might be willing to pay for a unit
improvement in outcome. To explore the uncertainty that exists around estimates of mean costs and effects
and the uncertainty regarding the maximum value of λ, cost-effectiveness acceptability curves (CEACs) are
presented by plotting these probabilities for a range of possible values of λ.101,102 CEACs show the probability
that MBCT-TS is the more cost-effective of the two options for different values of λ. These analyses were run
allowing for stratification variables (recruitment locality and participants’ symptomatic status).
Sensitivity analyses
A number of sensitivity analyses were carried out to test the robustness of the assumptions made:
1. The discount rate was varied from 0% to 6%.
2. The impact of missing data was considered using single imputation of individual missing values using
multiple covariates.
Results
Data completeness
At 24 months, full service use data for the entire follow-up period were available for 180 participants
in the m-ADM group and 181 participants in the MBCT-TS group, which was 85% of the total
number randomised.
Resource use
Trial MBCT-TS sessions
Full details of the MBCT-TS sessions are provided in Chapter 2 and associated costs are summarised in
Table 13.
Antidepressants and other medication
For details of the use of ADM see Table 9. The use of other medication is summarised in Table 15, which
shows that similar proportions of both the MBCT-TS group and the m-ADM group used painkillers (61%)
and sleeping tablets (15–16%).
Secondary care, primary care, social care and voluntary sector services
The use of secondary care, primary care, social care and voluntary sector services was broadly similar across
both randomised groups over 24 months’ follow-up and there is no evidence that treatment allocation had
any substantial impact on the scope or intensity of service use.
Productivity losses
Over 24 months’ follow-up the mean number of days off work was 9.8 in the m-ADM group and 11.0 in
the MBCT-TS group.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
Total costs
Changes over time
Changes in total cost per week over follow-up are summarised in Figure 7 (NHS/PSS perspective) and
Figure 8 (societal perspective). The charts demonstrate that costs were fairly consistent between groups
and over time, suggesting that randomisation to MBCT-TS or m-ADM had little impact on the cost of
health and social care services and productivity losses.
Total costs at follow-up
Total costs over follow-up are summarised in Table 16, including a breakdown of costs by service-providing
sector. From a NHS/PSS perspective, the mean total cost over 24 months’ follow-up was £2360 in the
m-ADM group and £2485 in the MBCT-TS group; the mean difference in costs was not statistically
significant (p= 0.80). From a societal perspective the mean total cost over 24 months’ follow-up was
£2755 in the m-ADM group and £3204 in the MBCT-TS group; again, the mean difference in costs of
£449 was not statistically significant (p= 0.68).
TABLE 15 Service use (unit) over 24 months’ follow-up
Service use
MBCT-TS m-ADM
Mean SD
% using at
least once Mean SD
% using at
least once
Inpatient stay (nights) 0.70 3.87 14.81 0.89 2.79 20.14
Outpatient appointments (number) 4.79 9.21 67.11 4.29 6.29 67.63
Accident and emergency (attendances) 0.59 1.25 30.20 0.60 1.09 33.09
Ambulance (calls) 0.07 0.34 4.70 0.72 0.26 7.19
GP (contact) 12.13 12.51 95.30 9.66 8.44 99.28
Other community health-care services
(contact)
1.27 4.43 87.92 6.99 17.22 86.33
Social care, local authority and voluntary
services (contact)
1.58 4.81 22.82 2.55 7.55 18.71
Use of painkillers 61.26 60.85
Use of sleeping tablets 15.09 15.57
Days off work over follow-up 11.01 32.66 43.40 9.76 27.06 51.89
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Outcomes
Health-related quality of life
Mean EQ-5D health state scores are summarised in Figure 9. The graph shows that the average health
state score was between 0.7 and 0.8 for both groups for the entire period between baseline and
24 months’ follow-up and that there is very little difference between the groups. The resultant QALYs over
follow-up are summarised in Table 16; the difference of –0.04 between the groups was not statistically
significant (p= 0.42, adjusted by stratification variables).
TABLE 16 Total costs (£) and outcomes over 24 months’ follow-up by randomised group
Cost category
MBCT-TS (n= 181) m-ADM (n= 180)
Mean
difference 95% CI p-valueMean Mean Mean SD
MBCT-TS 112.00 112.00 0.00 0.00
Antidepressants 40.10 72.13 69.79 168.48
Hospital and community
services
2332.43 4065.88 2290.62 4190.65
Total health-care costs
(NHS/PSS)
2484.52 4077.31 2360.41 4205.58 124.11 –749.98 to 972.57 0.80
Out-of-pocket costs to
patients
56.76 168.29 83.33 283.12
Productivity losses (n= 265) 504.26 1881.49 310.54 761.06
Societal costs (n= 252) 3204.05 4011.91 2754.92 4465.07 449.14 –842.18 to 1286.26 0.68
Relapse/recurrence (%)
(n= 402)
47 47 50 50 –3
QALYs (n= 213) 1.49 1.49 1.53 0.35 –0.04
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FIGURE 9 Mean EQ-5D health state scores over follow-up.
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Relapse/recurrence
Detailed information on the relapse/recurrence outcome measure is provided in Chapter 4. For the purpose
of the economic evaluation we used the percentage of individuals who relapsed in each of the randomised
groups. In the m-ADM group 50% had a relapse/recurrence over follow-up and in the MBCT-TS group
this figure was 47% (see Table 16).
Cost-effectiveness
Relapse/recurrence
In terms of relapse/recurrence, costs were higher in the MBCT-TS group and outcomes better, generating
an ICER (the additional cost of one intervention compared with another divided by the additional effects)
of £4955 from the NHS/PSS perspective and £17,930 from the societal perspective, including productivity
losses and patient costs. The ICER indicates that an additional £4955 (from the NHS/PSS perspective) or
£17,930 (from the societal perspective) would need to be invested to generate a unit reduction in the
percentage of participants who relapse.
Non-parametric bootstrapping from the cost and effectiveness data was used to generate a joint distribution
of incremental mean costs and effects for the treatments under comparison to explore the probability that
each is the optimal choice, subject to a range of maximum values (λ) that a decision-maker might be willing
to pay for improvements in outcomes. Figures 10 and 11 illustrate the scatterplots of the bootstrapped cost
and effectiveness pairs for MBCT-TS compared with m-ADM, from the NHS/PSS and societal perspectives
respectively. The points in the scatterplot fall in all four quadrants of the cost-effectiveness plane suggesting
that there is no clear conclusion to be made regarding cost-effectiveness in terms of relapse/recurrence.
It is important to note that, as positive values of relapse/recurrence correspond with worse outcomes, the
usual interpretation of the quadrants of the cost-effectiveness plane is reversed with respect to the x-axis so
that points that fall to the left of 0 denote better outcomes for MBCT-TS and those that fall to the right
denote worse outcomes. Statistical uncertainty around the ICER was explored through the calculation of
CEACs, shown in Figure 12, which demonstrate that the probability of MBCT-TS being more cost-effective
than m-ADM does not rise above 43%.
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FIGURE 10 Scatterplot showing the bootstrapped mean differences in costs and effects of MBCT-TS compared with
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FIGURE 11 Scatterplot showing the bootstrapped mean differences in costs and effects of MBCT-TS compared with
m-ADM using relapse/recurrence and societal costs.
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FIGURE 12 Cost-effectiveness acceptability curves showing the probability that MBCT-TS is cost-effective compared
with m-ADM for different values that a decision-maker is willing to pay for a unit reduction in the percentage of
patients who undergo relapse/recurrence.
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Quality-adjusted life-years
In terms of QALYs, costs were higher in the MBCT-TS group and outcomes slightly worse, suggesting that
MBCT-TS was dominated by m-ADM. The scatterplots in Figures 13 and 14 show points falling mainly in
the north-west quadrant (outcomes worse and costs higher) and south-west quadrant (outcomes worse
and costs lower). The probability that MBCT-TS is more cost-effective than m-ADM, shown in the CEACs in
Figure 15, does not rise above 52%.
Sensitivity analysis
Imputation of missing data and variation in the discount rate from 0% to 6% made no difference to the
results, as summarised in Table 17.
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FIGURE 13 Scatterplot showing the bootstrapped mean differences in costs and effects of MBCT-TS compared with
m-ADM using QALYs and service costs.
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FIGURE 14 Scatterplot showing the bootstrapped mean differences in costs and effects of MBCT-TS compared with
ADM-T using QALYs and adjusted societal costs.
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FIGURE 15 Cost-effectiveness acceptability curves showing the probability that MBCT-TS is cost-effective compared
with m-ADM for different values that a decision-maker is willing to pay for a QALY.
TABLE 17 Total costs and QALYs with discount rate varied from 0% to 6%
Cost category and
discount rate
MBCT-TS (n= 181) m-ADM (n= 180)
Mean
difference 95% CI p-valueMean SD Mean SD
Total NHS/PSS costs (£),
discount rate 0%
2439.98 3992.68 2319.75 4120.03 107.96 –735.63 to 951.55 0.80
Total societal costs (£),
discount rate 0%
3007.99 3970.62 2747.60 4468.00 214.72 –844.97 to 1274.42 0.69
Total NHS/PSS costs (£),
discount rate 6%
2516.34 4137.95 2389.46 4267.05 113.68 –760.28 to 987.64 0.80
Total societal costs (£),
discount rate 6%
3035.53 4041.78 2760.14 4468.15 227.27 –840.25 to 1294.78 0.68
QALYs, discount rate 0% 1.48 0.48 1.52 0.35 –0.05 –0.16 to 0.07 0.42
QALYs, discount rate 6% 1.46 0.47 1.5 0.35 –0.05 –0.16 to 0.06 0.42
Multiple imputation of
missing data, NHS/PSS
costs (£)
2423.68 3780.54 2348.59 3903.41 67.13 –668.39 to 802.65 0.858
Multiple imputation of
missing data, societal
costs (£)
2934.68 3177.99 2692.53 3595.67 229.16 –417.93 to 876.25 0.487
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Chapter 6 Quantitative process–outcome
evaluation
Introduction
Aim
The trial sought to address the following explanatory question: ‘Is an increase in mindfulness skills the key
mechanism of change of MBCT?’ We approached this question using embedded process–outcome studies
across the trial arms.
An important first step in establishing mechanisms of action is to identify whether or not the selected
mechanism variables mediate the effects of the target treatment (MBCT-TS) on outcome.103 In other words,
(1) are those mechanisms differentially altered by the treatment and (2) do those mechanisms explain all or
part of the effect of treatment on outcome?
This chapter reports our meditational analyses examining whether changes in mindfulness as measured
by the Five Factor Mindfulness Questionnaire (FFMQ)104 from pre treatment (baseline) to post MBCT
(1-month post-treatment follow-up point) mediate the effects of treatment arm on clinical outcome over
the course of the trial.
Establishing mediation
To establish mediation requires attention to several key aspects of study design103,105,106 that have been
instantiated in the PREVENT trial. First, MBCT is compared with a treatment that works but not through the
same mechanism of action (m-ADM),107 thus allowing a test of effects specific to MBCT. Second, assessment
of change in the hypothesised mediator occurred (1) during MBCT and (2) before the assessment of
outcome. For the current approach we assessed change in mindfulness at baseline and immediately following
MBCT and depressive relapse/recurrence over 24 months of follow-up was the dependent variable in our
mediation analyses. Finally, the design requires that all those in the intervention arm received an adequate
dose of the intervention to properly test the hypothesis that MBCT’s impact on the hypothesised mechanism
(mindfulness) mediates outcome. Therefore, only patients who attended four or more sessions were included
in the mediational analyses.
Hypothesis
Based on our previous work37 and on the theoretical and clinical rationale of MBCT, we predicted that
enhanced mindfulness over the active treatment period would significantly mediate outcome, with those
participants evidencing larger gains in mindfulness faring better. We did not predict an interaction with
treatment arm (see Mediation approach).
Methods
Measurement of mindfulness
As noted, mindfulness in the PREVENT trial was measured using the FFMQ.104 The FFMQ is a 39-item
measure that assesses five facets of a general tendency to be mindful in daily life: observing, describing,
acting with awareness, non-reactivity to inner experience and non-judging of inner experience. Items are
rated on a 5-point Likert scale, with higher scores indicating a greater tendency to be mindful. The FFMQ
was administered at the baseline and 1-month post-treatment assessment points.
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Analytic approach
Selection of the sample
Analyses that address mediation of treatment-specific effects require an adequate treatment dose.103 In the
PREVENT trial an adequate dose of MBCT was defined as participation in four of eight MBCT sessions. As
relapse/recurrence is the primary outcome it is also necessary that participants have not relapsed prior to the
post-MBCT assessment point. Finally, participants need to have full data on mindfulness skills (the FFMQ) at
baseline and post treatment as well as full data on GRID-HAMD-assessed depression at baseline and post
treatment. Participants satisfying all of these criteria make up the mediation sample.
Mediation approach
We used the mediation analytical framework recommended by Kraemer et al.105 for RCTs. This comprises
a regression approach in which treatment group (T), the mediator (M) and the treatment by mediator
interaction term (T ×M) are the independent variables. We examined the outcome of relapse/recurrence
using Cox proportional hazards regression.108 Within this regression approach, for M to be a mediator of
treatment, M must be an event occurring during or after treatment that is significantly altered by treatment
and temporally precedes the outcome. M must also then show a main effect and/or an interactive effect with
treatment on outcome, that is, the M and/or T ×M terms in the regression should be significant. Treatment
need not have a significant overall or main effect on outcome.105
A main (but not interactive) effect of mediation is therefore when treatment significantly changes the
mediator but the effect of the mediator on outcome does not significantly differ across treatment types.
In the present analysis, if MBCT-TS differentially improves mindfulness skills and any such improvement
translates into a better outcome, but the relationship between improvement and outcome does not differ
between MBCT-TS and m-ADM, this would be a main, but not interactive, effect of mediation. In contrast,
an interactive effect of mediation is when treatment significantly changes not only the mediator but also
the relationship between the mediator and outcome such that it is significantly different for the alternative
treatments. In the present study, if treatment significantly affects the acquisition of mindfulness skills, but the
relationship between change in mindfulness across treatment and outcome is then significantly different
between the m-ADM group and the MBCT group, this would be an interactive effect of mediation.
To ensure that any mediation effects found in the current analyses were present over and above the
influence of levels of depression, our regression models included change in depression severity on
the Hamilton Rating Scale for Depression (HRSD) from baseline to 1-month post treatment when evaluating
mediation, on the first step in the regression analysis.
Calculating change in mindfulness
Development of mindfulness as a potential mediator was computed as change over time, that is, from
baseline to 1-month post treatment. We calculated standardised residualised change scores for the
mindfulness variables using a simple linear regression model in which time 1 scores predicted time
2 scores.35,109 The standardised residuals were then used in the mediation analyses. However, we report
raw score equivalents when appropriate for ease of comprehension.
Results
Selection of the sample
The full treatment-adherent sample consisted of 388 participants (MBCT-TS n= 176; m-ADM n= 212).
However, 68 participants relapsed before the 1-month post-treatment assessment point and were,
therefore, not included in these mediation analyses. This reduced the sample to 320 participants (MBCT-TS
n= 156; m-ADM n= 164). A further 60 participants did not complete the FFMQ and/or GRID-HAMD at
baseline and/or 1-month post treatment, giving a mediation sample of 260 participants (MBCT-TS n= 135;
m-ADM n= 125). The baseline characteristics of the mediation sample are provided in Table 18.
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TABLE 18 Baseline characteristics of the mediation sample
Characteristic/variable MBCT-TS (n= 135) m-ADM (n= 125)
Demographic characteristics
Female, n (%) 96 (71) 102 (82)
White, n (%) 133 (99) 123 (98)
Age (years)
Mean (SD) 52 (11) 50 (13)
Range 25–78 20–79
Marital status, n (%)
Single 23 (17) 19 (15)
Married, cohabiting or civil partnership 88 (65) 90 (72)
Separated, divorced or widowed 24 (18) 16 (13)
Missing 0 (0) 0 (0)
Level of education, n (%)
No educational qualifications 9 (7) 6 (5)
Some school qualifications 19 (14) 25 (20)
High school and/or vocational qualification 56 (41) 57 (46)
University degree/professional qualification 50 (37) 36 (29)
Missing 1 (1) 1 (1)
Religion, n (%)
Christian 85 (63) 82 (66)
Other 9 (7) 4 (3)
None 41 (30) 39 (31)
Missing 0 (0) 0 (0)
Salary (£ sterling)
Mean (SD) 21,054 (14,649) 17,961 (12,910)
Range 1200–72,000 1200–75,000
Social class, n (%)a
Class 0 56 (41) 47 (38)
Class 1 37 (27) 29 (23)
Class 2 14 (10) 24 (19)
Class 3 4 (3) 4 (3)
Class 4 0 (0) 0 (0)
Class 5 24 (18) 21 (17)
Not classified 0 (0) 0 (0)
continued
DOI: 10.3310/hta19730 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 73
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Kuyken et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
TABLE 18 Baseline characteristics of the mediation sample (continued )
Characteristic/variable MBCT-TS (n= 135) m-ADM (n= 125)
Stratification variables
Depressive symptomology at randomisation, n (%)
Asymptomatic 105 (78) 99 (79)
Symptomatic 30 (22) 26 (21)
Recruitment site, n (%)
Bristol 26 (19) 21 (17)
Exeter and East Devon 48 (36) 47 (38)
North and Mid Devon 38 (28) 28 (22)
South Devon 23 (17) 29 (23)
Psychiatric characteristics
Current depressive symptomology, mean (SD)
GRID-HAMD score 4.6 (4.3) 4.2 (4.1)
BDI-II score 13.0 (10.0) 13.3 (9.4)
Previous major depressive episodes, n (%)
Fewer than six episodes 78 (58) 70 (56)
Six or more episodes 57 (42) 55 (44)
Age (years) at first depression onset, mean (SD) 26.2 (12.4) 27.5 (14.2)
Time (months) since last depressive episode, mean (SD) 21.5 (25.3) 18.2 (23.9)
Number of comorbid DSM-IV Axis I psychiatric diagnoses, mean (SD) 0.4 (0.7) 0.6 (0.8)
Received outpatient psychiatric or psychological treatment, n (%) 66 (49) 59 (47)
Attempted suicide, n (%) 23 (17) 27 (22)
Number of previous attempts, mean (SD) 1.7 (1.0) 1.5 (0.9)
Severity of reported childhood abuse, n (%)
High 61 (45) 55 (44)
Low 74 (55) 70 (56)
Missing 0 (0) 0 (0)
Quality of life, mean (SD)b
How would you rate your quality of life? 3.7 (0.8) 3.9 (0.7)
How satisfied are you with your health? 2.9 (1.0) 3.2 (0.9)
Physical 14.4 (5.2) 14.7 (2.8)
Psychological 12.7 (2.6) 12.7 (2.4)
Social 13.4 (3.5) 13.6 (3.1)
Environment 15.2 (2.4) 15.6 (2.2)
Health-related quality of life (EQ-5D tariffs) 0.786 (0.243) 0.798 (0.193)
a Social class was according to UK Office for National Statistics and the range was from professional and managerial
occupations (class 1) to semiroutine and routine occupations (class 5); class 0 represents those who have never worked,
the long-term unemployed, students or retired people [see www.ons.gov.uk/ons/guide-method/classifications/
current-standard-classifications/soc2010/index.html (accessed 20 July 2015)].
b Data determined on the basis of the WHOQOL-BREF assessment.
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Mindfulness
Baseline and 1-month post-treatment FFMQ data for the mediation sample are presented in Table 19. The
first criterion of mediation is whether treatment significantly changes the mediator.105 We examined this by
entering the FFMQ subscales as dependent variables together in a mixed-model multivariate analysis of
variance (MANOVA) with time (baseline, 1-month post treatment) as the repeated measure and group
(MBCT-TS, m-ADM) as the between-subjects variable. Multivariate output (broadly reflecting FFMQ total
scores) showed significant main effects of group (Wilks’ λ= 0.92, F5,254= 4.20, p< 0.001, ηp2= 0.08)
and time (Wilks’ λ= 0.67, F5,254= 24.63, p< 0.001, ηp2= 0.33), qualified by a significant time × group
interaction (Wilks’ λ= 0.88, F5,254= 7.05, p< 0.001, ηp2= 0.12), consistent with a greater increase in
mindfulness in the MBCT-TS group. Univariate output revealed the same significant interactions for all of
the subscales (F-values> 4.12, p-values< 0.05, ηp2> 0.015).
Mediation
To examine mediation effects we included the different FFMQ subscales and the FFMQ total score in
separate Cox regression analyses as outlined in the analysis plan. Main effect (M) and interaction (T ×M)
terms for these mediation analyses are presented in Table 20. There was no support for a relationship
between change in mindfulness and risk of relapse/recurrence over 24 months. Following the approach to
establishing mediation of Kraemer et al.,105 there was no support for the hypothesis that change in
mindfulness is the key mechanism of action of MBCT-TS.
Follow-up analyses within the MBCT-TS group
To further explore the patterns in the data we performed supplementary analyses focused on only those
participants within the MBCT-TS arm (who also met the criteria for inclusion in the mediation sample)
(n= 135). We again used Cox proportional hazard regressions, this time without the treatment arm
variable on step 1 and without the interactions between treatment and the FFMQ variables on step 3.
We therefore examined whether or not changes in FFMQ scores from baseline to 1-month post treatment
in the MBCT-TS group significantly predicted relapse/recurrence over 24 months. The results are presented
in Table 21. As can be seen, there was no significant relationship between FFMQ changes across treatment
and relapse/recurrence, even within the MBCT-TS group.
TABLE 19 Mean (SD) data for the potential mediator variables
Variable
Baseline MBCT+1
MBCT-TS (n= 135) m-ADM (n= 125) MBCT-TS (n= 135) m-ADM (n= 125)
FFMQ Total 120.12 (18.75) 119.94 (16.19) 133.44 (18.26) 123.57 (16.20)
FFMQ Observe 24.20 (5.46) 23.66 (5.66) 28.64 (4.99) 24.94 (5.45)
FFMQ Describe 26.11 (6.70) 26.51 (6.72) 27.81 (6.28) 26.60 (6.04)
FFMQ Awareness 21.12 (4.92) 21.58 (4.79) 22.64 (4.29) 22.03 (4.22)
FFMQ Non-judgement 25.07 (6.56) 25.51 (6.07) 27.93 (6.26) 26.19 (5.54)
FFMQ Non-reactivity 20.36 (5.01) 19.42 (4.46) 23.02 (3.98) 20.51 (3.96)
MBCT+1, assessment point 1 month after the end of MBCT treatment in the MBCT arm and at the equivalent time point in
the m-ADM arm.
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TABLE 20 Cox regression to test potential mediators in the prediction of relapse/recurrence at 24 months’
follow-up by examining main and interactive effects of treatment and change in hypothesised mediators
Variable Wald p-value Exp (B)
ΔGRID-HRSD 3.40 0.07 1.20
Treatment 1.57 0.21 1.31
ΔFFMQ Total 0.03 0.87 1.02
ΔFFMQ Total × treatment 0.40 0.83 0.86
ΔFFMQ Observe 0.04 0.85 0.98
ΔFFMQ Observe × treatment 1.66 0.20 0.75
ΔFFMQ Describe 0.07 0.79 1.03
ΔFFMQ Describe × treatment 0.01 0.93 0.98
ΔFFMQ Awareness 0.03 0.86 0.98
ΔFFMQ Awareness × treatment 0.001 0.98 1.01
ΔFFMQ Non-judgement 0.70 0.41 1.10
ΔFFMQ Non-judgement × treatment 0.32 0.57 1.13
ΔFFMQ Non-reactivity 0.72 0.40 0.91
ΔFFMQ Non-reactivity × treatment 1.42 0.23 0.77
Δ, standardised residualised change in a variable from baseline to MBCT+1 (the assessment point 1 month after the end of
MBCT-TS treatment in the MBCT-TS arm and at the equivalent time point in the m-ADM arm); treatment, MBCT-TS vs.
m-ADM.
Treatment and ΔGRID-HRSD were entered on step 1 of each regression. Reported values of each control for the effects
of the other. ΔFFMQ variables were entered on step 2 of separate regressions. Reported values control for the effects of
treatment and ΔGRID-HRSD. The ΔFFMQ× treatment interaction term variables were entered on step 3 of the separate
regressions. Reported values control for the effects of treatment, ΔGRID-HRSD and the relevant ΔFFMQ variable.
TABLE 21 Main effects of FFMQ variables in the prediction of relapse/recurrence at 24 months’ follow-up for the
MBCT-TS group only (n= 135)
Variable Wald p-value Exp (B)
ΔGRID-HRSD 0.13 0.71 1.06
ΔFFMQ Total 0.24 0.62 0.94
ΔFFMQ Observe 1.03 0.31 0.87
ΔFFMQ Describe 0.00 0.98 1.00
ΔFFMQ Awareness 0.10 0.75 0.96
ΔFFMQ Non-judgement 0.60 0.44 0.11
ΔFFMQ Non-reactivity 2.87 0.09 0.79
Δ, standardised residualised change in a variable from baseline to MBCT+1 (the assessment point 1 month after the end of
MBCT-TS treatment in the MBCT-TS arm and at the equivalent time point in the m-ADM arm).
ΔGRID-HRSD was entered on step 1 of each regression. ΔFFMQ variables were entered on step 2 of separate regressions.
Reported values for ΔFFMQ variables control for the effects of ΔGRID-HRSD.
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Discussion
The analyses presented in this chapter sought to address the following explanatory question: ‘Is an increase in
mindfulness skills the key mechanism of change of MBCT-TS?’ We approached this question by examining
whether or not change in mindfulness from baseline to 1 month post MBCT-TS (or the equivalent time point
in the m-ADM arm), as measured by the self-report FFMQ, was a significant mediator between trial arm
(MBCT-TS or m-ADM) and outcome as assessed by depressive relapse/recurrence over 24 months.
We found no support in the data for either main or interactive mediation effects, somewhat contrasting
with our earlier finding from the PREVENT pilot trial37 that change in mindfulness (assessed using a
different measure) mediated effects on residual symptoms of depression at 12 months.
Supplementary analyses examined whether or not change in mindfulness was significantly associated
with clinical outcome (time to relapse/recurrence) within the MBCT-TS group alone. Again, we found no
support for this prediction.
Future work will systematically explore whether or not there are any mediating effects of mindfulness
on secondary trial outcomes or whether or not any putative mediating effects are moderated by key
demographic variables (e.g. exposure to childhood abuse).
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Chapter 7 Barriers to participation in the
PREVENT trial: a qualitative exploration
Introduction
Qualitative research within RCTs can provide a patient-centred and in-depth perspective on the
implementation of complex interventions and on trial processes and outcomes.110 The PREVENT trial offers an
opportunity to build on previous qualitative work on MBCT in three important ways: (1) the follow-up period
(2 years) is longer than that in many other studies; (2) participant experiences can be explored across larger
numbers than in previous qualitative studies; and (3) these large numbers provide opportunities for purposive
sampling. Previous qualitative work on MBCT has included very small numbers111,112 and sociodemographically
homogeneous samples.30 As a consequence, analysis has tended to focus on commonalities, with little
exploration of variations in experiences of MBCT. The large number of participants in the PREVENT trial allows
exploration of both similarities and variations in their experiences.
One area of focus for the qualitative exploration was the acceptability of MBCT-TS (other qualitative work
within the PREVENT trial that is not reported here is listed at the end of the chapter). There are several
reasons for interest in acceptability issues: (1) attrition between possible case identification and recruitment
in MBCT trials is typically high;28 (2) between 7% and 25% of people do not complete the full MBCT
course and a 15% dropout rate from MBCT is typical;24,25,28 and (3) there are wide variations in the extent
to which people engage with mindfulness practices that are assumed to be the vehicle of change.112
Existing evidence about the acceptability of MBCT is limited111 and there is no published evidence on the
acceptability of MBCT-TS. Little is known about several elements of acceptability: why people choose not
to participate in MBCT; reasons for dropout from treatment; and why people fail to engage with or
continue mindfulness practices. The research reported here focuses on the first of these issues, namely
barriers to participation in MBCT-TS within the PREVENT trial, at the point of initial invitation into the trial
(other acceptability questions are addressed by data not reported here).
Methods
Development of data collection tools drew on the perspectives of both PREVENT MBCT therapists and
members of the trial LEG (see Chapter 3). This helped to enhance the relevance and acceptability of data
collection to patients and ensured that it was informed by the clinical judgements of MBCT therapists.
Reasons for declining participation at initial contact
Initial letters of invitation to participate in the PREVENT trial sent to potentially eligible patients identified by
GP practices provided a return envelope and reply form. This form allowed people who did not want to
participate to write their reasons for this, in response to the following prompt:
It helps us to plan research in the future if we know the reasons why this trial did not appeal to you.
We would be very grateful if you could write these reasons below, but we want to stress that this
is not something you have to do; we respect that this may be a private decision that you do not
want to share.
Space for up to four lines of text was provided. Basic demographic information was also collected using
this form.
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Telephone interviews with non-participants
The reply form referred to in the previous section also asked people who declined to participate in the trial
to indicate if they would be willing to conduct a brief telephone interview on their reasons for declining.
Of the 2157 individuals who indicated that they were not interested in participating in the trial, 290 (13%)
agreed to be interviewed and a sample of 16 was selected. Sampling was based on initial content analysis
of the first 50 written responses about reasons for non-participation provided on reply forms. Based on
this, we aimed to construct a sample of 16 interviewees using the following criteria: ADM issues – at least
four; therapy issues – at least four; lifestyle issues – at least four; others – up to four, including at least one
each from ‘research issues’ and ‘symptom issues’. We aimed to recruit from all of the four sites and to
ensure that a spread of basic demographic characteristics was included. This strategy ensured that the
diversity of the larger sample of people who gave reasons for non-participation was reflected in the sample
of people interviewed.
A smaller number of people declined trial participation after the initial telephone screening (n= 187;
see Figure 3). We aimed to conduct six to eight semistructured telephone interviews with members of this
group, with at least one person from each site in the sample. This subsample allowed exploration of any
impact of receiving additional information during a telephone screening interview on people’s reasons for
non-participation.
Telephone interviews for both of these groups were conducted within 1 month of the person declining
trial participation. They began with an initial open question about reasons for declining participation and
subsequently asked about the reasons identified by analysis of written responses provided on reply forms.
This included questions on participation in research, randomisation preferences, the nature of MBCT
and expectations of ADM use associated with each arm of the trial.
Data analysis
Written responses were transcribed verbatim into Microsoft Excel® 2010 (Microsoft Corporation, Redmond,
WA, USA). Content analysis was used to classify responses into basic categories of reasons for
non-participation. A collaborative approach to analysis was adopted by a small team of researchers who
worked together to establish, define and agree on content analysis categories using a subset of data
before these categories were used to analyse the complete data set.
Telephone interviews were audio recorded and transcribed, with any identifying information removed.
Data were analysed using thematic analysis113 in NVivo 10 software (QSR International, Warrington, UK).
The analytical strategy combined inductive and deductive approaches. Reasons for declining that were
used to categorise written response data were used as a starting point for data exploration. These were
added to as data analysis progressed, and main themes were divided into subthemes to capture complexity
and variation. A collaborative approach involving team working among a small group of researchers
enhanced the validity of the analytical process.
Results
Reasons for declining participation at initial contact
From a total of 19,608 invitations sent, 2157 people (11%) indicated that they were not interested in
participating in the PREVENT trial either by declining any further contact or after further discussion
with a member of the research team. Within this sample, 1535 (71%) participants were female and the
average age was 58.6 years (range 20–91 years; missing data for 25 cases). The sample was spread across
the different geographical areas: South Devon n= 490 (23%); North and Mid Devon n= 788 (37%);
Exeter and East Devon n= 580 (27%); and Bristol n= 299 (14%). These characteristics are similar to those
of the final sample of PREVENT trial participants (see Table 7) with the exception that the PREVENT trial
population was younger on average (mean age 49 years). Education and marital status are not reported as
fewer than half of the respondents provided this information.
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Because a minority of people gave more than one reason for not participating, responses added up to an
overall number of 2402 instances of coding. Of these, 120 codings (5%) were coded not eligible for
participation (mainly when participants did not fulfil trial inclusion criteria such as having three episodes of
depression or a diagnosis other than depression). Hence their responses were excluded from further
analysis. Furthermore, some 1109 (46%) codings did not reveal any reasons, yielding a final number of
valid codings of 1173 (49%).
Content analysis produced 10 categories of reasons, the distribution of which within the data is shown in
Figure 16. We further categorised these reasons into four broad areas as follows:
i. intervention-related issues – these are about use of ADM, therapy-related issues and the group-based
nature of the intervention
ii. personal circumstances – three categories of reasons relating to personal circumstances were found:
lifestyle issues, time issues and medical issues
iii. symptom-related issues – reasons relating to current symptoms and feelings of being in recovery
iv. research-related and other issues.
Other
7%
Lifestyle issues
13%
Medical issues 
12%
Time issues 
10%
Symptom
issues
8%
Research issues 
3%
ADM issues
19%
Recovering issues 
7%
Group issues
7%
Therapy issues
14%
FIGURE 16 Frequencies of reasons for non-participation provided in written responses on invitation reply forms.
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Intervention-related issues
The most commonly cited reasons for non-participation were related to the treatment interventions
provided in the PREVENT trial. Together these accounted for 40% of all reasons given. Within this, the
largest category related to use of ADM (19% of all responses). Most commonly, people reported that they
did not want to stop taking ADM (49% of ADM reasons). Other reasons were that people were no longer
taking ADM (24%), were currently coming off ADM (9%) and were happy with their current ADM use
(11%). The second most common category of reasons overall related to therapy issues (14% of all
responses). In total, 23% of responses in this category related to people having previously tried talking
therapies and a further 17% of responses related to reports that past therapy had not helped. Some
reported that they were currently receiving a different kind of therapy (19%) and others reported wanting
to avoid bringing up bad memories (16% of responses in this category). Related to this, a third category of
responses was about reluctance to participate, or anxiety about participating, in group-based therapy
(7% of all responses).
Personal circumstances
In total, 35% of responses described personal circumstances as a barrier to participation. The category of
lifestyle issues accounted for 13% of responses. Specific reasons within this category included feeling too
old (23%), moving house or relocating (17%), transport difficulties (14%) and feeling that participation
would mean taking on too much (15%). Health-related barriers were also common (given in 12% of
responses overall). Most frequently, people reported their own physical or health difficulties as a reason
preventing participation (47%), but caring for others (21%) and illness or death of a family member (15%)
were also cited. In total, 10% of responses overall cited lack of time, with one-quarter of these participants
specifically stating that they would be unable to take time off work.
Symptom-related issues
Symptom-related reasons for non-participation were cited in 15% of responses. Specific reasons within this
included considering that they suffered from anxiety more than depression (18%), feeling that they did not
suffer from depression (14%), that they were currently depressed (17%), that they were currently feeling
well or recovering (27%) or that they already had strategies in place to manage their depression (12%).
Research-related and other issues
The final 10% of responses referred to research-related issues (3%) and miscellaneous other reasons
that could not be categorised in other ways (7%). Just over half of the research-related reasons were that
people did not want to be involved in research or had concerns about this. Another common reason was
already being involved in research, currently or in the past.
Telephone interviews with non-participants
Telephone interviews were conducted with 16 people who declined to participate having received an
initial invitation letter and six people who declined to participate after telephone screening. Demographic
information for these subgroups in comparison with that for PREVENT trial participants is provided in
Table 22.
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Table 22 shows that the main differences between these non-participant samples and the PREVENT trial
participants are that there are slightly higher proportions of women in the non-participant samples and the
non-participant samples are older on average. The two non-participant subsamples are broadly similar to
each other.
Analysis identified nine broad thematic areas within the interview transcripts, with subthemes within each.
The frequency of coding across interviews using these themes is show in Table 23.
Table 23 shows the application of a theme at any point in an interview transcript but does not provide
further information on how often or where themes were used in interview transcripts or the relative weights
or meanings attached to these. To explore these more complex issues, a distinction was made between
reasons for non-participation provided in response to an initial open question at the beginning of the
interview (‘Could you tell me the reason or reasons why you are not interested in taking part in this research
study’) and reasons provided later in the interview in response to prompts about barriers to participation
identified from written replies. It was assumed that reasons given in response to the first open question
would usually be the most important for an individual. The distribution of themes and subthemes for first
question responses and later parts of the interview and the co-existence of themes within interview
transcripts is shown in Appendix 7. Details of each of the thematic areas are reported below in descending
order of frequency with which they occur as ‘principal’ reasons for declining participation (i.e. in response to
the initial open question). Exploration of these did not detect any obvious differences between the two
subsamples of interviewees (those interviewed before telephone screening and those interviewed after).
Accordingly, findings from the two subgroups are reported together, yielding a total sample of 22 interviews.
TABLE 22 Demographics of declining samples and the final PREVENT trial sample
Demographic characteristics
Pre-screen decliners
(n= 16)
Post-screen decliners
(n= 6)
PREVENT participants
(n= 424)
Age (years)
Mean (SD) 56.8 (11.1) 59.0 (11.8) 49.4 (12.3)
Range 40–72 44–77 20–79
Missing, n 1 1 0
Female, n (%) 13 (81) 5 (83) 325 (77)
Recruitment site, n (%)
Exeter and East Devon 3 (19) 1 (17) 148 (35)
North and Mid Devon 6 (38) 2 (33) 109 (26)
South Devon 5 (31) 2 (33) 103 (24)
Bristol 2 (13) 1 (17) 64 (15)
Marital status, n (%)
Single 2 (13) 0 (0) 80 (19)
Married or living together 10 (63) 2 (33) 264 (62)
Separated, divorced or widowed 2 (13) 1 (17) 77 (18)
Missing 2 (13) 3 (50) 3 (1)
Employment status, n (%)
Employed 5 (31) 3 (50) 240 (57)
Unemployed or retired 9 (56) 1 (17) 178 (42)
Missing 2 (13) 2 (33) 6 (1)
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TABLE 23 Frequency of themes and subthemes within interview transcripts
Theme Subthemes
Pre-screen
(n= 16)
Post-screen
(n= 6)
Total
(n= 22)
Taking part in a research trial No concerns 15 5 20
Safety and reliability concerns 4 1 5
Wanting to help others 2 2 4
Previously taken part in research 2 1 3
ADM-related issues Wants to remain on ADM 14 6 20
Wants to come off ADM 7 2 9
Does not want to take ADM for 2 years 1 0 1
Not regularly taking ADM 1 0 1
Being randomised to a trial arm Would like to choose group 9 4 13
Would like to be in the ADM group 7 2 9
Would like to be in the therapy group 2 2 4
No worries about randomisation 3 1 4
Time issues Not the right time 9 4 13
2 years is too long 2 0 2
Working full time 1 1 2
Attitudes to psychological intervention Had therapy before 7 4 11
Previous therapy unhelpful 3 3 6
Previous therapy helpful 4 1 5
Therapy and ADM complementary 2 0 2
MBCT-related issues Meditation is a good idea 7 4 11
Not keen on meditation 4 1 5
Conflicts with religious interests 1 0 1
Being in a group Unhappy with group therapy 9 1 10
No concerns about group therapy 3 2 5
Lifestyle and medical barriers Too unwell 3 2 5
Cannot travel to sessions 3 1 4
Too old 1 1 2
Symptom-related issues Not depressed enough 5 1 6
Depression is contextual 4 3 7
Depression because of chemical
imbalance
2 1 3
Worried about relapsing 4 0 4
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Antidepressant medication-related issues
The most prominent reasons for declining participation were related to ADMs. Concerns about ADMs
were raised by all of the interviewees, nearly half of whom (n= 10) discussed ADMs in response to the
initial open question. For the majority (18/22), the principal concern was about potentially stopping or
reducing their ADM. Most people felt that they needed to take ADM, or were well when they were taking
it, and they did not want to jeopardise this or risk relapse/recurrence if randomised to the treatment arm.
When I read through the literature I believe um it w- . . . t’was about stop taking medication and um
I wasn’t really prepared to do that because it has taken me a long time to sort of get the balance right
um and that would I think that would I didn’t want to stop and jeopardise that was I think that was
um what I recall.
2007
For nine people, the concerns around ADMs related to the fact that they would like to eventually come off
their medication. For some of these people the risk of being randomised to the m-ADM arm, and feeling
that this would entail a loss of choice or flexibility, was a bigger concern.
In agreeing to this I’d have to agree to keep taking my medication for you know the next 2 years. It
may be that I wanna come off my medication in a year or so’s time you know so that was an issue.
Um you know um so . . . you know I’d feel I’m sort of trapped on medication as it were you know, err,
I may not want to be trapped on medication or I might feel that at some point in the fairly near future
it might not be a bad idea to come off . . . I have a feeling if I committed to this then that would um
that would maybe cramp my options a bit.
2001
Three people described having already started to reduce their ADMs and their hopes that they would be
able to stop taking them in the near future.
Time issues
The second most common reasons for non-participation involved time-related issues, with more than half
(13/22) mentioning time constraints at some point in the interview and 10 people citing time constraints
in response to the initial open question. Reasons related to people’s circumstances and predominantly
included not having enough time for the study or it not being the right time in their lives. Two people
worked full-time and as such were not able to attend MBCT sessions that were mostly run during working
hours. Of those who were employed, nearly all mentioned time constraints as a reason for declining,
whereas only half of those who were retired discussed this. Those who were married also tended to give
time constraints as a reason for declining. Two people declined as they felt that 2 years was too long a
time to be involved in a research study.
Um it is time, it is purely because I just don’t have the time. I’ve taken on so many other new
commitments which are quite essential commitments you know jobs and things like that that really
need enough time to commit to properly. And rather than start it and give it up, it’s probably best not
to start it.
3005
I mean primarily I haven’t got time. Um I work 2 days a week um, I’ve got an elderly mother I look
after and I look after my grandson as well so in the literature that you sent out you said about going
to group meetings and things like that. I haven’t got time to do it basically.
2005
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Lifestyle and medical barriers
Ten people cited practical or medical reasons for non-participation, of whom six gave such reasons in
response to the first open question. Five respondents said that they were unable to participate in the
PREVENT trial because of physical health problems that meant they felt unable to commit to attending
treatment. For four people, travelling to and from sessions was a barrier. Two people felt that they were
too old to take part, although the exact reasons for this remained unstated:
I: To begin with it would be really helpful if you could tell me the reason or reasons why you are not
interested in taking part in this research study.
2013: Er it’s not so much not interested, er I wouldn’t like to put it like that really, but the fact is I can
hardly get about anyway myself ‘cause I walk on sticks, I’ve had problems with my back and also my
husband has recently been diagnosed with heart problems and so he’s not well himself. So he’s the
one that does the driving and all that so it’s something I don’t really want to be doing at this point
in time.
No no my general view is that at this stage in my life because of my age I really don’t need to
take part.
3008
Being in a group
Ten individuals reported feeling uneasy with the idea of group-based treatment or said that they would
feel more comfortable with one-to-one contact. Four of these people gave this reason in response to the
first question.
When my depression is really bad . . . and you’re sort of crying out for help um it’s very . . . the
thought of . . . being within a group of people you know um is quite daunting in a way, at the best
of times. . . . I really didn’t want to be in a group situation with people who were potentially my
neighbours or the people who worked in the café or the bank, you know, locally to me.
2014
You know I d- you know I I think there are a lot of people out there that probably feel the same as
me, but I realise that and I don’t really think I want to . . . go into a group (.2) you know I, I – just one
of those things, I just don’t want to do it really.
2009
However, the group-based nature of MBCT was not a universal barrier and five individuals said that they
would not mind taking part in group-based therapy.
But when you’re talking to a stranger sometimes if they can gain your confidence then you feel as
though you can talk to them more and tell exactly how you’re feeling. But I think that um group
therapy is a good thing actually.
2013
Attitudes to psychological intervention
Half of the individuals interviewed (11/22) had some previous experience of psychological therapy, of
whom six had found this unhelpful.
Because I’ve had therapy in the past, counselling sessions actually, the reason I considered this is
because the counselling session didn’t actually help, going back over and over again on all the issues
and actually why I was upset and feeling unhappy actually just made me feel more upset than happy.
So I found that wasn’t particularly beneficial for me, and I had a, you know, sort of aversion to therapy
to do with one particular therapy incidence.
3005
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Of the six that found psychological therapy unhelpful, three mentioned negative experiences of therapy in
the past in response to the first open question. The most common forms of therapy experienced were CBT
and counselling. One person had received hypnotherapy and another had seen a psychiatrist.
Mindfulness-based cognitive therapy-related issues
The nature of MBCT treatment was seen as a barrier to participation by some respondents but as a
facilitator by a larger proportion of respondents. Half of the individuals interviewed thought that therapy
incorporating meditation was a good idea. Some mentioned that they already practised some form of
meditative techniques such as breathing exercises, yoga or t’ai chi and so were open to the meditative
aspects of MBCT.
Um I think it sounds very good, I’ve tried meditating in the past and you know err breathing
techniques and stuff and the idea of it sounds really good.
2007
However, five people expressed concerns about meditation forming a large part of MBCT and appeared
sceptical of its benefits.
I’ve tried yoga in the past and tried to meditate. My problem with that is I just I find it very hard and I
end up making mental lists of all the different things I have to do and my mind doesn’t switch off.
3006
Only one person cited the nature of MBCT as a significant barrier in response to the first question.
This person’s concerns centred on perceived incompatibilities with religious beliefs.
No I think it was to do with somebody like you ringing up and explaining what was going to happen,
and I wasn’t happy with it because I’m a Christian and it didn’t hold with my beliefs I think. It was err,
I felt it was very based on Eastern religions, Eastern philosophy and that, and that was uncomfortable.
I thought the meditation where you’ve got to clear your mind I’m not happy with that anyway, and I
just felt it was more like younger based, and I think that’s what concerned me more than anything.
2010
Symptom-related issues
Twelve participants discussed symptom issues as a barrier to participation, although only one person cited
this in response to the first question. Six people said that they did not consider themselves to be depressed
enough or were no longer suffering from depression. Seven people described their depressive symptoms
as contextual or a consequence of specific life stressors. As such, they felt that their symptoms did not
warrant psychological therapy.
I’ve always been a person in c- basically in control of myself I mean m- much of my trouble was
caused all the work rather than anything else you know? Particularly when I took them [ADMs] before
I don’t remember when that was now um but it was caused too much work.
2002
Four people said that they had concerns about relapsing as a consequence of reducing their ADM during
MBCT-TS treatment.
I have twice in the past tried to come off the tablets um you know it was quite a long time ago, and
after I’d got down to a certain dose I became ill again and you know it’s not something I want to
happen, you know me taking 3 weeks off of work, which um is never good for me or the department
you know. With a responsible job you can’t um you can’t really do that.
2006
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Being randomised to a trial arm
Only one person cited trial randomisation as a barrier to participation in response to the first
open question.
I just saw it as an opportunity, and I think if I’d been in a group that wasn’t actually receiving the help,
in the other test group [m-ADM] I would find it very disappointing and it may even affect me and I’d
feel maybe unfairly treated perhaps. Whereas I should have been looking at it as a research project,
um I was probably looking at it as some sort of therapy for me really.
3003
However, when asked later in the interview about being randomised to MBCT or m-ADM, 13 people said
that they would prefer to have a choice rather than be randomised. Of these, nine said that they would
like to be placed in the m-ADM group and the remainder said that they would choose to receive MBCT.
Only four respondents did not mind which trial arm they were placed in.
Taking part in a research trial
In response to a question about taking part in research generally, the majority of respondents (20/22)
either had no concerns about taking part in a research study or said that they would be happy to do so if
the circumstances were right for them. Four people said that they would take part in research to help
other people and three individuals had previously taken part in a trial.
I’m absolutely fine with that, taking part in a research study, I don’t have any problem with that at all.
2007
Five people voiced concerns about the safety and reliability of research. These ranged from concerns about
data confidentiality to concerns about the qualifications and professionalism of research staff.
I guess it’s to do with things around privacy and confidentiality of data, stuff to do with that and to do
with the uses to which data might be put in the future by persons unknown, as it were, you know, or
authorities of note. There is an issue for me with that, but it wouldn’t necessarily put me off taking
part in something like this, but it is a nagging issue I feel, personally yeah.
2001
Discussion
Barriers to participation in the PREVENT trial
It is difficult to collect reliable data on why people choose not to participate in research or treatment and
hence there is little good evidence on this issue. Our attempts to do so yielded data from < 5% of the total
sample who were sent initial invitation letters. It is not possible to judge how representative this subsample is
of the larger number of people who were invited to take part, in terms of either their sociodemographic and
clinical characteristics or their reasons for not wanting to participate.
Given these sample-related caveats, data from reply forms allowing people to decline participation in the
PREVENT trial and provide brief reasons for this suggest that views on the interventions being tested within
the PREVENT trial were a principal barrier to participation. Overall, these accounted for 40% of the reasons
given at this early stage, with ADM issues – most typically people being reluctant to consider stopping their
ADM – being commonly cited (19%). A large proportion of people (21%) also expressed a reluctance to
engage with therapy or a group-based intervention (although this was not always about therapy per se as
some people reported already receiving another form of therapy). A further 33% of responses cited
personal circumstances as barriers to participation. These included health issues, time constraints, caring
commitments and transport issues.
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Data from telephone interviews allowed more in-depth exploration of reasons for non-participation.
Interviewees were carefully selected to be broadly representative of the larger non-participant group
according to reasons given on reply forms. Reasons provided in brief written responses were replicated in
these data and no new themes were detected. The same four broad clusters of reservations were expressed:
intervention-related concerns, personal circumstances, symptom-related issues and research-related concerns.
However, a richer understanding of these reasons was obtained and features that were attractive or at least
acceptable, as well as those perceived to be barriers to participation, were discussed. This highlights that
barriers are not universal. Many respondents had no problems with the prospect of participating in research,
psychological therapy and treatment that incorporates meditation practices. Smaller numbers did not object
to group-based treatment or being randomised. Interview data also shed light on relationships between these
themes. In particular, concerns about randomisation appeared to be primarily motivated by preferences
relating to ADM use.
Taking the findings from these two substudies together, the principal barrier to participation in the
PREVENT trial at the point of recruitment appeared to be expectations surrounding ADM use. This applies
to both arms of the trial. For most people, their concerns centred on being randomised to MBCT-TS,
as they did not consider themselves to be in a position to taper their ADM. Although ADM tapering is
presented as an invitation rather than a requirement by MBCT-TS therapists, the perceived expectation of
this presented a considerable barrier at this point. For a smaller group of people, reluctance to participate
related to being randomised to the m-ADM arm, as this carries an expectation of continuing on ADM for
2 years, a prospect that may not be acceptable to many.
Preferences for ADM use appeared to be the principal reason why randomisation within the PREVENT trial
was off-putting to many, as it is perceived to remove choice and flexibility. This may be a particularly large
barrier within the PREVENT trial, which involved a 2-year follow-up period, and for a participant group with
long-term mental health problems who may have developed functional self-management strategies based
on experiential knowledge of ADMs that they are reluctant to disrupt. As such, randomisation without
taking account of patient preferences runs counter to the promotion of self-management, patient choice
and expertise by experience that features in much current policy rhetoric in health and mental health.
Randomisation appeared to be the principal barrier to research participation as few other concerns about
involvement in research were expressed and the majority of interviewees were positive about participating
in research.
Other than ADM-related issues, several identified aspects of the acceptability of MBCT-TS may apply equally
to MBCT. The expected time commitment and the group-based nature of treatment appear to be two
important perceived barriers at the point when people are deciding whether or not to participate. The
considerable time commitment of MBCT participation and home-based practice may not be compatible with
many people’s life circumstances. Although the group-based nature of treatment is off-putting to some,
previous research on MBCT has found that initial concerns about group work are often replaced by
recognising the value of sharing experiences in a safe environment during and following treatment.111,114
For a significant minority, physical health may be a barrier to participation. Although negative experiences of,
or expectations of, talking therapies were cited as reasons for non-participation by some, the nature
of MBCT did not seem to be a concern for most at this stage. A small number of interviewees found the
prospect of meditation off-putting, but a larger number expressed interest in or positive views of a
meditation-based treatment.
There are some suggestions than non-participants may be older than participants (average age of 59 years
for written response data participants and 57 years for interviewees compared with 49 years for PREVENT
participants). Interestingly, feeling too old as a reason for non-participation appeared in a small number of
both written responses and telephone interviews.
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Findings can contribute to informing both clinical practice and future research trials on MBCT. The external
validity of RCTs can be undermined by low recruitment rates. These data provide a window on reasons for
the relatively low recruitment rate in the PREVENT trial (424 from an initial total of 19,608 people invited).
Exploring barriers to participation and their impact on the composition and characteristics of trial
participant groups is an important aspect of interpreting trial results. Findings also have implications for
clinical practice in highlighting features of MBCT-TS and MBCT that may prevent people who are offered
this treatment from taking it up. This counters the tendency in previous qualitative research to focus on
the benefits of MBCT for those who engage meaningfully with treatment,30 at the expense of exploring the
experiences of others who do not engage. Awareness of these barriers may help practitioners to put in
place strategies to overcome reluctance to commence therapy and may help to increase the accessibility of
mindfulness-based treatments.
Other qualitative studies within the PREVENT trial
As well as the data reported in this chapter, two further sources of qualitative data were collected within
the PREVENT trial with the aim of addressing the following research questions:
1. The acceptability of MBCT-TS. We conceptualise acceptability as dynamic and related to various levels of
knowledge and experience of MBCT-TS at different stages of recruitment and participation. Further
data analysis will focus on barriers to and facilitators of MBCT-TS at later stages of participation, during
and after treatment.
2. Mechanisms of change in MBCT. This extends previous qualitative work30 in two ways, first by using
larger numbers and purposive sampling and second by drawing on insights from quantitative studies of
change mechanisms.37 Qualitative explorations of processes that have been identified as mediating
outcome, such as self-compassion and reactivity, may strengthen understanding of how MBCT works.
3. Participants’ attitudes towards and experiences of ADM with and without MBCT (including ADM
tapering and continuation). Monitoring of ADM usage within the PREVENT trial suggests considerable
variability in adherence, especially in the MBCT arm (see Chapter 4). No previous qualitative work has
been carried out on experiences of combining MBCT with ADM tapering.
The following two sources of qualitative data were collected:
1. Feedback booklets. All trial participants were asked to provide written accounts of their experiences in
feedback booklets provided at two time points: 1 month post MBCT-TS (or the equivalent time point for
those in the m-ADM arm) and at 24 months’ follow-up. This design helps avoid the influence of memory
biases, allows longitudinal comparisons and ensures equipoise. Four feedback booklets were created
(1 month post MBCT-TS, 24 months post MBCT-TS, 1 month post m-ADM, 24 months post m-ADM).
Members of the LEG provided feedback about the wording of booklet questions, the choice of issues
covered and the time needed to complete them. To ensure sensitivity to the range of participants’
experiences, the design of the 24-month booklets was informed in part by responses obtained at the
1-month time point. Booklets covered the following topics:
i. 1 month post MBCT-TS: (i) attitudes towards and experiences of taking and reducing ADM;
(ii) experiences of taking part in MBCT-TS and MBCT-TS practices; (iii) the impact of MBCT-TS
ii. 24 months post MBCT-TS: (i) experiences of MBCT-TS reunions; (ii) carrying out mindfulness
practices; (iii) the impact of continued MBCT-TS practice; (iv) ongoing experiences of medication use
and possible tapering in relation to MBCT-TS impact
iii. 1 month post m-ADM: (i) acceptability of using ADMs in general; (ii) perceived effectiveness of
ADMS; (iii) experiences of ADM continuation within the trial
iv. 24 months post m-ADM: (i) attitudes to and experiences of continuing to take ADMs during the
trial; (ii) deviations from the ADM use protocol during the trial; (iii) reasons for and impacts of
any changes.
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2. End-of-trial interviews. Semistructured interviews were designed to explore experiences during the
follow-up period of use of ADMs and MBCT-based techniques, in relation to each other, during periods
of wellness and depressive relapse/recurrence and during transitions between them. The research team,
informed by responses from a sample of 1-month post-MBCT-TS feedback booklets and feedback from
the trial LEG, developed interview topic guides. Interviews were structured around discussion of periods
of wellness, early signs of depressive relapse/recurrence (referred to in interviews as ‘wobbles’) and
depressive relapses/recurrences. For each of these, questions explored the use and value of mindfulness
techniques, use of ADMs and use of a combination of mindfulness techniques and ADMs. The final
section of the interview asked about the broader impacts of participation in the trial on other life
domains, sense of self and views of depression. A sample of 40 interviewees was constructed according
to principles of maximum variation sampling, aiming to access a range of participant positions and
characteristics relevant to the research questions.115 Interviewees were selected evenly across the four
study sites and to broadly reflect the sociodemographic characteristics of the full trial sample. In
addition, we sampled according to treatment response (depressive relapse/recurrence or not) and
medication usage during follow-up (four categories: stopped, stopped and resumed, reduced but never
stopped and did not reduce or stop). Face-to-face interviews were conducted in participants’ homes
and lasted between 45 minutes and 1 hour.
These data collection strategies will enable a combination of depth of understanding within a purposively
selected sample and breadth of data collected from all PREVENT trial participants. The 2-year follow-up
period of the PREVENT trial allows exploration of how MBCT-TS impacts on people’s depressive symptoms
and lives over a much longer time period than has previously been studied. Careful sampling of
respondents for end-of-trial interviews ensures that this data set is genuinely reflective of the range
of relapse/recurrence, ADM use and MBCT-TS experiences across trial participants. Analysis of these data
sources will be reported in subsequent published papers, adding complexity and further understanding to
the trial’s results.
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Chapter 8 Discussion and conclusions
Principal findings
The overarching aim of the PREVENT trial was to establish whether or not MBCT-TS provides an effective
alternative relapse/recurrence prevention approach to m-ADM in primary care settings for patients with a
history of recurrent depression. Specifically, we asked a primary policy research question: ‘Is MBCT-TS
superior to m-ADM in terms of a primary outcome of preventing depressive relapse/recurrence over
24 months?’ Secondary outcomes were depression-free days, residual depressive symptoms, psychiatric and
medical comorbidities, quality of life and cost-effectiveness. The study was conducted in line with both
CONSORT guidance74–76 and our published protocol.78,83 Participant recruitment, flow and data completeness
were above estimated thresholds. We are, therefore, able to answer the key research questions.
There was no evidence for the superiority of MBCT-TS over m-ADM for patients with recurrent depression
in terms of either the primary outcome of time to depressive relapse/recurrence over 24 months or any of
the secondary outcomes (see Chapter 4). The cost-effectiveness analysis does not support the hypothesis
that MBCT-TS is more cost-effective than m-ADM, in terms of either relapse/recurrence or QALYs
(see Chapter 5).
In a predefined subgroup analysis,83 we found that time to relapse/recurrence at 24 months for
participants with a higher severity of reported childhood abuse was delayed in the MBCT-TS arm,
compared with the m-ADM arm.
Finally, the first results from our process studies suggest that, although changes in mindfulness were
greater in the MBCT-TS group than in the m-ADM group, they did not mediate time to relapse/recurrence
at 24 months (see Chapter 6). In terms of acceptability, the qualitative analyses suggest that people have
views about (dis)/continuing their ADM that can serve as a facilitator and barrier to taking part in a trial
that requires either continuation for 2 years or discontinuation (see Chapter 7).
Research findings in context
Relapse/recurrence rates in people with three or more previous episodes are as high as 80% over 2 years.6
Moreover, meta-analyses consistently suggest that m-ADM reduces the relative risk of relapse/recurrence
by two-thirds compared with placebo, a halving of the absolute risk.9 Therefore, it is likely that MBCT
would provide benefits over and above either no treatment or pill placebo.
Outcomes were comparatively good across both treatment arms in the PREVENT trial in terms of
relapse/recurrence over the 2 years of follow-up compared with those in previous trials (i.e. MBCT-TS 44%,
m-ADM 47%). Moreover, PREVENT trial participants reported residual depressive symptoms within the
minimal range and quality of life in the range ‘good’ at each follow-up point. This suggests that participants
in both arms experienced relatively good mental health and quality of life over the follow-up period.
Before the PREVENT trial, only two small studies had compared MBCT-TS with m-ADM. In our pilot trial
with 123 participants, MBCT-TS (n= 62) was compared with m-ADM (n= 61) over 15 months’ follow-up.28
The relapse/recurrence rate was 47% for MBCT-TS and 60% for m-ADM. In a second study, 84 patients
with recurrent depression who had remitted on ADM were randomised to MBCT-TS, m-ADM or pill
placebo.51 Relapse/recurrence rates observed over 18 months of follow-up did not differ between
MBCT-TS (28%) and m-ADM (27%; p= 0.93) and both MBCT-TS and m-ADM were superior to placebo
(71%; p= 0.007).
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Since the start of the PREVENT trial, a key systematic review and meta-analysis has been published that
included six RCTs comparing MBCT with usual care, m-ADM or placebo (including the two previously
described trials) (n= 593). The pooled estimate from this review shows that MBCT reduces the risk of
relapse/recurrence compared with usual care or placebo (risk ratio 0.66, 95% CI 0.53 to 0.82).116
Since this systematic review/meta-analysis, several additional large-scale trials of MBCT have been
published117–119 or are due to be published soon.120 The Staying Well After Depression (SWAD) trial
compared MBCT with cognitive psychoeducation plus usual care and usual care alone in 274 participants
currently in remission but reporting at least three previous episodes of depression.117 The SWAD trial
reported no significant effect of treatment on risk of depressive relapse/recurrence over the 12-month
follow-up (MBCT vs. psychoeducation: HR 0.88, 95% CI 0.58 to 1.35; MBCT vs. usual care: HR 0.69, 95% CI
0.42 to 1.12). In another recent RCT, 203 non-depressed adults with a history of three or more previous
episodes of depression were randomised to MBCT plus depression relapse active monitoring (i.e. training
in self-management of depression and monthly monitoring of symptoms) (n= 101) or active monitoring
alone (n= 102).119 The DARE trial found no significant difference between the two treatment arms for the
primary outcome of time to first relapse/recurrence over 24 months, although there was some evidence that
proportionally fewer people relapsed in the MBCT arm than in the active monitoring alone arm (odds ratio
0.68, 95% CI 0.38 to 1.23). It is noteworthy that the absolute rates of relapse/recurrence in the usual care
arms of these two more recent trials are lower than those seen in earlier RCTs. In total, 66% relapsed in the
usual care arms in the Piet and Hougaard systematic review116 compared with approximately 50% in the usual
care arms in the DARE119 and SWAD117 trials at 12 months’ follow-up.
Economic evaluation found group-based MBCT-TS to be a relatively inexpensive intervention compared
with individual therapies. In line with previous results from our pilot study,28 there was little difference in
the use of other health and social services between the groups, resulting in only a small difference
in the total costs of care over 24 months between the two groups. Coupled with small, non-significant
differences in outcome, MBCT-TS failed to demonstrate cost-effectiveness compared with m-ADM.
Consistent with an emergent pattern of findings,117 MBCT may confer most benefit to patients at greatest
risk of relapse/recurrence. Earlier trials24,25 and NICE guidance8 suggest that MBCT is indicated for patients
who have a history of three or more previous episodes of depression. In the SWAD trial,117 a subgroup
analysis compared participants reporting greater or lesser childhood adversity. For participants reporting
greater childhood adversity MBCT conferred better protection against relapse/recurrence than both
psychoeducation and usual care (MBCT vs. psychoeducation: HR 0.61, 95% CI 0.34 to 1.09; MBCT vs.
treatment as usual: HR 0.43, 95% CI 0.22 to 0.87). The PREVENT trial results replicate the SWAD
finding and converge with those of earlier studies suggesting that patients at greatest risk of depressive
relapse/recurrence may benefit most from MBCT. Trials of other psychosocial approaches have shown that
more intensive psychosocial treatments result in greater protection for those most at risk. For example, in a
two-arm RCT with 21 months’ follow-up, relapse/recurrence rates were 51% for maintenance CBT and
60% for psychoeducation but, among those at greatest risk, CBT conferred greater protection than
psychoeducation.121 A reported history of abuse and adversity is associated with worse outcomes among
people who suffer depression.122 Perhaps MBCT confers resilience in this group at highest risk because
patients learn skills that address some of the underlying mechanisms of relapse/recurrence, a question
that we will seek to explore in a subsequent publication from this trial. Future trials of MBCT need to
focus on the question of the effectiveness and mechanism of action of MBCT for those at differing risk of
relapse/recurrence, with broad and robust measures of risk.
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Strengths and limitations
Strengths of the PREVENT trial include the following.
l The pragmatic main study question is of high relevance to the NHS. The study answered an important
clinical question of high relevance to GPs and patients at risk of depressive relapse/recurrence.
l The trial was a multicentre RCT conducted in accord with both CONSORT guidance and our published
protocol/statistical analysis plan.
l This is the largest trial of MBCT for recurrent depression to date. Good recruitment/retention rates and
low levels of missing data mean that the trial was adequately powered and able to answer the primary
research question.
l The study benefited from a comprehensive economic evaluation, providing evidence to support
resource allocation decision-making of both clinical and policy relevance.
l Treatment fidelity with respect to both arms of the trial was designed into the trial and high levels of
fidelity ensured high internal validity.
l The 2-year follow-up allowed assessment of the impact of MBCT-TS over a time period that was
comparable to or longer than that in all MBCT trials completed to date.
l A parallel process evaluation was undertaken to provide contextual understanding and examine the
mechanism of action of MBCT.
Limitations of the PREVENT trial include the following.
l Our recruitment strategy involved searching primary care databases and inviting patients who were
currently taking m-ADM rather than recruiting patients who were discussing their options with their GP
for preventing relapse/recurrence.
l The design included neither a usual care nor an attention control arm. The absence of an attention
control arm means that any effects of MBCT-TS or m-ADM cannot be inferred to be specific to
these treatments.
l The m-ADM arm included active monitoring of adherence by the research team and in this sense might
best be represented as enhanced m-ADM.
The pragmatic nature of the trial resulted in a proportion of patients in both arms not complying with the
invitation to (dis)continue ADM. We undertook a per-protocol analysis to examine the impact on the primary
outcome inference compared with ITT analysis. This is both a strength (pragmatism and generalisability) and
a limitation (the ADM was not completely controlled). Finally, the sample consisted of a group at high risk
of depressive relapse/recurrence,123 currently taking ADM, who were open both to considering a group-based
psychosocial treatment and to (dis)continuing their ADM. This is both a strength and limitation of the study.
The findings of the PREVENT trial are therefore generalisable to only those individuals who are in equipoise
about the type of preventative treatment that they choose, that is, m-ADM or switch to psychosocial
intervention and reduce their ADM.
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Implications for practice
Depression is a major public health problem that tends to run a recurrent course, producing substantial
decrements in health and well-being. The cost of mood disorders to the UK economy is substantial. Most
of the prevalence, burden and cost of depression is a consequence of recurrent depression and could be
offset through providing a range of psychosocial low- and high-intensity treatments.4
Mindfulness-based cognitive therapy with support to taper/discontinue ADM may confer ongoing
protection for patients who would like an alternative to m-ADM. Many patients with recurrent depression
may have been on m-ADM for many years and for a variety of reasons would prefer to learn skills that
they can use to stay well. The results further suggest that psychosocial treatments such as MBCT and
CBT117,121,124 offer added value for patients who need them most, that is, those at highest risk of depressive
relapse/recurrence. The investment of effort by these patients in learning the skills taught in psychosocial
treatments such as CBT and MBCT pays off. However, for patients at low risk, treatments such as
psychoeducation or m-ADM, which require less patient commitment and cost, may be indicated. This has
significant potential to improve prevention by maximising the delivery of treatments through stratified
approaches, which also have the potential to improve patient choice. As patients with recurrent depression
select options to stay well in the long term, these findings taken together with the broader emergent
literature suggest a number of alternatives. It is clear that m-ADM is an effective mainstream approach.
For patients at low risk of relapse low-intensity interventions may be indicated and for patients at high risk
high-intensity treatments such as MBCT may be indicated.
Future research
There are several key areas for future research:
l Given the completion of the PREVENT trial and the recent publication of other large RCTs, an updated
meta-analysis is indicated to re-examine evidence for MBCT as a strategy for the prevention of
depressive relapse/recurrence in the context of alternative treatments that include usual care, other
active treatments such as m-ADM and additive therapy approaches (e.g. MBCT plus m-ADM). An
alternative strategy would be to conduct a large cohort study or effectiveness study to examine the
effectiveness of MBCT and m-ADM in various real-world scenarios.
l Furthermore, an individual patient data meta-analysis of published trials would help address the
question of which specific patient subgroup MBCT is best indicated for. There is emerging evidence
that MBCT is most effective for those at highest risk of relapse/recurrence and an individual patient
data analysis could provide the empirical evidence to address this question.
l Studies have tended to operationalise risk in somewhat different ways (e.g. early adversity, unstable
remission, a greater number of previous episodes, early age of onset) and, although these risk factors
overlap, future research should examine how and through what mechanism risk is conferred and
resilience learned.
l In addition to further analysis of the process data from the PREVENT trial and recently completed large
MBCT RCTs, future trials need to incorporate process studies and consider dismantling designs to
further unpack MBCT’s mechanism of action. This could enhance the specificity and efficacy of MBCT.
l Given the current NICE guidance that MBCT should be offered to patients with three or more previous
episodes of depression, and the limited availability of MBCT within the NHS, research is needed to explore
the facilitators and barriers to implementation. This National Institute for Health Research-funded work is
in progress.22
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Conclusions
In a large, rigorous yet pragmatic RCT we have demonstrated that MBCT-TS is not superior to m-ADM
over 2 years of follow-up for patients with recurrent depression. Benchmarked against epidemiological
data, both treatments were associated with enduring positive outcomes in terms of relapse/recurrence,
residual depressive symptoms and quality of life. This study provides important evidence that MBCT-TS may
confer ongoing protection for patients who would like an alternative to m-ADM. The results further
suggest that psychosocial treatments, such as MBCT and CBT,117,121,124 offer added value for patients who
need them most, that is, those at highest risk of depressive relapse/recurrence. However, studies have
tended to operationalise risk in somewhat different ways (e.g. early adversity, unstable remission, a greater
number of previous episodes, early age of onset) and, although these risk factors overlap, future research
should examine how and through what mechanism risk is conferred and resilience learned. In the interim,
the implication is that, for patients at low risk, treatments such as psychoeducation or m-ADM, which
require less patient commitment and cost, may be indicated, whereas for patients at highest risk more
intensive treatments such as MBCT may be indicated. This has significant potential to improve prevention
by maximising the delivery of treatments through stratified approaches, which also have the potential to
improve patient choice.
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Appendix 1 Serious adverse event form and
suicidal thoughts protocol
Serious adverse event form
Report of Serious Adverse Event, version 3.0, April 2007 
 
 
REPORT OF SERIOUS ADVERSE EVENT (SAE) 
 
The Chief Investigator should report any SAE that is both related to the research procedures 
and is unexpected.  Send the report to the Research Ethics Committee that gave a 
favourable opinion of the research within 15 days of the CI becoming aware of the event.  
For further guidance see: http://www.nres.npsa.nhs.uk/applicants/review/after/safety.htm. 
 
1. Details of Chief Investigator 
 
Name: Prof Willem Kuyken 
Address: 
 
Mood Disorders Centre 
School of Psychology 
Washington Singer Laboratories 
University of Exeter 
Perry Road, Exeter 
EX4 4QG 
Telephone: 01392 724659 
Email: w.kuyken@exeter.ac.uk 
Fax: 01392 264623    
 
2. Details of study 
 
Full title of study: 
Preventing depressive relapse/recurrence in 
NHS settings through mindfulness-based 
cognitive therapy (MBCT) 
Name of main REC: South West Research Ethics Committee 
Main REC reference number: 09/H0206/43 
PCT number: (NHS Devon) 0739 
Research sponsor: University of Exeter 
Sponsor’s reference for this report: 
(if applicable) 
 
 
3. Type of event 
Please categorise this event, ticking all appropriate options: 
 
Death Life threatening  
                               
 
Hospitalisation or  
prolongation of existing 
hospitalization  
 
Persistent or significant 
disability or incapacity 
Congenital anomaly  
or birth defect 
 
Other 
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Report of Serious Adverse Event, version 3.0, April 2007 
4. Circumstances of event 
 
Date of SAE:  
Location:  
Describe the circumstances of 
the event: 
 
(Attach copy of detailed report if 
necessary) 
 
What is your assessment of the 
implications, if any, for the 
safety of study participants and 
how will these be addressed? 
 
Causality:  
Expectedness:  
 
 
 
 
5. Declaration 
 
Signature of Chief Investigator:  
Print name: 
Professor Willem Kuyken 
Date of submission: 
 
 
 
 
 
 
 
6. Acknowledgement of receipt by main REC (please insert name): 
 
The South West Research Ethics Committee Research Ethics Committee acknowledges 
receipt of the above. 
 
Signed:  
Name:  
Position on REC:  
Date:  
 
Signed original to be sent back to Chief Investigator (or other person submitting report) 
Copy to be kept for information by main REC. 
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Suicidal thoughts protocol
Disclosure of Suicidal Thoughts Protocol 
 
PREVENT Policy Statement 
GPs are responsible for the on-going clinical care of participants. Therefore, all trial 
staff directly involved with research participants, including MBCT therapists, have a 
duty of care to ensure that the GP is aware of any suicidal thoughts expressed by 
participants. 
 
Researchers must initiate the suicidal thoughts protocol each time a participant 
expresses potentially significant suicidal thoughts or thoughts of self harm above a 
certain level. This may be as a result of responses to questionnaire items or the 
participant may disclose information during an interview that leads the researcher to 
believe that there are thoughts of suicide or harm to self or others.  In both 
instances, the researcher should inform the participant’s GP and notify the site 
Clinical Lead (or nominated deputy).  
 
Therapists are expected to use their clinical judgement to assess the seriousness of 
risk and follow normal clinical procedures with respect to communicating disclosure 
to the participant’s GP. Therapists may contact the study team to seek advice from 
the Clinical Lead and/or to determine history of previous disclosure. Therapists must 
communicate any disclosure made to GPs to the trial manager. 
 
Symptoms of depression include low self-esteem, feelings of hopelessness, thoughts 
of self harm, and suicide ideation, particularly with severe episodes.  Consequently, 
the questionnaires administered to trial participants include items to detect these 
thoughts.  Participants may also disclose information during an interview or therapy 
session leading the researcher/therapist to believe that there is potentially a 
significant suicidal risk.  It is important that participants discuss these thoughts with 
an appropriate health professional to ensure access to necessary support.  
 
In the case of PREVENT, GPs are responsible for the on-going clinical care of 
participants. Therefore, researchers and therapists have a duty of care to ensure that 
the GP is aware of any potentially significant suicide ideation expressed by 
participants.  
 
It is expected that therapists will use their clinical judgement to assess the 
seriousness of risk and follow normal clinical procedures with respect to 
communicating disclosure to the participant’s GP.  In addition, therapists may 
contact the study team to seek advice from the clinical lead and/or to determine 
history of previous disclosure.  Therapists must communicate any disclosure made to 
GPs to the trial manager.   
 
Researchers are not clinically trained and should receive adequate 
training/supervision and work within their competence.  If a participant discloses any 
potentially significant thoughts of suicide or self-harm, researchers should complete 
a Suicidal Thoughts Report (below) and inform the participant’s GP of the nature of 
information disclosed.   
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Definition of ‘Potentially Significant Suicidal Thoughts’ 
 
In the PREVENT study, significant suicidal thoughts are identified by: 
 
 
1. A response of 2 or above to question 9 (suicidal thoughts or wishes) on the BDI 
questionnaire.  
 
Q9. 
0. I don’t have any thoughts of killing myself 
1. I have thoughts of killing myself, but I would not carry them out 
2. I would like to kill myself 
3. I would kill myself if I had the chance 
 
OR 
 
2. A rating of 3 or above on the GRID-HAMD question number 3. 
 
Q3. Suicide 
This past week, have you had any thoughts that life is not worth living, or that 
you’d be better off dead?  What about having thoughts of hurting or even killing 
yourself? 
0. Absent 
1. Feels life is not worth living 
2. Wishes he/she were dead or any possible thoughts of death to self 
3. Suicidal ideas of gesture 
4. Attempts at suicide 
 
OR 
 
3. Patients who disclose information during the SCID interview (face-to-face or 
telephone) that they have had recurrent thoughts of death or suicide at a similar 
level to those described in items 1 and 2 above. 
 
OR 
 
4. Information disclosed at any other time that would indicate significant suicidal 
thoughts 
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Researcher Action required 
 
Before conducting an assessment with a participant (either telephone or face-to-
face), the researchers should review all previous data on suicidal thought and ensure 
that contact details for the site Clinical Lead (or nominated deputy) are current.  
When assessments are being conducted over the telephone it is important that the 
researcher has accurate information about where the participant is calling from so 
that if needed this can be forwarded to the participant’s GP and/or emergency 
services.   
  
Whenever a researcher becomes aware that a participant has thoughts of suicide, 
the researcher should reinforce the importance of maintaining a dialogue with 
his/her GP and ask for permission to pass the information to his/her GP. Suggested 
scripts can be found  in Figure 1. 
 
If the participant agrees to this communication, the researcher should telephone the 
participant’s GP within 48 hours* to pass on the information obtained. If the 
participant’s GP is not available then the researcher should ask to speak to the duty 
doctor. The researcher should make it clear to the GP that no clinical risk assessment 
has been performed and that clinical responsibility for the study participants remains 
with the GP. A letter counter-signed by the site Clinical Lead should be sent to the 
GP confirming this notification.  A copy of this letter should be filed in the Participant 
Contact File. If the participant does not agree to their GP being informed, the 
researcher should contact the site Clinical Lead to discuss. 
 
The researcher will also complete a Suicidal Thoughts Report (below) and files this in 
the Participant’s Research File. This report should not contain any information that 
could identify the patient. 
*If the participant discloses something to the researcher that leads them to believe 
the participant to be in immediate danger of acting on suicidal thoughts, the 
researcher must immediately contact the participant’s GP.  If it not possible to speak 
to the participant’s GP the researcher should request to talk to the duty GP.  If the 
assessment is being conducted outside of office hours the researcher should contact 
the Crisis Team.  Once this contact has been completed, the researcher should 
contact the site Clinical Lead to inform them of the situation.  If possible, this contact 
should be made whilst the participant is still with the researcher, if this is not 
possible the researcher must make every effort to obtain a contact telephone 
number and address for the participant. 
 
If the assessment is being carried out over the telephone there are instructions at 
the end of this protocol detailing how to call another person using a VOIP phone 
without cutting off the participant. 
 
A letter should be sent to the participant’s GP, copying in the participant, detailing 
the disclosure made and the resulting action taken.  
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         Suicidal Thoughts Report – File in Research File 
 
Participant ID (Do not include any identifiable information):            Date:  
 
Time period: Telephone Screen / Baseline /Rand Assessment / MBCT+1month  /  9m  
/ 12m  / 18m  /  24m 
 
BDI suicide item score: 
Hamilton suicide item score: 
Suicide risk information: 
 
Include whether the participant has reported any of the following: 
 History of previous suicide attempts  
 Current suicidal ideation 
 Suicide plans / preparations 
 Escalation in suicidal ideation 
 Protective factors 
 Regular contact with GP? 
 
 
 
 
Date reported: ___/___/___ 
Additional notes / actions taken: 
As part of the PREVENT protocol, suicide risk is managed by the patient’s GP. 
                                                                
 
 
 
 
                                                             
 
 
 
                                                               Date action taken: ___/___/___ 
 
Researcher: _________________ Signed: ________________ Date: ___/___/___ 
 
 
Clinical Lead: _________________  Signed: ______________ Date: ___/___/___ 
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GP Risk Letter – Copy filed in Patient Contact File 
 
Surgery Address 
 
 
Date 
 
 
Dear Dr _______________ 
 
POTENTIAL SUICIDE RISK 
 
Re: Participant Name _____________ DOB 
 
 
As you know, PATIENT NAME, is taking part in the PREVENT trial comparing 
mindfulness-based cognitive therapy with antidepressant medication for the treatment 
of recurrent depression.  As part of this research I speak with him/her on a number of 
occasions to assess his/her wellbeing and depressive symptoms.  I am writing to 
update you about our discussions/meeting today. 
 
As part of the assessment we ask about depression using a standardised interview and 
questionnaire. PATIENT NAME reported that he / she 
………………………………(verbal report / score on relevant item).  I have not 
undertaken a formal assessment with PATIENT NAME but I have recommended that 
he / she arrange to make an appointment to come and see you to discuss this further.   
 
As ever, the clinical management of this patient remains your responsibility, but it is 
part of our study protocol to inform you of any suicidal thoughts disclosed to 
ourselves so that you can take account of them in your clinical management of this 
patient. 
 
 
Yours sincerely, 
 
 
 
 
 
Site Researcher    Supervised by Site Clinical Lead 
 
Cc: Participant 
= 
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Appendix 2 Antidepressants prescribed
TABLE 24 Total number of weeks that each antidepressant was prescribed over the 24-month follow-up period
Antidepressant m-ADM MBCT-TS
Agomelatine 64 0
Amitriptyline 660 350
Citalopram 7311 4258
Clomipramine 224 0
Dosulepin 212 376
Doxepin 0 16
Duloxetine 222 156
Escitalopram 272 128
Fluoxetine 2915 2493.5
Flupentixol 24 0
Fluvoxamine 0 12
Lofepramine 324 224
Mirtazapine 919 622
Moclobemide 0 14
Nortriptyline 0 200
Paroxetine 394 653
Sertraline 1668 1538
Trazodone 144 0
Venlafaxine 1225 1087
Other 0 32
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Appendix 3 Baseline characteristics of
participants who received an adequate dose
of treatment
TABLE 25 Baseline characteristics of participants who received an adequate dose of treatment
Characteristic/variable MBCT-TS (n= 176) m-ADM (n= 162) Difference test
Demographic characteristics
Female, n (%) 122 (69) 136 (84) χ2(1)= 10.00; p= 0.002
Ethnicity, n (%) χ2(3)= 4.01; p= 0.26
White 174 (99) 160 (99)
Other (including three categories) 2 (1) 2 (1)
Age (years) t(336)= –1.21; p= 0.23
Mean (SD) 51 (12) 50 (12)
Range 22–78 24–79
Marital status, n (%) χ2(5)= 7.18; p= 0.21
Single 30 (17) 22 (14)
Married, cohabiting or civil partnership 107 (61) 115 (71)
Separated, divorced or widowed 39 (22) 24 (15)
Missing 0 (0) 1 (1)
Level of education, n (%) χ2(6)= 8.50; p= 0.20
No educational qualifications 10 (6) 7 (4)
Some school qualifications 24 (14) 36 (22)
High school and/or vocational qualification 71 (40) 72 (44)
University degree/professional qualification 69 (39) 44 (27)
Missing 2 (1) 3 (2)
Religion, n (%) χ2(7)= 5.04; p= 0.66
Christian 109 (62) 103 (64)
Other 10 (6) 3 (2)
None 57 (32) 55 (34)
Missing 0 (0) 1 (1)
Salary (£ sterling) t(190)= –1.92; p= 0.06
Mean (SD) 20,560 (13,707) 16,884 (12,777)
Range 1200–72,000 792–75,000
continued
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TABLE 25 Baseline characteristics of participants who received an adequate dose of treatment (continued )
Characteristic/variable MBCT-TS (n= 176) m-ADM (n= 162) Difference test
Social class, n (%)a χ2(5)= 7.39; p= 0.19
Class 0 72 (41) 58 (36)
Class 1 49 (28) 38 (23)
Class 2 19 (11) 31 (19)
Class 3 5 (3) 4 (2)
Class 4 0 (0) 2 (1)
Class 5 31 (18) 28 (17)
Not classified 0 (0) 1 (1)
Stratification variables
Depressive symptomology at randomisation, n (%) χ2(1)= 0.03; p= 0.87
Asymptomatic 136 (77) 124 (77)
Symptomatic 40 (23) 38 (23)
Recruitment site, n (%) χ2(3)= 0.61; p= 0.90
Bristol 32 (18) 25 (15)
Exeter and East Devon 62 (35) 57 (35)
North and Mid Devon 45 (26) 42 (26)
South Devon 37 (21) 38 (23)
Psychiatric characteristics
Current depressive symptomology, mean (SD)
GRID-HAMD score 4.7 (4.2) 4.7 (4.4) t(336)= –0.14; p= 0.89
BDI-II score 13.4 (10.3) 14.3 (9.9) t(329)= 0.79; p= 0.43
Previous major depressive episodes, n (%)
Fewer than six episodes 98 (56) 76 (47)
Six or more episodes 78 (44) 86 (53)
Age (years) at first depression onset,
mean (SD)
24.8 (11.8) 24.8 (12.3) t(336)= 0.02; p= 0.98
Time (months) since last depressive episode,
mean (SD)
21.5 (25.0) 18.6 (25.4) t(336)= –1.05; p= 0.30
Number of comorbid DSM-IV Axis I psychiatric
diagnoses, mean (SD)
0.5 (0.8) 0.6 (0.9) t(336)= 2.06; p= 0.04
Received outpatient psychiatric or psychological
treatment, n (%)
86 (49) 87 (54) χ2(1)= 1.58; p= 0.21
Attempted suicide, n (%) 34 (19) 42 (26) χ2(1)= 2.30; p= 0.13
Number of previous attempts, mean (SD) 1.7 (1.2) 2.0 (1.6) t(73)= 0.73; p= 0.47
Severity of reported childhood abuse, n (%) χ2(1)= 0.12; p= 0.73
High 88 (50) 84 (52)
Low 88 (50) 78 (48)
Missing 0 (0) 0 (0)
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TABLE 25 Baseline characteristics of participants who received an adequate dose of treatment (continued )
Characteristic/variable MBCT-TS (n= 176) m-ADM (n= 162) Difference test
Quality of life, mean (SD)b
How would you rate your quality of life? 3.7 (0.8) 3.7 (0.9) t(327)= 0.05; p= 0.96
How satisfied are you with your health? 2.9 (1.0) 3.1 (1.0) t(327)= 1.25; p= 0.21
Physical 14.3 (4.8) 13.9 (2.8) t(327)= –0.90; p= 0.37
Psychological 12.7 (2.6) 12.2 (2.6) t(327)= –1.70; p= 0.09
Social 13.4 (3.5) 13.1 (3.4) t(327)= –0.87; p= 0.39
Environment 15.1 (2.4) 14.9 (2.6) t(327)= –0.81; p= 0.42
Health-related quality of life (EQ-5D tariffs) 0.773 (0.252) 0.762 (0.219) t(325)= –0.43; p= 0.67
a Social class was according to UK Office for National Statistics and the range was from professional and managerial
occupations (class 1) to semiroutine and routine occupations (class 5); class 0 represents those who have never worked,
the long-term unemployed, students or retired people [see www.ons.gov.uk/ons/guide-method/classifications/
current-standard-classifications/soc2010/index.html (accessed 20 July 2015)].
b Data determined on the basis of the WHOQOL-BREF assessment.
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Appendix 4 Baseline characteristics of
participants who did follow invited treatment with
respect to antidepressant medication use
TABLE 26 Baseline characteristics of participants who did follow invited treatment with respect to ADM use
Characteristic/variable MBCT-TS (n= 153) m-ADM (n= 162) Difference test
Demographic characteristics
Female, n (%) 105 (69) 136 (84) χ2(1)= 10.28; p= 0.001
Race, n (%) χ2(2)= 2.95; p= 0.23
White 152 (99) 160 (99)
Other (including two categories) 1 (1) 2 (1)
Age (years) t(313)= –1.85; p= 0.07
Mean (SD) 52 (12) 50 (12)
Range 25–78 24–79
Marital status, n (%) χ2(5)= 6.72; p= 0.24
Single 23 (15) 22 (14)
Married, cohabiting or civil partnership 96 (63) 115 (71)
Separated, divorced or widowed 34 (22) 24 (15)
Missing 0 (0) 1 (1)
Level of education, n (%) χ2(6)= 7.10; p= 0.31
No educational qualifications 10 (7) 7 (4)
Some school qualifications 22 (14) 36 (22)
High school and/or vocational qualification 63 (41) 72 (44)
University degree/professional qualification 56 (37) 44 (27)
Missing 2 (1) 3 (2)
Religion, n (%) χ2(7)= 4.31; p= 0.74
Christian 91 (59) 103 (64)
Other 8 (5) 3 (2)
None 54 (35) 55 (34)
Missing 0 (0) 1 (1)
Salary (£ sterling) t(175)= –1.84; p= 0.07
Mean (SD) 20,657 (14,444) 16,884 (12,777)
Range 1200–72,000 792–75,000
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TABLE 26 Baseline characteristics of participants who did follow invited treatment with respect to
ADM use (continued )
Characteristic/variable MBCT-TS (n= 153) m-ADM (n= 162) Difference test
Social class, n (%)a χ2(5)= 6.46; p= 0.26
Class 0 65 (42) 58 (36)
Class 1 39 (25) 38 (23)
Class 2 17 (11) 31 (19)
Class 3 3 (2) 4 (2)
Class 4 0 (0) 2 (1)
Class 5 29 (19) 28 (17)
Not classified 0 (0) 1 (1)
Stratification variables
Depressive symptomology at randomisation, n (%) χ2(1)= 0.02; p= 0.88
Asymptomatic 116 (76) 124 (77)
Symptomatic 37 (24) 38 (24)
Recruitment site, n (%) χ2(3)= 1.68; p= 0.64
Bristol 27 (18) 25 (15)
Exeter and East Devon 57 (37) 57 (35)
North and Mid Devon 42 (27) 42 (26)
South Devon 27 (18) 38 (24)
Psychiatric characteristics
Current depressive symptomology, mean (SD)
GRID-HAMD score 4.8 (4.2) 4.7 (4.4) t(313)= –0.33; p= 0.74
BDI-II score 13.8 (10.4) 14.3 (9.9) t(306)= 0.45; p= 0.65
Previous major depressive episodes, n (%)
Fewer than six episodes 84 (55) 76 (47)
Six or more episodes 69 (45) 86 (53)
Age (years) at first depression onset,
mean (SD)
25.3 (12.0) 24.8 (12.3) t(313)= –0.37; p= 0.71
Time (months) since last depressive episode,
mean (SD)
20.5 (23.7) 18.6 (25.4) t(313)= –0.68; p= 0.50
Number of comorbid DSM-IV Axis I psychiatric
diagnoses, mean (SD)
0.4 (0.7) 0.6 (0.9) t(313)= 2.33; p= 0.02
Received outpatient psychiatric or psychological
treatment, n (%)
72 (47) 87 (54) χ2(1)= 2.35; p= 0.13
Attempted suicide, n (%) 30 (20) 42 (26) χ2(1)= 1.95; p= 0.16
Number of previous attempts, mean (SD) 1.8 (1.2) 2.0 (1.6) t(69)= 0.50; p= 0.62
Severity of reported childhood abuse, n (%) χ2(1)= 0.15; p= 0.70
High 76 (50) 84 (52)
Low 77 (50) 78 (48)
Missing 0 (0) 0 (0)
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TABLE 26 Baseline characteristics of participants who did follow invited treatment with respect to
ADM use (continued )
Characteristic/variable MBCT-TS (n= 153) m-ADM (n= 162) Difference test
Quality of life, mean (SD)b
How would you rate your quality of life? 3.7 (0.8) 3.7 (0.9) t(305)= –0.14; p= 0.89
How satisfied are you with your health? 3.0 (1.0) 3.1 (1.0) t(305)= 0.86; p= 0.39
Physical 14.3 (5.0) 13.9 (2.8) t(305)= –0.92; p= 0.36
Psychological 12.7 (2.6) 12.2 (2.6) t(305)= –1.69; p= 0.09
Social 13.6 (3.5) 13.1 (3.4) t(305)= –1.29; p= 0.20
Environment 15.2 (2.5) 14.9 (2.6) t(305)= –1.08; p= 0.28
Health-related quality of life (EQ-5D tariffs) 0.775 (0.256) 0.762 (0.219) t(303)= –0.50; p= 0.62
a Social class was according to UK Office for National Statistics and the range was from professional and managerial
occupations (class 1) to semiroutine and routine occupations (class 5); class 0 represents those who have never worked,
the long-term unemployed, students or retired people [see www.ons.gov.uk/ons/guide-method/classifications/
current-standard-classifications/soc2010/index.html (accessed 20 July 2015)].
b Data determined on the basis of the WHOQOL-BREF assessment.
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Appendix 5 Baseline characteristics of
participants who scored high and low on severity of
childhood abuse
TABLE 27 Baseline characteristics of participants who scored high and low on severity of childhood abuse
Characteristic/variable
Lower severity
of childhood
abuse (n= 206)
Higher severity
of childhood
abuse (n= 216) Difference test
Demographic characteristics
Female, n (%) 162 (78.6) 161 (74.5) χ2(1)= 0.99; p= 0.32
Ethnicity, n (%) χ2(3)= 4.23; p= 0.24
White 202 (98.1) 216 (100.0)
Other (including three categories) 4 (2.0) 0 (0.0)
Age (years) t(420)= 1.02; p= 0.31
Mean (SD) 50.9 (13.2) 48.9 (11.4)
Range 20–79 21–74
Marital status, n (%) χ2(5)= 9.47; p= 0.09
Single 36 (17.5) 44 (20.4)
Married, cohabiting or civil partnership 130 (63.1) 134 (62.0)
Separated, divorced or widowed 39 (18.9) 38 (17.6)
Missing 1 (0.5) 0 (0.0)
Level of education, n (%) χ2(6)= 3.27; p= 0.78
No educational qualifications 13 (6.3) 7 (3.2)
Some O levels/GCSEs 38 (18.4) 43 (19.9)
Some AS/A levels 21 (10.2) 21 (9.7)
NVQ or other vocational qualification 61 (29.6) 72 (33.3)
University bachelor’s degree 42 (20.4) 47 (21.8)
University master’s degree 10 (4.9) 10 (4.6)
University professional training or PhD 16 (7.8) 13 (6.0)
Missing 5 (2.4) 3 (1.4)
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TABLE 27 Baseline characteristics of participants who scored high and low on severity of
childhood abuse (continued )
Characteristic/variable
Lower severity
of childhood
abuse (n= 206)
Higher severity
of childhood
abuse (n= 216) Difference test
Religion, n (%) χ2(7)= 8.63; p= 0.28
Atheist 7 (3.4) 11 (5.1)
Christian 142 (68.9) 130 (60.2)
Muslim 1 (0.5) 0 (0.00)
Spiritualist 3 (1.5) 1 (0.5)
Buddhist 1 (0.5) 1 (0.5)
Other 3 (1.5) 4 (1.9)
Agnostic 5 (2.4) 3 (1.4)
None 43 (20.9) 66 (30.6)
Missing 1 (0.5) 0 (0.0)
Smokes, n (%) χ2(1)= 5.23; p= 0.02
Yes 34 (16.5) 56 (25.9)
Missing 3 (1.5) 0 (0.0)
Salary (£ sterling) t(231)= –0.26; p= 0.80
Mean (SD) 18,687 (13,938) 19,147 (13,091)
Range 792–80,000 1200–72,000
Social class, n (%)a χ2(5)= 7.86; p= 0.16
Class 0 82 (39.8) 89 (41.2)
Class 1 43 (20.9) 62 (28.7)
Class 2 38 (18.4) 22 (10.2)
Class 3 6 (2.9) 5 (2.3)
Class 4 1 (0.5) 1 (0.5)
Class 5 35 (17.0) 37 (17.1)
Not classified 1 (0.5) 0 (0.0)
Stratification variables
Depressive symptomology at randomisation: n (%) χ2(1)= 0.78; p= 0.38
Asymptomatic 162 (79) 162 (75)
Symptomatic 44 (21) 54 (25)
Recruitment site, n (%) χ2(3)= 10.38; p= 0.02
Bristol 28 (13.6) 36 (16.7)
Exeter and East Devon 76 (36.9) 72 (33.3)
North and Mid Devon 64 (31.1) 45 (20.8)
South Devon 38 (18.4) 63 (29.2)
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TABLE 27 Baseline characteristics of participants who scored high and low on severity of
childhood abuse (continued )
Characteristic/variable
Lower severity
of childhood
abuse (n= 206)
Higher severity
of childhood
abuse (n= 216) Difference test
Psychiatric characteristics
Current depressive symptomology, mean (SD)
GRID-HAMD score 4.2 (4.2) 5.1 (4.3) t(420)= –2.18; p= 0.03
BDI-II score 12.9 (9.6) 15.3 (10.5) t(413)= –2.44; p= 0.02
Previous major depressive episodes, n (%)
Fewer than six episodes 126 (61.2) 100 (46.3)
Six or more episodes 80 (39) 116 (54)
Age (years) at first depression onset, mean (SD) 28 (13) 22 (12) t(420)= 4.31; p< 0.0001
Time (months) since last depressive episode,
mean (SD)
17 (23) 21 (27) t(420)= –1.7; p= 0.09
Severity of last depressive episode (no. of
DSM-IV symptoms recorded), mean (SD)
6.5 (1.1) 7.1 (1.2) t(420)= –5.67; p< 0.0001
Number of comorbid DSM-IV Axis I psychiatric
diagnoses, mean (SD)
0.5 (0.9) 0.7 (0.95) t(420)= –1.72; p= 0.09
Ever been hospitalised for emotional or psychiatric reason? n (%) χ2(1)= 19.896; p< 0.0001
Yes 11 (5.3) 43 (19.9)
Missing 2 (1.0) 1 (0.5)
Ever received outpatient psychiatric or psychological treatment? n (%) χ2(1)= 2.78; p= 0.10
Yes 95 (46.1) 115 (53.2)
Missing 2 (1.0) 6 (2.8)
Ever made a suicide attempt? n (%)
Yes 30 (14.6) 70 (32.4) χ2(1)= 18.12; p< 0.0001
Number of previous attempts, mean (SD) 1.6 (0.78) 1.9 (1.4) t(97)= –1.28; p= 0.21
Family history of mental illness or alcohol or drug abuse, n (%) χ2(2)= 20.36; p< 0.0001
Yes 77 (37.4) 121 (56.0)
No 114 (55.3) 74 (34.3)
Not sure 12 (5.8) 21 (9.7)
Missing 3 (1.5) 0 (0.0)
Quality of life, mean (SD)b
How would you rate your quality of life? 3.7 (0.8) 3.6 (0.8) t(411)= 1.96; p= 0.05
How satisfied are you with your health? 3.1 (1.0) 2.9 (1.0) t(411)= 1.57; p= 0.12
Physical 14.4 (2.9) 14.5 (7.6) t(411)= –0.04; p= 0.97
Psychological 12.7 (2.6) 12.2 (2.6) t(411)= 1.91; p= 0.06
Social 13.9 (3.2) 12.7 (3.5) t(411)= 3.46; p= 0.001
Environment 15.4 (2.3) 14.7 (2.6) t(411)= 2.87; p= 0.004
a Social class was according to UK Office for National Statistics and the range was from professional and managerial
occupations (class 1) to semiroutine and routine occupations (class 5); class 0 represents those who have never worked,
the long-term unemployed, students or retired people [see www.ons.gov.uk/ons/guide-method/classifications/
current-standard-classifications/soc2010/index.html (accessed 20 July 2015)].
b Data determined on the basis of the WHOQOL-BREF assessment.
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Appendix 6 Adult Service Use Schedule
TO BE COMPLETED BY RESEARCHER: 
 
ID Number  
 
Date of baseline interview: dd mm 20 yy 
 
 
We want to know about your use of psychological treatments and certain 
medications commonly taken by people with depression for the three months 
preceding this interview. 
 
Please try and complete this form without discussing your answers with the 
researcher. 
 
  
DOI: 10.3310/hta19730 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 73
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Kuyken et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
Medication 
NB See opposite page for list of common medications in each category to guide you. 
1. Have you been prescribed an antidepressant over the last three months? 
Yes         Go to question 2                 No   Go to question 9 
  
2. What is the name of the antidepressant and your 
    daily dose (see list opposite)? Example: Fluoxetine 20mg 
 
 
3. How many weeks have you been prescribed this 
    antidepressant over the last three months? 
 Weeks   
 
4. In an average week, how many days do you     
    actually take this medication? 
 Days   
     
We realise that there are lots of reasons why people do not like and sometimes do not take the 
medication which is prescribed to them. We are interested in your experience.  Please answer the 
questions thinking about the last three months.  
5. Did you ever forget to take your antidepressant medication? 
Yes                                                 No  
6. Were you careless at times about your antidepressant medication? 
Yes                                                 No  
 
7. When you felt better did you sometimes stop taking your antidepressant medication? 
Yes                                                 No  
8. Sometimes when you feel worse do you stop taking your antidepressant medication? 
Yes                                                 No  
 
 
9. Have you been prescribed a sleeping tablet or medication for anxiety over the last three months?  
Yes         Go to question 10                 No   Go to question 13 
10. What is the name of this medication and your 
    daily dose (see list opposite)? Example: Diazepam 2mg 
 
 
 
11. How many weeks have you been prescribed this 
    medication over the last three months? 
 Weeks   
 
12. In an average week, how many days do you  
    actually take this medication? 
 Days   
     
 
13. Have you taken a painkiller over the last three months (prescribed by doctor or bought from chemist)?  
Yes         Go to question 14                 No   Go to question 18 
14. What is the name of the painkiller and your 
      daily dose (see list opposite)? Example: Codeine 30mg 
 
15. Is this painkiller prescribed by your doctor?  Yes  Go to qu. 12  No  Go to qu. 13 
 
16. Over the last three months, how many weeks 
      have you been prescribed this painkiller 
 Weeks   
 
17. In an average week, how many days do you  
      take these pain killers? 
 Days   
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 MEDICATION  
Antidepressants:   
Amitriptyline/Triptafen 
Amoxapine/Asendis 
Citalopram/Cipramil 
Clomipramine 
Dosulepin/Dothiepin/Prothiaden 
Doxepin/Sinequan 
Escitalopram/Cipralex 
Fluoxetine/Prozac 
Fluvoxamine/Faverin 
Flupentixol/Fluanxol 
Imipramine/Tofranil 
Isocarboxazid 
Lofepramine/Gamanil 
Maprotiline/Ludiomil 
Mianserin 
Mirtazepine/Zispin 
Moclobemide/Manerix 
Nortriptyline/Allegron/Motival 
Paroxetine/Seroxat 
Phenelzine/Nardil 
Reboxetine/Edronax 
Sertraline/Lustral 
Tranylcypromine  
Trazodone/Molipaxin 
Trimipramine/Surmontil 
 
Sleeping tablets/medication for anxiety: 
Alprazolam 
Buspirone/Buspar 
Chlorazepate/Tranxene 
Chlordiazepoxide 
Diazepam 
Flurazepam/Dalmane 
Loprazolam 
Lorazepam 
Lormetazepam 
Meprobamate 
Nitrazepam 
Oxazepam 
Temazepam 
Zapelon/Sonata 
Zolpidem/Stilnoct 
Zopiclone/Zimovane 
 
 
Alka-Selzer 
Anadin 
Aspirin 
Buprenorphine/Transtec 
Codeine 
Dihydracodeine 
Dipapnone/Dicolnal 
Disprin 
Fentanyl/Durogesic 
Hedex 
Hedex 
Ibuprofen 
Lemsip 
Morphine 
Nefopam/Acupan 
Neurofen 
Night nurse 
Panadol 
Paracetamol 
Paracetamol with co-codamol 
Solpadeine 
Tramadol/Zamadol 
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Psychological treatments 
 
18. Have you had any psychological treatments or counselling over the last 3 months, excluding marriage guidance 
and art/drama/music therapy? 
Yes         Go to question 19                 No   Go to question 33 
Details of first therapist:  
19. What is the name of your therapist? 
 
    
 
20. How many sessions have you had with your 
      therapist in the last three months? 
 Number of 
sessions 
  
21. What was the average duration of each 
     session with your therapist? 
 Minutes   
22. Was your therapy individual (one-to-one) or 
      group therapy?    
Individual 
   
Group 
 
23. How did you travel to your therapy? 
 
 
Train/Bus    Go to question 24 
Car/motorcycle    Go to question 25 
Walk/Cycle    Go to question 26 
 
24. If you used public transport, what was the 
     one-way fare? £  
  
25. Approximately how many miles was the  
      journey one-way? 
 Miles   
Details of second therapist, if applicable:  
26. What is the name of your second therapist? 
 
    
27. How many sessions have you had with your 
      second therapist in the last three months? 
 Number of 
sessions 
  
28. What was the average duration of each session 
      with your second therapist? 
 Minutes   
29. Was your second therapy individual (one-to- 
      one) or group therapy?    
Individual 
   
Group 
 
30. How did you travel to your second therapy? 
 
 
Train/bus    Go to question 31 
Car/motorcycle    Go to question 32 
Walk/cycle    Go to question 33 
 
31. If you used public transport, what was the 
      one-way fare? £  
  
32. Approximately how many miles was the  
      journey one-way? 
 Miles   
 
END OF QUESTIONNAIRE 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
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Preventing depressive relapse/recurrence in NHS settings through mindfulness-based 
cognitive therapy (PREVENT) - adult SERVICE USE Schedule (ad-sus), Interview 
 
 
ID Number  
 
Date of interview: dd mm 20 yy 
 
Period(s) covered (tick all that apply) 
Baseline  
3-month  
9-month  
12-month  
18-month  
24-months  
If previous interviews missed, this schedule should 
cover the entire period from previous to current 
interview date. Please tick all periods that apply 
 
 
 
This schedule should be given in interview. 
 
The schedule covers: 
- At baseline, the patient’s use of services for the three months preceding the interview 
 - At any follow-up point, the patient’s use of services since the previous interview 
  
If the patient was not interviewed at an earlier follow-up point, this schedule can be used to cover the entire 
period from previous to current interview – please tick all periods that apply. 
 
Please tell the patient that you want to know about their use of all services except psychological interventions and 
medications. Please ask the patient not to mention any psychological treatments or medications received and tell 
them that details of these treatments will be collected in a separate schedule to be completed by the patient. 
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Section A: Hospital Services 
 
A1 – Have you had a hospital admission (if baseline) in the last three months / (if follow-up) since you were 
last interviewed approximately [X] months ago? 
1 Yes Go to A2 
0 No Go to A3 
666 Research worker unable to evaluate Go to A3 
999 Not completed  Go to A3 
 
A2 – If yes, record details below 
Hospital code Speciality code Details if hospital=92 (other) and/or speciality code=28 (other) Number of nights 
    
    
    
    
 
A3 – Have you been to hospital for an outpatient/day patient appointment (if baseline) in the last three 
months / (if follow-up) since you were last interviewed approximately [X] months ago? 
1 Yes Go to A4 
0 No Go to A5 
666 Research worker unable to evaluate Go to A5 
999 Not completed  Go to A5 
 
A4 - If yes, record details below 
Hospital code Speciality code Details if hospital=92 (other) and/or speciality code=28 (other) 
Number of 
appointments 
    
    
    
    
 
A5 – Have you attended an accident and emergency (A&E) department (if baseline) in the last three 
months / (if follow-up) since you were last interviewed approximately [X] months ago? 
1 Yes Go to A6 
0 No Go to B1 
666 Research worker unable to evaluate Go to B1 
999 Not completed  Go to B1 
 
A6 - If yes, record details below 
Hospital code Details Admitted Ambulance Number of contacts 
  Yes/no Yes/no  
  Yes/no Yes/no  
  Yes/no Yes/no  
  Yes/no Yes/no  
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Section B: Community-based health, social and complementary services 
 
B - Which of the following community based professionals or services have you had contact with (if 
baseline) in the last three months / (if follow-up) since you were last interviewed approximately [X] months 
ago? 
  Number of contacts Average duration in minutes per contact 
1 General practitioner – surgery   
2 General practitioner – home   
3 General practitioner – telephone   
4 Practice nurse (nurse in GP surgery)   
5 District nurse, health visitor, midwife   
6 Community psychiatric nurse in the community   
7 Psychiatrist in the community   
8 Occupational therapist in the community   
9 Art/drama/music therapy in the community   
10 Social worker   
11 Marriage counselling service e.g. Relate   
12 Advice service e.g. Citizen’s Advice Bureau   
13 Helpline e.g. Samaritans, MIND   
14 Day centre/drop-in centre   
15 Chiropractor/osteopath   
16 Homeopathy   
17 Acupuncture   
18 Other – give details   
19 Other – give details   
20 Other – give details   
 
 
Section C: Employment and time off work 
 
C1 – What is your current occupational status? 
1 Full-time employment (30+ hours per week) Go to C3 7 Voluntary worker Go to C2 
2 Part-time employment (<30 hours per week) Go to C3 8 Unemployed & looking for work Go to C2 
3 Employed & currently unable to work Go to C3 9 Unemployed & not looking for work (e.g. housewife) Go to C2 
4 Part-time employment & part-time student Go to C3 10 Unemployed & unable to work for medical reasons Go to C2 
5 Full-time student Go to C2 11 Medically retired Go to C2 
6 Part-time student Go to C2 12 Retired  Go to C2 
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666 Research worker unable to evaluate Go to C2    
999 Not completed  Go to C2    
 
C2 – Have you been in paid employment (if baseline) in the last three months / (if follow-up) since you were 
last interviewed approximately [X] months ago? 
0 No END 
1 Yes Go to C3 
666 Research worker unable to evaluate  
999 Not completed  
 
C3 – What is your approximate gross pay per year (before tax) for your current or most recent 
employment? 
1 Under £5,000 8 £35,001-£40,000 
2 £5,001-£10,000 9 £40,001-£45,000 
3 £10,001-£15,000 10 £45,001-£50,000 
4 £15,001-£20,000 11 £45,001-£50,000 
5 £20,001-£25,000 12 £50,001-£75,000 
6 £25,001-£30,000 13 £75,001-£100,000 
7 £30,001-£35,000 14 £100,001 + 
666 Research worker unable to evaluate   
999 Not completed    
 
C4 – How many DAYS have you been absent from work due to illness (if baseline) in the last three months 
/ (if follow-up) since you were last interviewed approximately [X] months ago? 
1 Days Number of days 
666 Research worker unable to evaluate  
999 Not completed  
 
C5 – How many HOURS does/did your employer expect you to work in a typical 7-day week for your 
current or most recent employment? If it varies, estimate the average. If more than 97, enter 97. 
1 Hours Number of hours 
666 Research worker unable to evaluate  
999 Not completed  
 
C6 – Have you been in paid employment in the last four weeks? 
0 No END 
1 Yes Go to C7 
666 Research worker unable to evaluate  
999 Not completed  
 
C7 – Please think about your work experiences over the past 4 weeks (28 days). In the past 4 weeks (28 
days), how many days did you… 
1 
miss an entire work day because of problems with your physical or mental health? Please include only 
days missed for your own health. Number of days 
2 miss an entire work day for any other reason (including holiday)? Number of days 
3 miss part of a work day because of problems with your physical or mental health? Please include only Number of days 
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days missed for your own health. 
4 miss part of a of a work day for any other reason (including holiday)? Number of days 
666 Research worker unable to evaluate  
999 Not completed  
 
C8 – About how many HOURS altogether did you work in the past 4 weeks (28 days)? See examples for 
calculating hours worked below 
1 Hours Number of hours 
666 Research worker unable to evaluate  
999 Not completed  
 
C9 – On a scale from 0 to 10 where 0 is the worst job performance anyone could have at your job and 10 is 
the performance of a top worker, how would you rate the usual performance of most workers in a job 
similar to yours? Place a  in the circle below the number that best describes this. 
 
Worst performance      Top performance 
0 1 2 3 4 5 6 7 8 9 10 
           
 
C10 – Using the same 0-to-10 scale, how would you rate your usual job performance over the past year or 
two? Place a  in the circle below the number that best describes this. 
 
Worst performance      Top performance 
0 1 2 3 4 5 6 7 8 9 10 
           
 
C11 – Using the same 0-to-10 scale, how would you rate your overall job performance on the days you 
worked during the past 4 weeks (28 days)? Place a  in the circle below the number that best describes 
this. 
 
Worst performance      Top performance 
0 1 2 3 4 5 6 7 8 9 10 
           
 
Examples for Calculating Hours Worked in the Past 4 weeks 
40 hours per week for 4 weeks = 160 hours 
35 hours per week for 4 weeks = 140 hours 
40 hours per week for 4 weeks with 2 8-hour days missed = 144 hours 
40 hours per week for 4 weeks with 3 4-hour partial days missed = 148 hours 
35 hours per week for 4 weeks with 2 8-hour days missed and 3 4-hour partial days missed = 112 hours 
Employment and time off work section taken from the WHO Health Productivity Questionnaire (HPQ), questions B5-B11. 
 
 
End of interview.  
 
AD-SUS designed by Sarah Byford at the Institute of Psychiatry 
For further information please contact: 
Centre for the Economics of Mental Health 
Box P024 
Institute of Psychiatry 
De Crespigny Park 
London SE5 8AF 
Email: s.byford@iop.kcl.ac.uk  
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Appendix 7 Distribution of themes in
telephone interviews
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TABLE 28 Distribution of themes in telephone interviews
Theme Subtheme 2012 2006 2004 2005 2007 2015 3006
ADM issues Wants to remain on ADM ✗ ✗ ✗ ✗ ✗ ✗ ✗
Wants to come off ADM ✗ ✗
Not wanting to take ADM
for 2 years
Not regularly taking ADM
Worried about relapse ✗ ✗
Time issues Not the right time ✗ ✗ ✗ ✗ ✗
Study too long
Working full time ✗
Attitudes to psychological
intervention
Had therapy before ✗ ✗ ✗ ✗
Previous therapy unhelpful ✗ ✗
Previous therapy helpful ✗ ✗
Therapy and ADM
complementary
✗
MBCT issues Meditation is a good idea ✗ ✗ ✗
Not keen on meditation ✗ ✗
Conflicts with religious
views
Being in a group Unhappy with group
therapy
✗ ✗
No concerns about
group therapy
✗
Lifestyle and medical
barriers
Too unwell ✗
Cannot travel to sessions ✗ ✗ ✗
Too old
Symptom issues Depression because of
chemical imbalance
Not depressed enough ✗
Depression is contextual ✗ ✗
Taking part in research No concerns ✗ ✗ ✗ ✗ ✗ ✗ ✗
Safety/reliability concerns ✗
Wanting to help others
Previously taken part
in research
Being randomised Would like to choose
group
✗ ✗ ✗
Would like ADM arm ✗ ✗ ✗
Would like MBCT arm
No worries about
randomisation
Shaded boxes represent reasons for non-participation given in response to the first open question.
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3008 2009 2010 2001 2002 2003 3005 3007 2013 3004 2011 3003 2008 2014 2016
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗
✗ ✗ ✗
✗
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗
✗ ✗
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗
✗ ✗ ✗
✗
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗
✗
✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗
✗ ✗ ✗ ✗
✗
✗ ✗
✗ ✗ ✗
✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗
✗ ✗ ✗
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗ ✗ ✗
✗ ✗ ✗ ✗
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